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Abstract:  Flavonoids are plant-derived dietary components with a substantial impact on 196 
human health. Research has expanded massively since it began in the 1930s, and the 197 
complex pathways involved in bioavailability of flavonoids in the human body are now well 198 
understood. In recent years, it has been appreciated that the gut microbiome plays a major 199 
role in flavonoid action, but much progress still needs to be made in this area. Since the first 200 
publications on the health effects of flavonoids, their action is understood to protect against 201 
various stresses, but the mechanism of action has evolved from the now debunked simple 202 
direct antioxidant hypothesis into an understanding of the complex effects on molecular 203 
targets and enzymes in specific cell types. This review traces the development of the field 204 
over the past 8 decades, and indicates the current state of the art, and how it was reached. 205 
Future recommendations based on this historical analysis are (i) to focus on key areas of 206 
flavonoid action, (ii) to perform human intervention studies where possible, especially for 207 
studies on bioavailability, and (iii) to carry out cellular in vitro experiments using 208 
appropriate cells together with the chemical form of the flavonoid found at the site of action; 209 
this could be the native form of compounds found in the food for studies on digestion and the 210 
intestine, the conjugated metabolites found in the blood after absorption in the small 211 
intestine for studies on cells, or the chemical forms found in the blood and tissues after 212 
catabolism by the gut microbiota.  213 
 Keywords: dietary flavonoids, bioavailability, transport, metabolism, bioactivity  214 
 215 
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Introduction to Bioavailability and Transport 216 
Although research on flavonoids spans over 80 years, for many nutritionists the origins of 217 
their absorption, disposition, metabolism, and excretion, commonly referred to as bioavailability, 218 
and their protective role in the diet, began in the 1990s in The Netherlands. At that time, routine 219 
HPLC-based quantitative analysis of flavonoid glycosides in fruits, vegetables, and their derived 220 
products was not straight-forward because of the number of compounds involved which were 221 
conjugated to varying degrees with different sugars. A further complication was the limited number 222 
of reference compounds that were available from commercial sources. Initially, this was overcome 223 
by the use of an acid hydrolysis procedure, developed originally by Harborne (1965), that converted 224 
flavonol and flavone glycosides to their aglycones, such as quercetin 1, kaempferol 2, isorhamnetin 225 
3, myricetin 4, luteolin 5, and apigenin 6. Reference compounds were readily available for the 226 
released aglycones, which were quantified using reverse-phase HPLC with absorbance detection at 227 
370 nm (Hertog, Hollman, & Venema, 1992). Two further papers followed in which the procedure 228 
was used to quantify the flavonol and flavone contents of 28 vegetables and 9 fruits (Hertog, 229 
Hollman, & Katan, 1992) and teas, wines and fruit juices (Hertog, Hollman, & van de Putte, 1993).  230 
Shortly thereafter, an assessment based on dietary history, of quercetin, kaempferol, myricetin, 231 
luteolin, and apigenin consumption, principally from onions, tea, and apples, over a 5-year period by 232 
805 men aged 65-84 years, associated flavonol and flavone intake with reduced mortality from 233 
coronary heart disease (CHD) (Hertog, Feskens, Hollman, Katan, & Kromhout, 1993).   Insert 234 
Structures 1-6 235 
In the ensuing years there was a growing interest in the protective effects of flavonoids and 236 
this review will focus on major developments with the principal dietary flavonoids, namely 237 
anthocyanins, flavan-3-ols, flavonols, and flavanones.  There has been only limited research on 238 
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flavones which are minor dietary components, and isoflavones have also been excluded as they have 239 
their own unique history warranting separate review. 240 
A key to the advancement of research has been obtaining information on the metabolism of 241 
flavonoids within the body following ingestion and, in particular, the identification and 242 
quantification of the phase II metabolites that enter the circulatory system from the upper 243 
gastrointestinal (GI) tract and the lower bowel.  The substantial progress that has been made in this 244 
area can be linked to the increasing availability of synthesized reference compounds (see Barron, 245 
Smarrito-Menozz, Fumeaux, & Viton, 2012), an increasing number of which are now available from 246 
commercial sources, together with the use of HPLC/UPLC linked to an ion trap mass spectrometer, 247 
instruments which became available at relatively affordable prices in the early 2000s.  This 248 
facilitated identification/partial identification, and quantification of trace amounts of metabolites in 249 
biological samples. More recent advances in this area can also be linked to the enhanced selectivity 250 
and sensitivity of orbitrap and triple quadrupole mass spectrometers (Hird, Lau, Schuhmacher, & 251 
Krska, 2014). 252 
 253 
Interaction of Flavonoids with the Gastrointestinal Tract  254 
After ingestion of food or a beverage, flavonoids in the ingested matrix must pass from the gut 255 
lumen into the circulatory system in order to be absorbed. Since in planta almost all flavonoids are 256 
in the form of glycosides, the attached sugar must be removed following consumption before 257 
absorption can take place. This was a matter of some controversy before the discovery that 258 
flavonoid glucosides are hydrolyzed by lactase phlorizin hydrolase (LPH) in the brush-border of the 259 
small intestine epithelial cells, thereby removing the attached sugar and releasing the aglycone. LPH 260 
exhibits broad substrate specificity for flavonoid-O-glycosides and the released aglycone may then 261 
enter the epithelial cells by passive diffusion as a result of its increased lipophilicity and its 262 
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proximity to the cellular membrane (Day et al., 2000b).  An alternative means of hydrolysis is a 263 
cytosolic β-glucosidase (CBG) within the epithelial cells.  In order for CBG-mediated hydrolysis to 264 
occur, the polar glycosides must be transported into the epithelial cells, possibly with the 265 
involvement of the active sodium-dependent glucose transporter (SGLT1) (Gee, DuPont, Day, Plumb, 266 
Williamson, & Johnson, 2000).  267 
Prior to passage into the blood stream the aglycones undergo metabolism forming sulfate, 268 
glucuronide and/or methylated metabolites through the respective action of sulfotransferases, 269 
uridine-5′-diphosphate glucuronosyltransferases, and catechol-O-methyltransferases.  There is 270 
also efflux of at least some of the metabolites back into the lumen of the small intestine by specific 271 
transporters (see Section 2.2). Once in the bloodstream, metabolites can be subjected to further 272 
phase II metabolism with conversions occurring in the liver, prior to urinary excretion. Flavonoids 273 
not absorbed in the small intestine pass into the distal GI tract where they are subjected to the 274 
action of the intestinal microbiota which cleave conjugating moieties and the resultant aglycones 275 
are subject to ring fission, leading to the production of phenolic acids and aromatic compounds.  276 
These too can be absorbed, subjected to phase II metabolism, and ultimately excreted in urine in 277 
substantial quantities that, in most instances, are well in excess of metabolites that enter the 278 
circulatory system via the small intestine without prior microbial catabolism. 279 
The identity and concentration of metabolites that pass through the circulation provide 280 
important information for studies with ex vivo and in vitro test systems designed to elucidate the 281 
modes of action underlying the protective effects of dietary flavonoids.  It is these metabolites to 282 
which cells within the body are likely exposed, rather than their parent compounds that occur in 283 
fruits, vegetables, and their derived products.  284 
 285 
Transport of flavonoids around the body 286 
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Biological membranes surround mammalian cells and consist of a lipid bilayer, through which 287 
hydrophilic molecules cannot pass. Cells control passage through this physical barrier using 288 
transporters, which are proteins embedded in the membrane with parts of the protein often 289 
exposed on both sides and protruding from it. As an example, glucose, which is a highly water-290 
soluble sugar, cannot pass through lipid bilayers, and requires various transporters to allow entry 291 
into the cell. Transporters can be considered as similar to enzymes, except they catalyze the spatial 292 
translocation of molecules rather than chemical transformation. The GLUT family of glucose 293 
transporters acts on the basis of facilitated diffusion, and does not require energy (Augustin, 2010). 294 
Other types of transporters require either ATP hydrolysis directly, as is the case with the ABC 295 
transporters (Degorter, Xia, Yang, & Kim, 2012), or indirectly, such as SGLT1 (Wright, Loo, & 296 
Hirayama, 2011), and some require another molecule which is transported in the same or opposing 297 
direction (Meredith, & Christian, 2008). There are three organic anion transporter families: the 298 
organic anion transporter (OAT) family (SLC22A), the organic anion-transporting peptide (OATP) 299 
family (SLC21A), and the multidrug resistance-associated protein (MRP) family (ABC transporters), 300 
which carry out transepithelial transport of organic anions in the kidneys, liver, and brain. These 301 
transporters are responsible for most of the absorption, distribution, and excretion of flavonoids 302 
around the body. An important part of bioavailability research on flavonoids are studies on the 303 
specificity of these transporters that control the movement of flavonoids and their metabolites 304 
across the wall of the GI tract into the circulatory system, in and out of tissues and organs, and their 305 
excretion. 306 
In earlier studies on flavonoid bioavailability, it was assumed that the ingested compound 307 
would be absorbed passively and appear chemically unchanged in blood or urine, in the same way 308 
as many drugs (Gugler, & Dengler, 1973; Gugler, Leschik, & Dengler, 1975). However, the ability of 309 
flavonoids to cross biological membranes depends on their size, hydrophobicity, and any 310 
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intracellular reactions that promote diffusion by maintaining a concentration gradient (Camenisch, 311 
Alsenz, van de Waterbeemd, & Folkers, 1998). Once conjugated by phase II enzymes, the ability of 312 
the flavonoid conjugates to cross membranes is greatly reduced, and specific transporters are 313 
required (Williamson et al., 2007). In addition, when using cultured cells as a model to assess 314 
flavonoid actions, it is relevant that tumor and cultured cells often have higher levels of ABC 315 
transporters that rapidly remove conjugates from the cell, limiting the action of flavonoids 316 
compared to the tissue in vivo.  317 
 318 
Cellular efflux of flavonoids by ABC transporters 319 
One of the first papers to examine the interaction of flavonoids with ABC transporters was for 320 
the interaction of the flavonols, quercetin 1, kaempferol 2, and galangin 7 with P-glycoprotein 321 
(ABCB1, MDR1) (Critchfield, Welsh, Phang, & Yeh, 1994; Scambia et al., 1994) followed by genistein 322 
8 (Castro, & Altenberg, 1997) and grapefruit juice (Takanaga, Ohnishi, Matsuo, & Sawada, 1998). 323 
Soon after, Walle, French, Walgren, & Walle, (1999) demonstrated that genistein-7-O-glucoside 9 324 
could interact with the ABC transporter MRP2 (ABCC2). Prenylation of the flavone chrysin 10 325 
increased its interaction with ABCB1 (Comte et al., 2001), and the structural requirement for 326 
binding of other flavonoids have been reported (Di Pietro et al., 2002). It is now clear that many 327 
flavonoid conjugates interact with ABC transporters, and that these transporters are crucial for 328 
determining their distribution around the body. For example, ABCC2 is situated on the brush border 329 
of small intestine enterocytes, and effluxes some conjugates back towards the gut lumen and, in 330 
effect, these compounds per se are no longer bioavailable to the body (Brand et al., 2007; Williamson 331 
et al., 2007). ABCG2 also plays an important role in the efflux of flavonoid conjugates from cells 332 
(Zhang, Yang, & Morris, 2004). The specific roles of ABC transporters in flavonoid bioavailability are 333 
shown in Figure 1. 334 
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Insert Structures 7-10 335 
 336 
 337 
Cellular uptake of flavonoids by organic anion transporters (OATs) 338 
One of the first papers to show that flavonoid could interact with intake transporters reported 339 
that the (poly)phenol ellagic acid 11 could inhibit OAT1 (Whitley et al., 2005). In addition, genistein 340 
8, but not genistein-7-O-glucoside 9 and (–)-epigallocatechin-3-O-gallate 12 interacted with the 341 
OATP family of transporters (OATP1B1). Quercetin-3-O-rutinoside 13 (rutin) appeared to stimulate 342 
uptake of an OATP1B1 substrate, whereas quercetin 1 had no effect (Wang, Wolkoff, & Morris, 343 
2005). This was followed by further data showing that the flavonoids morin 14 and silybin 15, but 344 
not quercetin 1, naringenin 16, and narigenin-7-O-rutinoside 17 (narirutin) interacted with human 345 
OAT1, but only weakly with OAT3 (Hong, Seo, Lim, & Han, 2007). The first study to examine 346 
flavonoid conjugates such as sulfates and glucuronides, as found in the blood, was conducted by 347 
Wong et al. (2011a, 2011b) who showed that flavonoid metabolites as present in plasma could be 348 
taken up into cells via OAT transporters, and that the transporters were quite specific for the class 349 
of flavonoid, its conjugated group and conjugation position. The specific roles of OAT transporters in 350 
flavonoid bioavailability are shown in Figure 1.     Insert Structures 11-17 351 
 352 
Bioavailability 353 
Attention will focus on key aspects of flavonoid bioavailability studies with humans. 354 
Investigations with animals can be helpful, but because of differences in endogenous metabolism 355 
and gut microflora, they can produce data that are difficult to apply to human studies (see Borges, 356 
van der Hooft, & Crozier, 2016).  Human studies are the gold standard and typically involve acute 357 
ingestion of food or a beverage by volunteers who have been on a low-(poly)phenol diet for ~2 days. 358 
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Investigations have utilized individuals with an intact colon and ileostomists who have had their 359 
colon removed surgically, supported by analysis of plasma, urine and, ileal effluent.  Studies with 360 
ileostomists have helped distinguish transformations occurring in the upper GI tract from those 361 
associated within the colon, and in this regard are especially useful when parallel studies are carried 362 
out in which flavonoids, known to pass from the small to the large intestine, are incubated under 363 
anaerobic conditions with feces and fecal bacteria.   364 
 365 
Flavonols 366 
Pioneering research on flavonols by Hollman and colleagues in The Netherlands produced a series 367 
of papers on the bioavailability of quercetin glycosides, in the form of quercetin-3,4′-O-diglucoside 368 
18 and quercetin-4′-O-glucoside 19, which occur in especially high concentrations in onions, along 369 
with small amounts of other flavonols such as isorhamnetin-4'-O-glucoside 20. Quercetin 1 itself 370 
enters the circulatory system, at best, in only trace amounts, and instead appears predominantly as 371 
phase II glucuronide, sulfate, and methyl metabolites (Crozier, Del Rio, & Clifford, 2010). At the time 372 
of the initial bioavailability investigations, standards of quercetin metabolites were unavailable and 373 
so samples of biofluids were subjected to the acid hydrolysis procedures developed by Hertog et al. 374 
(1992), in order to release the quercetin aglycone. The levels found, compared to the amounts found 375 
in most fruits and vegetables were extremely low, so to facilitate detection HPLC was used with 376 
post-column chelation with aluminum.  This produced fluorescent derivatives which could be 377 
detected in 300-fold lower quantities than absorbance detection (Hollman, van Trijp, & Buysman, 378 
1996).  [Insert Structures 18-20] 379 
The first study using this method of analysis involved feeding fried onions, quercetin-3-O-380 
rutinoside 13, and quercetin 1 to volunteers with an ileostomy (Hollman, de Vries, van Leeuwen, 381 
Mengelers, & Katan, 1995). In vitro incubation with gastrointestinal fluids resulted in minimal 382 
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breakdown. Absorption of quercetin, defined by Hollman et al. (1995) as oral intake minus 383 
excretion in ileal fluid, was 52% for the onion quercetin glucosides, 17% for quercetin-3-O-384 
rutinoside and 24% for quercetin aglycone. It was concluded that humans absorb substantial 385 
amounts of quercetin and that absorption is enhanced by conjugation with glucose, but not the 386 
disaccharide rutinose.  387 
A further paper reported a study in which volunteers with a functioning colon ingested fried 388 
onions containing 212 µmol of quercetin glucosides after which plasma was collected. HPLC analysis 389 
of the acid hydrolyzed plasma revealed the presence of quercetin with a peak plasma concentration 390 
(Cmax) of 649 nmol/L that was attained 2.9 h (Tmax) after ingestion (Hollman et al., 1996). A number 391 
of other studies carried out over the intervening years established that the sugar moiety was the 392 
major determining factor influencing the absorption of flavonol glycosides. Conjugated quercetin 393 
appearing in the plasma after intake of quercetin monoglucosides had a Cmax ~10-fold higher than 394 
after ingestion of quercetin-3-O-rutinoside (Hollman et al., 1999), while the Tmax after quercetin-3-O-395 
rutinoside ingestion was ~6-7 h compared to ≤1 h for the monoglucosides (Erlund et al., 2000; 396 
Graefe et al., 2001; Moon, Nakata, Oshima, Inakuma, & Terao, 2000; Olthof, Hollman, Vree, & Katan, 397 
2000). These findings suggested that the metabolites of quercetin monoglucosides are absorbed in 398 
the proximal GI tract, while those derived from the rutinoside are absorbed in the colon.   399 
At this juncture the identities of the quercetin conjugates in plasma were not known, although 400 
there was one report based on HPLC with diode array detection of the presence of 400-600 nmol/L 401 
concentrations of quercetin-3-O-rutinoside and several quercetin glycosides in the circulatory 402 
system of two non-supplemented volunteers (Paganga and Rice-Evans 1997).  In addition, Mauri et 403 
al. (1999) used HPLC-MS to identify and quantify seemingly high amounts of quercetin-3-O-404 
rutinoside (up to 300 nmol/L) in plasma following the daily ingestion of tomato puree for a period 405 
of 14 days. Neither of these early reports has been supported by subsequent investigations. 406 
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The results of a more detailed feeding study were reported by Aziz, Edwards, Lean, & Crozier 407 
(1998) in which, following the ingestion of lightly fried onions, plasma, and urine samples were 408 
collected at a range of time points over a 24-h period.  The samples were analysed, both before and 409 
after acid hydrolysis, by HPLC using the post-column chelation procedure of Hollman et al. (1996). 410 
Analysis of hydrolyzed samples showed a plasma Cmax of conjugated quercetin of 1.3 µmol/L and a 411 
Tmax of 1.9 h, while 0-24 h urinary excretion was equivalent to 0.8% of the ingestion quercetin 412 
glycosides.  Analysis of samples prior to hydrolysis identified and quantified fluorescent HPLC peaks 413 
which co-chromatographed with quercetin-4'-O-glucoside and isorhamnetin-4'-O-glucoside. 414 
However, subsequent research revealed these were misidentifications and that the compounds 415 
involved were almost certainly glucuronides for which reference compounds were not available at 416 
the time. 417 
Using a mixture of undefined quercetin glucuronides as reference compounds both Sesink, 418 
O’Leary, & Hollman (2001) and Wittig, Herderich, Graefe, & Veit (2001)  provided evidence for the 419 
accumulation of five quercetin-O-glucuronides in plasma after the ingestion of quercetin-O-420 
glucosides. The key breakthrough, however, came with the study of Day et al. (2001) which, with the 421 
use of fully characterized quercetin and isorhamnetin metabolites, identified quercetin-3-O-422 
glucuronide 21, quercetin-3'-sulfate 22, and isorhamnetin-3-O-glucuronide 23 in plasma collected 423 
1.5 h after the ingestion of an onion supplement. [Insert Structures 21-24] 424 
Later, having been given access to these reference compounds along with quercetin-3’-O-425 
glucuronide 24, Mullen, Edwards, & Crozier (2006) used HPLC-MS2 to analyze flavonol metabolites 426 
appearing in plasma and urine 0-24 h after the ingestion of 270 g of lightly fried onions by four male 427 
and two female volunteers. The onion supplement containing quercetin-3',4'-O-diglucoside 18 (107 428 
µmol),  quercetin-4'-O-glucoside 19 (143 µmol), and 275 µmol of  isorhamnetin-4'-O-glucoside 20 429 
(11) µmol)  which accounted for 95% of the 275 µmol flavonol intake. The plasma profiles of the 430 
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five main metabolites, quercetin-3-O-glucuronide, quercetin-3'-sulfate, and isorhamnetin-3-O-431 
glucuronide along with two partially identified metabolites, a quercetin-O-glucuronide-sulfate and a 432 
quercetin-O-diglucuronide1 are illustrated in Figure 2.  Table 1 contains details of a pharmacokinetic 433 
analysis with information on Cmax, Tmax and the apparent elimination half-life (AT1/2). It should be 434 
noted that true T1/2 values can only be determined by intravenous dosing of metabolites. Estimates 435 
based on elimination after oral intake overestimate the true T1/2  because the metabolite is still 436 
entering the circulatory systems when the elimination is being estimated.  437 
The two major metabolites, quercetin-3'-sulfate (Cmax – 665 nmol/L) and quercetin-3-O-438 
glucuronide (Cmax – 351 nmol/L) appeared in plasma within 30 min of onion intake, both had Tmax 439 
values of under 1 h and AT1/2 values of 1.7 and 2.3 h, respectively (Figure 2, Table 1) (Mullen et al., 440 
2006). The quercetin-O-diglucuronide had a lower Cmax and similar Tmax and AT1/2 values. The 441 
pharmacokinetic profiles of isorhamnetin-3-O-glucuronide and the quercetin-O-glucuronide-442 
sulfate were somewhat different in that both had a much longer AT1/2,while the sulfated 443 
glucuronide also had a much delayed ATmax (Table 1). However, the total contribution of these two 444 
compounds to the overall absorption profile was minimal, having no effect on the overall Tmax and 445 
only extending the AT1/2 to 2.6 h. This AT1/2 is much shorter than values obtained in earlier flavonol 446 
absorption studies which is almost certainly a consequence of the enhanced accuracy of analytical 447 
data obtained with HPLC-MS2. 448 
The data obtained by Mullen et al. (2006) indicated absorption in the proximal part of the 449 
small intestine. However, it provided no information on the mechanisms involved or the efficiency 450 
                                                        
1 The availability of reference compounds enables specific metabolites to be identified by HPLC-MS2 and MS3.  
In the absence of standards it is not possible to distinguish between isomers and to ascertain the position of 
conjugating groups on the flavonoid skeleton.  Thus, the quercetin-O-diglucuronide and the quercetin-O-
glucuronide-sulfate, along with other metabolites detected in the onion study, could only be partially 
identified on the basis of their MS fragmentation pattern.  Nonetheless, the use of MS in this way represents a 
useful HPLC detection system, as with low ng limits of detection it provides structural information on analytes 
of interest that is not obtained with absorbance, fluorescence, or electrochemical detectors. 
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with which quercetin-3',4'-O-diglucoside 18 and quercetin-4'-O-glucoside 19 are hydrolyzed and 451 
the resultant aglycone transported into the enterocyte. On the basis of the plasma metabolite 452 
profile, it is evident that following the release of the aglycone, quercetin is subjected to sulfation, 453 
glucuronidation, and possibly methylation.  Arguably, the short Tmax times of quercetin-3-O-454 
glucuronide, quercetin-3'-sulfate, and the quercetin-O-diglucuronide are indicative of sulfation and 455 
glucuronidation taking place in enterocytes prior to passage of the metabolites into the circulatory 456 
system.  The longer plasma Tmax  of isorhamnetin-3-O-glucuronide, arguably, could reflect post-457 
absorption 3'-O-methylation of quercetin-3-O-glucuronide in the liver. Potential routes for the 458 
formation of the fully identified metabolites are illustrated in Figure 3. 459 
Jaganath, Mullen, Lean, Edwards, & Crozier (2006) carried out a parallel feeding study in 460 
which volunteers ingested 250 mL tomato juice containing 176 μmol of the rhamnose-glucose 461 
conjugate, quercetin-3-O-rutinoside. In this instance, only two metabolites were detected in 462 
plasma, quercetin-3-O-glucuronide and isorhamnetin-3-O-glucuronide (Figure 4). They were 463 
present in ~25-fold lower quantities than in the onion study with respective Cmax values of 12 and 464 
4.3 nmol/L.  The Tmax times were extended to ~ 5 h (Table 2) indicating absorption in the lower 465 
bowel rather than the small intestine. A total of nine methylated and glucuronidated quercetin 466 
metabolites were detected in urine, but some volunteers excreted only 3-4 metabolites.  The 467 
overall 0-24 h urinary excretion of metabolites ranged from 0.02 to 2.8 % of quercetin-3-O-468 
rutinoside intake, which is probably a reflection of variations in the colonic microflora of the 469 
individual volunteers (Jaganath et al., 2006).   470 
Confirmation of large intestine absorption was obtained using ileostomists in a study by 471 
Jaganath, Mullen, Lean, Edwards, & Crozier (2009).  Unlike the volunteers with a functioning colon, 472 
neither plasma nor urinary metabolites were detected, and ileal fluid, collected after tomato juice 473 
consumption, contained 86 % of the ingested quercetin-3-O-rutinoside. Urine collected from the 474 
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ileostomy volunteers did not contain quercetin metabolites and also lacked the phenolic acid 475 
catabolites 3',4'-dihydroxyphenylacetic acid 25, 3'-hydroxyphenylacetic acid 26, and 3'-methoxy-476 
4'-hydroxyphenylacetic acid 27.  [Insert Structures 25-27] These catabolites were present in the 477 
urine of the volunteers with a functioning colon in quantities corresponding to 22% of quercetin-478 
3-O-rutinoside intake, having probably originated from colonic bacteria-mediated deglycosylation 479 
of the rutinoside, and ring fission of the released aglycone followed by the conversions illustrated 480 
in Figure 5. In vitro fecal incubations of quercetin-3-O-rutinoside and [4- 14C]quercetin revealed 481 
other potential conversions, as shown in Figure 5, with the formation of  hydroxybenzoic acids.  482 
Although excreted in urine after ingestion of tomato juice containing quercetin-3-O-rutinoside, 3'-483 
methoxy-4'-hydroxyphenylacetic acid was not a product of fecal-mediated quercetin degradation. 484 
This implies that its formation involves mammalian enzymes with 3'-methylation of 3',4'-485 
dihydroxyphenylacetic acid 25 potentially taking place in colonocytes and/or the liver  486 
Despite it being almost 10 years since these HPLC-MS-based studies on the bioavailability 487 
of onion- and tomato-derived flavonols were reported, there have been few subsequent new 488 
developments.  However, there have been substantial advances in our knowledge of the 489 
bioavailability of other dietary flavonoids including increasing information on microbiota-490 
mediated events occurring in the GI tract. This recent research with other flavonoids suggests that 491 
the quercetin degradation pathways illustrated in Figure 5 are almost certainly an over-492 
simplification of the potential conversions involved. 493 
 494 
Flavan-3-ols 495 
Early research with (+)-catechin   496 
Early research into the bioavailability of the flavan-3-ol (+)-catechin 28 was reported in a series 497 
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of papers originating from the University of Singapore and the University of Birmingham in the UK 498 
(see Das, 1971, 1974; Griffith, 1964; Hackett, & Griffith, 1981, 1983; Hacket, Griffith, Broillet, & 499 
Wermeille, 1983; Hackett, Griffith, & Wermeille, 1985; Hackett, Shaw, & Griffith, 1982; Shaw, 500 
Hackett, & Griffith, 1982).  Much of this research was funded by the Swiss pharmaceutical company 501 
Zyma SA, and it was not related to nutrition but to the possible use of high doses of (+)-catechin as a 502 
drug to protect against hepatitis.  Despite the analyses being based mainly on paper 503 
chromatography and reagent color reactions, numerous (+)-catechin-derived products were 504 
identified. These identifications, as summarized by Das (1974), are presented in Table 3. It would be 505 
more than 20 years later before these microbial-derived catabolites were identified in nutrition-506 
based bioavailability studies. Insert Structures 28-37 507 
 508 
(–)-Epicatechin 509 
(–)-Epicatechin 38 itself enters the circulatory system, at best, in trace amounts and, like 510 
quercetin, appears predominantly as phase II glucuronide, sulfate, and methyl metabolites (Crozier, 511 
2013; Crozier, Del Rio, & Clifford, 2010; Ottaviani et al., 2016). At the time of the initial 512 
bioavailability investigations reference compounds of (−)-epicatechin metabolites were unavailable, 513 
so human studies on the post-ingestion fate of cocoa-based products treated plasma and urine 514 
samples with mollusc β-glucuronidase/sulfatase prior to the analysis of the released (−)-epicatechin 515 
by reverse-phase HPLC, typically with fluorescence (Richelle, Tavazzi, Enslen, & Offord, 1999) or 516 
electrochemical detection (Rein et al., 2000; Wang et al., 2000).  With this methodology, Richelle et 517 
al. (1999) showed that following the consumption of 40 g of dark chocolate containing 282 µmol of 518 
(–)-epicatechin, the epicatechin plasma levels rose rapidly and reached a Cmax of 355 nmol/L after 519 
2.0 h with an AT½ of 1.9 h.  520 
β-Glucuronidase/sulfatase treatment of samples in such studies was convenient as a number of 521 
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metabolites are converted to a single product, (–)-epicatechin, thus simplifying the subsequent 522 
quantitative analysis. However, as with flavonols, which were converted to their aglycones by acid 523 
hydrolysis, relatively little is known about the individual metabolites present prior to enzyme 524 
treatment. A further limitation that has become apparent is that β-glucuronidase/sulfatase 525 
preparations fail to fully hydrolyze most (−)-epicatechin-sulfates and methyl-(−)-epicatechin 526 
sulfates and, as a consequence, (−)-epicatechin bioavailability is underestimated (Saha et al., 2012). 527 
This problem has been largely overcome with the increasing use of HPLC-MS alongside the 528 
development of methods for the synthesis of a range structurally related (−)-epicatechin 529 
metabolites (SREMs) (Mull et al., 2012; Zhang et al. 2013a, 2013b) as well as 5C-ring fission 530 
metabolites (5C-RFMs) such a 5-(hydroxyphenyl)-γ-valerolactones and their phase II metabolites 531 
(Brindani et al. 2017; Curti et al. 2015; Lambert, Rice, Hong, Hou, & Yang, 2005; Sánchez-Patán et al. 532 
2011). Although detected earlier in the Singapore/Birmingham studies with (+)-catechin (Table 3), 533 
5C-RFMs were also identified, albeit almost three decades later, in blood and urine collected after 534 
green tea consumption (Li et al., 2000, 2001). 535 
 536 
Identification of (−)-epicatechin metabolites 537 
Ottaviani, Momma, Kuhnle, Keen, & Schroeter (2012) fed volunteers a cocoa-based drink which, 538 
when consumed by a 75-kg subject, contained 476 µmol of (−)-epicatechin 38 and 66 µmol of a 539 
mixture of (+)-catechin 28 and (−)-catechin 39, and through the use of reference compounds the 540 
investigators were able to identify and quantify SREMs in human plasma, all of which attained Cmax 2 541 
h after cocoa intake, indicative of absorption in the small intestine. The main metabolite was (−)-542 
epicatchin-3'-O-glucuronide 40 (Cmax 589 nmol/L). The main sulfated SREM was (−)-epicatchin-3'-543 
sulfate 41 (Cmax 331 nmol/L), together with lower amounts of (−)-epicatchin-5-sulfate 42 (Cmax  37 544 
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nmol/L) and (−)-epicatchin-7-sulfate 43 (Cmax  12 nmol/L). Among the other SREMs detected in low 545 
concentrations were 4'-O-methyl-(−)-epicatchin-7-O-glucuronide 44, and a number of methylated 546 
sulfates.  [Insert Structures 38-45] 547 
Actis-Gorreta et al. (2012) also identified and quantified an array of SREMs in plasma after the 548 
ingestion of 100 g dark chocolate containing 241 µmol of (−)-epicatechin and 90 µmol of (±)-549 
catechin. Once again the main metabolites were (−)-epicatchin-3'-O-glucuronide (Cmax 290 nmol/L) 550 
and (−)-epicatechin-3'-sulfate (Cmax 233 nmol/L). The Cmax of the metabolites was reached after ~3 h 551 
rather than 2 h after intake, presumably reflecting matrix differences between the cocoa drink and 552 
the dark chocolate. In this study, urine was collected 0-24 h after supplementation and the overall 553 
excretion of SREMs was 55.7 μmol, which is equivalent to 20.1% of the ingested (−)-epicatechin 554 
which, when considering the different analytical strategies utilized, is broadly in line with urinary 555 
recoveries in earlier cocoa-based feeding studies (Baba et al., 2000; Mullen et al., 2009). 556 
 557 
Epicatechin stereochemistry and bioavailability 558 
Ottaviani et al. (2012) also investigated the impact of flavan-3-ol stereochemistry on the plasma 559 
SREM profile after volunteers ingested (−)-epicatechin 38 and (+)-epicatechin 45. This revealed 560 
that epicatechin-3′-O-glucuronide was the sole glucuronidated metabolite to be detected in plasma 561 
regardless of the enantiomer consumed, but the Cmax was 336 nmol/L after (−)-epicatechin intake 562 
and only 13 nmol/L after ingestion of the (+) enantiomer.  There was a similar trend with the Cmax of 563 
epicatechin-3′-sulfate which was ~4-fold higher after (−)-epicatechin consumption. In contrast, 564 
epicatechin-5-sulfate reached a Cmax of 50 nmol/L after (−)-epicatechin intake and 270 nmol/L 565 
following (+)-epicatechin ingestion, a 5-fold difference in favor of the (+) enantiomer (Figure 6). 566 
Thus, the concentrations and the relative amounts of individual glucuronide and sulfate metabolites 567 
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were dependent on the stereochemical configuration of the epicatechin ingested.   568 
In an earlier study equal quantities of (–)-epicatechin (38), (+)-epicatechin (45) (+)-catechin 569 
(28) and (–)-catechin (39) were consumed in a cocoa drink (Ottaviani et al., 2011). Based on plasma 570 
concentrations and urinary excretion obtained using enzyme hydrolysis, the bioavailability of the 571 
stereoisomers was ranked as (–)-epicatechin > (+)-epicatechin = (+)-catechin > (–)-catechin. There 572 
were also differences in the metabolic fate of the catechin and epicatechin epimers as reflected in 573 
the ratios of their 3'- and 4'-O-methylated metabolites.  Thus, stereochemistry ihas an effect on 574 
phase II methylation as well as sulfation and glucuronidation of flavan-3-ol monomers. As the 575 
individual flavan-3-ol stereoisomers in cocoa products used in feeding studies are usually not fully 576 
determined, this finding raises the possibility that varying stereochemical ratios could be a 577 
contributing factor in the differing metabolite profiles reported across research groups (Actis-578 
Goretta et al. 2012; Mullen et al. 2009; Ottaviani et al. 2012; Roura et al. 2005; Tomás-Barberán et al. 579 
2007;). 580 
 581 
Use of the Loc-I-gut intestinal perfusion technique  582 
Actis-Goretta et al. (2013) carried out a novel study on (−)-epicatechin bioavailability using 583 
a Loc-I-gut intestinal perfusion technique previously employed to study certain aspects of drug 584 
metabolism (Dahan, Lennernäs, & Amidon, 2012).  A multilumen perfusion catheter was introduced 585 
into the small intestine and three balloons inflated to isolate two 20-cm sections of the jejunum. The 586 
upper balloon was positioned ~20 cm below the papilla of Vater.  As a consequence, when (−)-587 
epicatechin was introduced into the proximal and distal segments of the catheter, this enabled 588 
biliary excretion of flavan-3-ols to be monitored by analysis of perfusates collected from the lumen 589 
above the upper balloon. 590 
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Utilizing six volunteers, 50 mg (172 µmol) of (−)-epicatechin was introduced into isolated 591 
jejunum sections, which were then perfused for 2.5 h.  An average of 23.4 mg of unchanged (−)-592 
epicatechin was recovered along with 0.84 mg of metabolites, indicative of low-level efflux of 593 
metabolites formed in the enterocytes back into the lumen of the jejunum.  This implies that ~50% 594 
of the administered (−)-epicatechin was absorbed into the systemic circulation. (−)-Epicatechin 595 
metabolites reached sub-µmol/L peak plasma concentrations 1 h after the initiation of perfusion.  596 
Urinary excretion of metabolites by the individual volunteers ranged from 2.4 to11.8% of the 597 
amount of perfused (−)-epicatechin, which is somewhat lower than the urinary excretion of 20.1% 598 
of the ingested dose obtained when the same investigators fed chocolate to volunteers (Actis-599 
Goretta et al., 2012). Arguably, this reflects the fact that absorption in the perfusion model occurred 600 
in a 20-cm section of the jejunum compared to that occurring during passage through the full ~6 601 
meter length of the small intestine following ingestion. 602 
Actis-Goretta et al. (2013) observed that the main metabolite effluxing back into the lumen 603 
of the jejunum was  (–)-epicatechin-3'-sulfate, while (–)-epicatechin-3'-O-glucuronide was present in 604 
higher amounts in plasma and urine. This suggests that the sulfate formed in enterocytes is 605 
preferentially effluxed back into the lumen of the jejunum, while (–)-epicatechin-3'-glucuronide is 606 
absorbed into the circulatory system to a greater extent.  This observation is in line with studies in 607 
which ileostomists ingested either green tea (Stalmach et al., 2010), Concord grape juice (Stalmach, 608 
Edwards, Wightman, & Crozier, 2012), or a (poly)phenol-rich drink (Borges, Lean, Roberts, & 609 
Crozier, 2013) in the course of which ~90% of the (–)-epicatechin recovered in ileal fluid was 610 
sulfated.  611 
A further aspect of the study of Actis-Goretta et al. (2013) is that the use of the perfusion 612 
model enabled enterohepatic recirculation of (–)-epicatechin to be directly determined in humans 613 
for the first time.  Over the 2.5 h-perfusion period, 2.6-18.4 µg of metabolites were excreted in the 614 
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bile of individual volunteers. This is equivalent to 0.005-0.04% of the perfused (–)-epicatechin, 615 
demonstrating that enterohepatic recirculation of metabolites of the flavan-3-ol is, at best, a minor 616 
event, assuming that the perfusion model is adequate for drawing conclusions in the context of 617 
dietary intake under life-like conditions.  618 
 619 
Impact of theobromine on (−)-epicatechin absorption 620 
A recent study with cocoa revealed that the Cmax of SREMs 2 h after intake of cocoa was 621 
enhanced significantly by co-ingestion of the purine alkaloid, theobromine 46, in parallel with an 622 
accompanying significant increase in flow-mediated vasodilation (Sansome et al., 2017). The 623 
mechanism by which theobromine mediates an increased plasma concentration of SREMs remains 624 
to be determined. The study does, however, suggest that matrix effects with other components may 625 
well have an impact on the absorption of not just flavan-3-ols, but also on other flavonoids and 626 
(poly)phenols when they are consumed in foods as part of a regular, daily diet.  [insert structure 627 
46] 628 
 629 
Bioavailability of [2-14C](−)-epicatechin  630 
There are reports of a feeding study that was carried out using the radiolabeled flavan-3-ol, [2-631 
14C](−)-epicatechin ([14C]EC) (Ottaviani, et al., 2016; Borges, Ottaviani, van der Hooft, Schroeter, & 632 
Crozier, 2017).  Eight male volunteers each ingested a drink containing 300 μCi (207 μmol) of 633 
[14C]EC after which blood samples were obtained at intervals over a 48-h period.  All urine excreted 634 
and feces voided over a 72-h period were collected or until total excreted radioactivity was <1.0% of 635 
the administered dose over two consecutive 24-h periods. The use of a radiolabeled substrate and 636 
analysis of samples in the first instance by liquid scintillation counting and, subsequently, by HPLC-637 
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MS2 in combination with an on-line radioactivity detector (RC) provided a wealth of novel data 638 
pertaining to the bioavailability of (−)-epicatechin. 639 
 640 
Recovery of radioactivity in urine, feces, and plasma 641 
Analysis of blood revealed that radioactivity was associated almost exclusively with plasma 642 
rather than red blood cells. The levels of radioactivity in plasma, on the basis of each subject having 643 
a total volume of 3 L of plasma, were used to assess passage through the circulatory system, and this 644 
is illustrated in Figure 7. The profile is biphasic with maxima at 1 h and 6 h. The total radioactivity in 645 
plasma never exceeded 2% of intake, although ~0.2% of intake, presumably derived from colonic 646 
absorption, was still present 24 h after ingestion. The 0-48 h recovery of 14C in feces and urine was 647 
91.6 ± 1.3% of the ingested [14C]EC indicating that tissue deposition of compounds derived from 648 
acute intake of the flavan-3-ol was <10%.  649 
 650 
Pharmacokinetics of plasma metabolites 651 
A total of 12 (–)-epicatechin sulfate, glucuronide, and methyl metabolites were detected in 652 
plasma in nmol/L concentrations, namely: (–)-epicatechin-3'-O-glucuronide 40, (–)-epicatechin-7-653 
O-glucuronide 47,  (–)-epicatechin-3'-sulfate 41, (–)-epicatechin-5-sulfate 42, (–)-epicatechin-7-654 
sulfate 43, 3'-O-methyl-(–)-epicatechin-4'-sulfate 48, 3'-O-methyl-(–)-epicatechin-5-sulfate 49, 3'-O-655 
methyl-(–)-epicatechin-7-sulfate 50, 4'-O-methyl-(–)-epicatechin-5-sulfate 51, 4'-O-methyl-(–)-656 
epicatechin-7-sulfate 52, 3'-O-methyl-(–)-epicatechin-5-O-glucuronide 53, and 3’-O-methyl-(–)-657 
epicatechin-7-O-glucuronide 54.  [Insert Structures 47-54]  As illustrated in Figs. 8A and 8B, all the 658 
SREMs had a Tmax of ~1.0 h, indicative of absorption in the proximal GI tract.  Several of the 659 
metabolites were detected in plasma 30 min after (–)-epicatechin ingestion with a mean 660 
concentration of 854 nmol/L (Table 4).  After attaining an overall Cmax, of 1223 nmol/L, 1.0 h after 661 
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[14C]EC intake the SREMs declined rapidly with an AT1/2  of 1.9 h (Table 4), and in almost all 662 
instances had disappeared from the circulatory system within 8 h (Figure 8A and 8B).  663 
 664 
 5C-RFMs were also detected in plasma but with different pharmacokinetic profiles and Tmax 665 
times of ~6 h, which is characteristic of colon-derived products (Table 4, Figure 8C).  The main 666 
catabolites were 5-(4'–hydroxyphenyl)-γ-valerolactone-3'-sulfate 55 (Cmax 272 nmol/L) and 5-(4'–667 
hydroxyphenyl)-γ-valerolactone-3'-O-glucuronide 56 (Cmax 125 nmol/L). Lower concentrations of 668 
other 5C-RFMs were also detected, namely 5-(3'–hydroxyphenyl)-γ-valerolactone-4'-O-glucuronide 669 
57 (52 nmol/L), two 5-(phenyl)-γ-valerolactone-O-glucuronide-sulfates (39 nmol/L), and three 5-670 
(hydroxyphenyl)-γ-hydroxyvaleric acid derivatives, which had a combined Cmax of 95 nmol/L 671 
(Figure 8C). The combined Cmax of the 5C-RFMs was 588 nmol/L and their ATmax was 5.8 h. They 672 
were retained in the circulatory systems for longer than the SREMs with an AT1/2 of 5.7 h, and they 673 
also had an area-under-the-curve concentration ~3-fold higher than that of the SREMs (Table 4). 674 
The main 5C-RFM, 5-(4'–hydroxyphenyl)-γ-valerolactone-3'-sulfate, was still present in plasma, at a 675 
concentration of ~50 nmol/L, 24 h after (–)-epicatechin ingestion (Figure 8C).  [Insert Structures 676 
55-57] 677 
 678 
Urinary metabolites 679 
The main urinary SREM, as in plasma, was (–)-epicatechin-3'-O-glucuronide, along with (–)-680 
epicatechin-3'-sulfate and 3'-O-methyl-(–)-epicatechin-5-sulfate. These compounds, together with 681 
related SREMs, were excreted mainly in the initial 0-4 h collection period with relatively small 682 
amounts in urine collected over later time periods (Table 5), in keeping with the plasma 683 
pharmacokinetic profiles (Figs. 8A and 8B). 684 
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The 5C-RFMs were excreted later, mainly over the 4-8 h, 8-12 h, and 12-24 h collection 685 
periods (Table 5), which again is in line with their plasma pharmacokinetic profiles (Figure 8C). As 686 
far as 2/3C-RFMs are concerned, excretion of 14C-labeled 3-(3’-hydroxyphenyl)hydracrylic acid 37  687 
continued more than 24 h after ingestion of [14C]EC, as did excretion of radiolabeled hippuric acid 688 
58 and 3'-hydroxyhippuric acid 33 (Table 5).  [Insert Structure 58] The mean total urinary 689 
excretion of SREMs, 5C-RFMs, 2 and 3 carbon ring-fission metabolites (2/3-RFMs), and hippuric 690 
acids was 185 ± 16 μmol of the ingested radioactivity, a recovery of 89%.  The recovery of 691 
radioactivity as 5C-RFMs was 42% of intake, that of 2/3-RFMs 7%, and hippuric acids 21%. Thus, 692 
recovery of metabolites absorbed in the colon was 70% of the ingested radioactivity, while recovery 693 
of SREMs, absorbed in the small intestine, was 20%  (Table 5). 694 
 695 
Fecal metabolites 696 
Feces did not contain radiolabeled SREMs, but quantifiable amounts of three 5-(phenyl)-γ-697 
valerolactones, five 5-(phenyl)-γ-hydroxyvaleric acids, 3-(3'-hydroxyphenyl)propionic acid, and 698 
three unknown metabolites were detected (Borges et al., 2017).  The metabolite profiles of the 0-72 699 
h feces are presented in Table 6. Although there were large variations in the individual profiles, on 700 
average the main fecal metabolites were 5-(phenyl)-γ-hydroxyvaleric acids (12.3 μmol) followed by 701 
5-(phenyl)-γ-valerolactones (4.8 μmol) and 3-(3'-hydroxyphenyl)propionic acid 32 (3.3 μmol), 702 
along with lower amounts, 0.7 μmol, of three unknown metabolites. The average total recovery of 703 
radioactivity was 10.1% of intake, with individual values ranging from 0% to 15.5%. 704 
 705 
Overview of [2-14C](−)-epicatechin bioavailability 706 
The overall picture obtained is that 20% of the ingested [14C]EC was converted to SREMs 707 
which rapidly entered the circulatory system via the small intestine. As they were excreted via the 708 
kidneys, the SREMs were gradually replaced, over a 24-h period, by 5C-RFMs and 3-(3′-709 
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hydroxyphenyl)hydracrylic acid, absorbed at more distal points in the GI tract, as well as by 710 
hippuric acids, which are hepatic in origin.  The presence of SREMs in plasma within 30 min of 711 
[14C]EC ingestion (Table 4) points to their presence in the systemic circulatory system being 712 
associated with rapid enhancement of flow-mediated dilatation induced by (–)-epicatechin intake 713 
(Schroeter et al., 2006). 714 
The potential main routes for the metabolism that occur in the proximal GI tract after 715 
ingestion of [2-14C]EC are illustrated in Figure 9.  It is of note that an absence of methyl-(−)-716 
epicatechin metabolites which, arguably, indicates that methylation only occurs after prior sulfation 717 
or glucuronidation. Most of the conversions probably take place in enterocytes prior to absorption 718 
into the circulatory system with some post-absorption metabolism possibly occurring in the liver.  719 
A portion of the SREMs formed in enterocytes, most notably (–)-epicatechin-3'-sulfate, efflux 720 
back into the lumen of the small intestine (see Section 3.3.2.3) and then along with unabsorbed 721 
[14]EC pass along the GI tract to the colon in quantities equivalent to ~70% of intake. The flavan-3-722 
ols entering the colon are converted by the microbiota to 5C-RFMs, which remain in the circulatory 723 
system for an extended duration compared to SREMs (Table 4), as sulfate and glucuronide, but not 724 
as methylated metabolites.  725 
Unabsorbed radioactivity voided in 0-72 h feces varied substantially from volunteer to 726 
volunteer, but on average was equivalent to 10.1% of intake (Table 6). With the exception of the 3C-727 
RFM, 3-(3′-hydroxyphenyl)propionic acid, and minor amounts of three unidentified metabolites, the 728 
radioactivity was associated exclusively with di-, mono-, and de-hydroxyvaleric acids and 729 
valerolactones, ~25-30% of which were sulfated (Table 6). The 3’-sulfates potentially could 730 
originate from (−)-epicatechin-3′-sulfate which passed along the GI tract from the small intestine to 731 
the colon, while,  arguably, the two 5C-RFM 4’-sulfates may have been formed in coloncytes and 732 
effluxed back into the lumen of the colon. 733 
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The possible metabolism of [2-14C]EC and (–)-epicatechin-3'-sulfate moving from the small 734 
to the large intestine, where ring fission is followed by phase II metabolism, is illustrated in Figure 735 
10. Although it is feasible that the sulfate moiety remains intact, for simplicity it is assumed that it is 736 
removed by the colonic bacteria releasing (–)-epicatechin. There is evidence that (–)-epicatechin is 737 
subjected to microbiota-induced opening of the C-ring by breaking the O1-C2 bond, yielding a 738 
diaryl-propan-2-ol (Kutschera, Engst, Blaut, & Braune, 2011), followed by opening of the A-ring, 739 
resulting in the formation of 5-(3′,4'-dihydroxyphenyl)-γ-valerolactone, which is further converted 740 
by the microflora to 5-(3′,4'-dihydroxyphenyl)-γ-hydroxyvaleric acid. The 14C-labeled metabolites in 741 
the voided feces suggest that both these dihydroxy-5C-RFMs are dehydroxylated by the colonic 742 
microbiota (Table 6), most, however, is absorbed and converted to sulfate and glucuronide 743 
metabolites by colonoycte and/or hepatic enzymes as illustrated in Figure 10.  744 
Feces, in addition to the 5C-RFMs also contained 3-(3’-hydroxyphenyl)propionic acid 32 745 
(Table 6), a 3C-RFM produced from (−)-epicatechin by in vitro fecal incubations (Roowi et al.  2010), 746 
Its likely immediate precursor is 5-(3′-hydroxyphenyl)-γ-hydroxyvaleric acid 59. The conversion 747 
could be carried out by microbial enzymes although an involvement of β-oxidation by mammalian 748 
enzymes catalyzing the removal of two carbons from the side chain is also feasible. In view of its 749 
accumulation in fecal incubates with (−)-epicatechin, further metabolism of 3-(3’-750 
hydroxyphenyl)propionic acid would appear to involve mammalian enzymes with, potentially, a β-751 
oxidation yielding 3′-hydroxybenzoic acid, which glycination would convert to 3’-hydroxyhippuric 752 
acid,  while  dehydroxylation and glycination would yield hippuric acid (Figure 10). The glycination 753 
step involves hepatic enzymes (Crozier, Clifford, & Del Rio, 2012) and urinary excretion indicated 754 
there was a 21% conversion of the ingested [14C]EC to hippuric acids (Table 5).   [Insert Structures 755 
59-60] 756 
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Radiolabeled 3-(3’-hydroyphenyl)hydracrylic acid 37 was excreted in urine after ingestion 757 
of [14C]EC (Table 5). The origins of this 3C-RFM are unclear. It is not formed in vitro when (−)-758 
epicatechin is incubated with fecal bacteria (Roowi et al., 2010). (Phenyl)hydracrylic acids derived 759 
from the flavanone hesperetin 60 are excreted in urine after orange juice consumption but they are 760 
not in vitro fecal products of hesperetin (Pereira-Caro et al., 2014, 2015a).  3-(3’-761 
Hydroxyphenyl)hydracrylic acid would, therefore, appear to be a microbial product that requires 762 
metabolism by  mammalian enzymes after absorption. 5C-RFMs are products of colon metabolism 763 
of flavan-3-ols, but not hesperetin, which when subjected to ring fission yields 3C-RFMs (Section 764 
3 ?). This suggests that (−)-epicatechin-derived 3-(3’-hydroxyphenyl)hydracrylic acid is produced 765 
by a pathway that does not involve a 5C-RFM intermediate (Figure 10).  766 
The metabolism of [14C]EC in rats (Borges et al., 2016) is very different to that which occurs in 767 
humans (Ottaviani et al., 2016). The main human plasma and urinary SREMs are (−)-epicatechin-3′-768 
O-glucuronide and (−)-epicatechin-3’-sulfate. Neither of these metabolites are detected in rats 769 
where the principal components in plasma and urine are unmetabolized (–)-epicatechin along with 770 
3’-O-methyl-(−)-epicatechin 61, (−)-epicatechin-5-O-glucuronide 62, and 3’-O-methyl-(−)-771 
epicatechin-5-O-glucuronide 53.   [Insert Structures 61-62]  These differences, especially the 772 
absence of (–)-epicatechin and 3’-O-methyl-(–)-epicatechin in the circulatory system of humans, are 773 
of importance in the context of in vivo and ex vivo studies investigating the potential protective 774 
effects and underlying modes of action of dietary flavan-3-ols.  The current paradigm is that not only 775 
should appropriate physiological doses be used, but also that metabolites to which the cells would 776 
be exposed in vivo should be utilized.  This is in line with the complete lack of correlation between 777 
human and animal drug bioavailability, suggesting animal models are not appropriate to make the 778 
types of assumptions we tend to be making these days (Musther, Olivares-Morales, Hatley, Lui, & 779 
Hodjegan, 2014). 780 
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The use of a radiolabeled substrate in both the rat and human studies enabled very 781 
comprehensive metabolomic profiles of (–)-epicatechin to be obtained. HPLC-RC-MS analysis 782 
produces data that are more reliably interpreted than those generated by feeds with unlabelled 783 
substrates, irrespective of whether a targeted or an untargeted analytical strategy is employed.  784 
Now that an overall picture of (−)-epicatechin metabolism has been obtained, further elucidation of 785 
the complex pathways associated with intestinal microbial and subsequent phase II metabolism 786 
leading to the formation of 5C-RFMs, 3/2C-RFMs, hippuric acids, and other phenolics will 787 
necessitate the use of stable isotope-labelled intermediates and analysis with HPLC and high-788 
resolution mass spectrometry.  789 
 790 
Do (–)-epicatechin metabolites reach the brain? 791 
In the study by Borges et al. (2016) 1 x 103 dpm of radioactivity, corresponding to 29 pmol of 792 
flavan-3-ols, was detected in the saline-perfused brains of rats at 1, 3, 6, and 9 h after [14C]EC intake. 793 
The mean fresh weight of the rat brain was 1.9 g, so the concentration of radiolabeled compounds 794 
was 15.2 pmol/g.  With the volume of each brain at ~1.5 mL, the concentration of radioactivity in 795 
the brain is ~19 nM.  In a study in which a mixture of (+)-catechin and (−)-epicatechin, derived from 796 
a grape extract, was fed to rats at 17 mg/kg, compared to the 1.21 mg (−)-epicatechin/kg in the 797 
Borges et al. (2016) study, low, unquantifiable amounts of metabolites were detected in the brain 798 
after acute intake (Wang et al. 2012). However, after 10 days of chronic supplementation, plasma 799 
metabolite levels increased substantially and the brain contained trace amounts of unmetabolized 800 
(−)-epicatechin and ~363 pmol/g of a mixture of an (−)-epicatechin-O-glucuronide, presumably (−)-801 
epicatechin-5-O-glucuronide, and 3′-O-methyl-(−)-epicatechin-5-O-glucuronide (Wang et al., 2012).  802 
This corresponds to a concentration of ~484 nM and potentially could be higher, if 5C-RFCs, which 803 
were not analyzed, were also present. Nonetheless, based on the very few studies that investigated 804 
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this question, (−)-epicatechin metabolites seem to be present in the brain of rodents at levels that 805 
offer the possibility of being of physiological relevance, such as in animal models of Alzheimer’s 806 
disease, where the grape flavan-3-ol monomer extract has been shown to improve cognitive 807 
function (Wang et al., 2012). 808 
 809 
Biomarkers of flavan-3-ol consumption  810 
There currently exist several limitations with epidemiological studies into the potential health 811 
benefits of dietary flavonoids. In most investigations intake is assessed by combining self-reported 812 
information on diet with food composition flavonoid databases in order to generate insights on 813 
intake. There is doubt about the reliability of self-reported dietary assessments, as well as the merits 814 
of food composition databases, with regard to the accuracy the flavonoid content of fruits, 815 
vegetables, and beverages, which in practice can fluctuate enormously because of local growing 816 
conditions, in addition to seasonal and varietal differences (Rodrigues-Mateos et al., 2014c). As 817 
more is learnt about flavonoid bioavailability, these limitations can be overcome, resulting in 818 
improvements in the interpretation of epidemiological data, through the use of plasma and/or 819 
urinary flavonoid metabolites as more objective measures of flavonoid intake (Kuhnle, 2017) 820 
In this context it is of note that following (–)-epicatechin intake, microbial-derived 5-821 
(hydroxyphenyl)-γ-valerolactone and hydroxyphenylvaleric acid sulfate and glucuronide 822 
metabolites began to appear in the circulatory system after 2 h and that 5-(4'-hydroxyphenyl)-γ-823 
valerolactone-3'-sulfate was still present, albeit in reduced amounts, 22 h later as shown in Figure 824 
8C.  The substantial amounts of these 5C-RFMs that appear in urine over the same period (Table 5) 825 
indicate that the plasma pools are being continually turned over, being replenished by absorption 826 
from the colon which is counter balanced by removal via urinary excretion.  Thus, regular 827 
consumption of products containing (–)-epicatechin, such as cocoa, teas, red wine, apples, plums and 828 
Page 38 of 257Comprehensive Reviews in Food Science and Food Safety
 37
berries, is likely to result, not just in the transient appearance of SREMs in the circulatory system, 829 
but in the more long-term presence of 5C-RFMs, albeit at sub-µmol/L concentrations.  Thus, in 830 
epidemiological studies, 5-(4'-hydroxyphenyl)-γ-valerolactone-3'-sulfate 55 and 5-(4'-831 
hydroxyphenyl)-γ-valerolactone-3'-O-glucuronide 56, the principal 5C-RFMs in both plasma and 832 
urine, could serve as key biomarkers of (–)-epicatechin intake (Ottaviani et al., 2016).  In this regard 833 
it is of note that 5C-RFMs are also derived from catechins and gallocatechins, such as (−)-834 
epigallocatechin-3-O-gallate 12, which occur in tea (van der Hooft et al. 2012).  Furthermore, 5C-835 
RFMs also originate to some degree from colonic catabolism of procyanidins (Appeldoorn, Vincken, 836 
Aura, Hollman, & Gruppen, 2009; Stoupi, Williamson, Drynan, Barron, & Clifford, 2010), but they 837 
appear not to be formed from theaflavins, and presumably thearubigins, after the ingestion of black 838 
tea (Pereira-Caro et al., 2017). 839 
 840 
Anthocyanins  841 
Progress of research since 1997  842 
Moderate to high anthocyanin intakes are reported in those who regularly consume berries 843 
and red grapes and their derived juices, red apples, plums, red cabbage, or red wine. Early reports 844 
identified the presence of unmetabolized anthocyanins in plasma (Paganga, & Rice-Evans, 1997) 845 
and urine (Lapidot, Harel, Granit, & Kanner, 1998), however, the HPLC profiles on which the 846 
identifications were based now appear somewhat unconvincing in light of data obtained with more 847 
modern analytical methodology.  In contrast, the later detection of unmetabolized cyanidin-3-O-848 
glucoside 63 and cyanidin-3-O-sambubioside 64 in plasma and urine after the consumption of an 849 
elderberry extract are much more plausible (Cao, & Prior, 1999; Cao, Muccitelli, Sánchez-Moreno, & 850 
Prior, 2001). Although many other early studies “identified” unmetabolized precursor anthocyanins 851 
in biofluids using HPLC with absorbance detection, with the increasing use of HPLC-MS, it has 852 
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become apparent that, like other flavonoids, anthocyanins are absorbed primarily as methyl, 853 
glucuronide, and sulfated phase II conjugates (Wu, Cao, & Prior, 2002; Felgines et al., 2003, 2005; 854 
Kay, Mazza, Holub, & Wang, 2004; Kay, Mazza, & Holub, 2005; Kay, 2006; Kay, Pereira-Caro, Ludwig, 855 
Clifford, & Crozier, 2017; Sandhu et al., 2016; Zhong, Sandu, Edirisinghe, & Burton-Freeman, 2017).  856 
[Insert Structures 63-65] 857 
Until recently, anthocyanins were widely believed to have low bioavailability, with the 858 
majority of feeding studies, typically with berries, reporting Cmax concentrations ranging from 1 to 859 
120 nmol/L and urinary recoveries <1% of intake (Kay et al., 2005; Prior, 2012; Sandhu et al., 2016; 860 
Stalmach et al., 2012), with one report of excretion as low as 0.005% (Wu et al., 2002). Differences 861 
in reported recoveries are likely, in part, to be the result of differing degree of hydroxylation of the 862 
B-ring of the anthocyanidin unit, with the excretion of metabolites of strawberry pelargonidin-3-O-863 
glucoside 65 being equivalent 1.8% of intake (Felgines et al., 2003) while metabolites of blackberry 864 
cyanidin-3-O-glucoside 63 are reported at 10-fold lower concentrations (Felgines et al., 2005). 865 
Alternatively, differences could be the result of differing methodology and quantification techniques. 866 
Acetylation of anthocyanins also appears to affect bioavailability, as >10-fold reductions in 867 
anthocyanin recovery in urine have been reported relative to non-acylated structures (Kurilich, 868 
Clevidence, Britz, Simon, & Novotny, 2005).  869 
Some recent publications have suggested anthocyanins exist as hundreds of derivations of phase II 870 
conjugates and persist in the circulation almost indefinitely (Kalt, Lui, McDonald, Vinqvist-Tymchuk, & 871 
Fillmore, 2014; Kalt, MacDonald, Lui & Fillmore, 2017; Kalt, McDonald, Vinqvist-Tymchuk, Lui, & 872 
Fillmore, 2017). These inferences are based on an untargeted metabolomics approach using single-ion 873 
monitoring and low-resolution triple-quadrupole MS and are not supported by more suitable analyses 874 
based on high-resolution time-of-flight (TOF) or orbitrap MS (Bajad & Shulaev, 2007; Pimpão et al., 875 
2014; van der Hooft et al., 2012; Zhou, Xiao, Tuli, & Ressom, 2012).  In a review on the use of HPLC-MS 876 
Page 40 of 257Comprehensive Reviews in Food Science and Food Safety
 39
for analyzing chemical contaminants in foods, Hird et al. (2014) emphasized that identification of 877 
unknowns using only multiple reaction monitoring/selective reaction monitoring approaches has a 878 
high propensity for false positive identification, and additional scanning techniques within the 879 
MS/MS platform are required for further confirmation. These would include using multiple 880 
transitions and information-dependent acquisition (IDA) approaches. MS/MS is well suited as the 881 
scanning speed is high, and it can be highly accurate when multiple transitions, IDA, or MS3 882 
approaches are used.  However, it suffers from having poor mass accuracy. Therefore, single 883 
scanning techniques in untargeted analysis requires more high-resolution techniques such as time-884 
of-flight (TOF) and orbitrap MS. In short, targeted approaches cannot be exchanged for untargeted 885 
approaches as they require different platforms or highly optimized methodology using 886 
fragmentation-profiling. 887 
 888 
Metabolism and sites of absorption of anthocyanins 889 
Plasma pharmacokinetic data suggest the proximal GI tract is the site of the absorption of 890 
phase II metabolites of anthocyanins (de Ferrars et al., 2014b; Del Rio, Rodriguez-Mateus, Spencer, 891 
Tognolini, Borges, & Crozier, 2013; Mullen, Edwards, Serafini, & Crozier, 2008b; Rodriguez-Mateo et 892 
al., 2014c). However, it is now becoming apparent that the majority of ingested anthocyanins are 893 
absorbed as low-molecular-weight products of chemical and microbial degradation (Czank et al., 894 
2013, de Ferrars et al., 2014b, Ludwig et al., 2015; Rodriguez-Mateos et al., 2014c).  The presence of 895 
anthocyanin-derived phenolic acids in the blood within 30 to 90 min after consumption suggests 896 
deglycosylation and chemical degradation can occur in the upper small intestine (Czank et al., 2013, 897 
de Ferrars et al., 2014b), although the majority of ingested anthocyanins appear to reach the colon 898 
where they are subject to microbial catabolism (González-Barrio, Edwards, & Crozier, 2011; 899 
MacDougall, et al., 2014). When ileostomists were fed raspberries, blueberries, lingonberries, and 900 
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grapes up to 40% of the ingested anthocyanins remained in the ileal fluid (Kahle et al., 2006, 901 
González-Barrio, Borges, Mullen, & Crozier, 2010; Stalmach et al., 2013; Brown et al., 2014; 902 
McDougall et al., 2014). In volunteers with a functioning colon this portion of anthocyanins would 903 
pass into the large intestine where it would be deglycosylated and the resulting aglycones broken 904 
down by fission of the C-ring, with the A- and B-ring fragments being converted to a diversity of 905 
phenolic constituents (González-Barrio et al., 2011, Rodriguez-Mateos et al., 2014c, Feliciano,et al., 906 
2016), some of which are also produced by catabolism of other classes of flavonoids and related 907 
dietary (poly)phenols, such as chlorogenic acids (Clifford, Jaganath, Ludwig, & Crozier, 2017; 908 
Williamson, & Clifford, 2010, 2017).  909 
 910 
Bioavailability of raspberry anthocyanins  911 
 Plasma 912 
In a recent study volunteers consumed 300 g raspberries, containing 292 μmol of mainly 913 
cyanidin-based anthocyanins, in the form of cyanidin-3-O-sophoroside (66, 175 μmol), cyanidin-3-914 
O-(2”-O-glucosyl)rutinoside (67, 56 μmol), cyanidin-3-O-glucoside (63, 37 μmol). and cyanidin-3-O-915 
rutinoside (68, 20 μmol) (Ludwig et al., 2015).  Only two anthocyanins, cyanidin-3-O-glucoside and 916 
a cyanidin-O-glucuronide ,were subsequently detected in plasma, with sub-nmol/L Cmax values and 917 
Tmax of 1 h and 4 h, respectively.  None of the parent anthocyanins were detected in 0-24 h urine, 918 
except for cyanidin-3-O-glucoside (19.9 nmol). In addition, 1.4 nmol of peonidin-3-O-glucoside 69, a 919 
3'-methyoxy analog of cyanidin-3-O-glucoside, was also detected in urine. [Insert Structures 66-920 
69] Thus, of the 292 μmol of anthocyanins ingested only 21.3 nmol was excreted, indicating a 921 
0.007% retrieval and corroborating previously reported urinary recoveries. This very low 922 
bioavailability is likely the result of raspberry anthocyanins consisting of primarily di-and 923 
trisaccharides, and as LPH and/or CBG-mediated cleavage of the sugar moieties is unlikely to occur 924 
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in the proximal GI tract, absorption in the small intestine would be restricted substantially (Prior, 925 
2012).  926 
In the Ludwig et al. (2015) study, phenolic metabolites of cyanidin appeared in plasma in 927 
more substantial nmol/L concentrations following raspberry consumption (Figure 11). These 928 
included ferulic acid-4′-sulfate 70, ferulic acid-4’-O-glucuronide 71, isoferulic-3’-O-glucuronide 72, 929 
and 4′-hydroxyhippuric acid 73, all of which had 1.0-1.5 h Tmax, indicating absorption in the upper GI 930 
tract.  It is possible that pH-dependent transformation of cyanidin to a retro-chalcone structure 931 
occurred in the small intestine, followed by metabolism to caffeic acid (Clifford, 2000).  The findings 932 
of Stalmach et al. (2009) indicate that the conversion of caffeic acid to ferulic acid and isoferulic acid 933 
and their phase II metabolites can take place in enterocytes. However, microbial-mediated ring 934 
fission of cyanidin in the upper bowel is also plausible as significant bacterial populations ranging 935 
from 105 to 107 per mL exist between the duodenum and lower ileum (Mowat & Agace, 2014).  936 
[Insert Structures 70-74] 937 
It is of interest that 4'-hydroxyhippuric acid 73, a product of hepatic glycination of 4′-938 
hydroxybenzoic acid 74, was detected in plasma, with a Cmax of 78 nmol/L and a Tmax of 1.0 h 939 
following the ingestion of the cyanidin-based raspberry anthocuaniny (Figure 11). This implies that 940 
caffeic acid, derived from cyanidin, underwent conversion to 4′-hydroxybenzoic acid in the upper GI 941 
tract.  In contrast, 3’,4’-dihydroxyphenylacetic acid 25 had a Tmax of  6 h, which is in line with 942 
absorption in the lower bowel (Ludwig et al., 2015). However, low concentrations were also found 943 
at earlier time points, indicating that the phenylacetic acid is formed and also absorbed, to some 944 
extent, in the small intestine (Figure 11). The major phenolic in plasma was hippuric acid 58, which 945 
had a relatively stable 1-2 µM concentration over 24 h (Figure 11). These findings reflect those 946 
observed following [13C5]cyanidin-3-O-glucoside consumption (Czank et al., 2013, de Ferrars et al., 947 
2014b). 948 
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 949 
Urine 950 
 Sixteen phenolic catabolites of anthocyanins were found in relatively high amounts in urine 951 
collected over 48 h following raspberry consumption (Table 7) (Ludwig et al. 2015). Once again, 952 
this finding is in agreement with studies involving other berry sources such as blueberries and 953 
elderberries (de Ferrars, Cassidy, Curtis, & Kay, 2014a; Rodrigues-Mateos et al., 2013; Zhong et al., 954 
2017). The overall 0-48 h increase in urinary excretion of phenolic compounds after baseline 955 
subtraction was 43.9 ± 8.0 µmol, which is equivalent to 15% of the ingested raspberry anthocyanins. 956 
The extent of hippuric acid formation resulting from cyanidin degradation is difficult to quantify, 957 
because of high background levels originating from other dietary and endogenous sources and 958 
significant person-to-person variation (Self, Brown, & Price, 1960; Gruemer, 1961). Due to this 959 
uncertainty, hippuric acid was not used in the estimated 15% recovery (Table 7) (Ludwig et al. 960 
2015). However, following consumption of [13C5]cyanidin-3-O-glucoside, the greatest proportion of 961 
the label was recovered as hippuric acid (de Ferrars et al., 2014b), confirming its significant 962 
contribution to the metabolic fate of anthocyanins. 963 
In an earlier raspberry feeding study González-Barrio et al. (2010) identified urinary phenolic 964 
catabolites of cyanidin, using GC-MS rather than HPLC-ion trap MS2, and they reported a significant 965 
increase in 4'-hydroxymandelic acid 75, which was not detected in the later study by Ludwig et al. 966 
(2015). This is likely to be the consequence of differing analytical methodologies, as many small 967 
molecules with a benzene backbone are prone to significant ion-suppression in HPLC-MS 968 
environments. Therefore, GC-MS should be considered a more suitable method of analysis for some 969 
phenolic catabolites, although with orbitrap and TOF mass spectrometry the limits of detection for 970 
these compounds are improved substantially.  [Insert Structures 75-79] 971 
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Gonzáles-Barrio et al. (2011) also incubated raspberry anthocyanins, under anaerobic 972 
conditions, with human fecal slurries and found the first catabolic step included cleavage of the 973 
sugar moiety, with subsequent degradation of cyanidin, resulting in the accumulation of catechol 76, 974 
(1,2-dihydroxybenzene), resorcinol 77 (1,5-dihydroxybenzene), pyrogallol 78  (1,2,3-975 
trihydroxybenzene), 4-hydroxybenzoic acid 74, 3,4-dihydroxybenzoic acid (35, protocatechuic 976 
acid), 3-(3′-hydroxyphenyl)propionic acid 32, and 3-(3′,4′-dihydroxyphenyl)propionic acid 79 977 
(dihydrocaffeic acid).  Except for catechol, resorcinol, and pyrogallol, all these compounds were also 978 
detected in the urine of human volunteers after ingestion of raspberries (Gonzáles-Barrio et al. 979 
2010).  Other urinary phenolics not produced by fecal incubations were 4′-hydroxymandelic acid, 980 
hippuric acid, and 4’-hydroxyhippuric acid, implying they are at least in part, products of 981 
mammalian enzymes.  None of the fecal metabolites that were detected were methylated products. 982 
It should be noted that ex vivo fecal culture may not accurately reflect in vivo events, as not all GI 983 
tract microbiota are voided in feces and many which are cannot be cultured successfully in vitro 984 
(Stewart, 2012). 985 
Potential pathways for the production of the various phenolic catabolites derived from 986 
cyanidin are illustrated in Figure 12. In the preparation of the proposed pathways the following 987 
points were considered: 988 
• The conversion of cyanidin to caffeic acid could involve pH-mediated degradation as 989 
well as microbial and mammalian enzymes.  990 
• Subsequent methylation as well as glucuronide, sulfate, and glycine conjugation are 991 
most probably mammalian in origin.   992 
• Dehydroxylation and demethoxylation are almost certainly mediated by the gut 993 
microflora, while hydrogenation steps may be catalyzed by both microbial and 994 
mammalian enzymes.  995 
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For convenience, the pathways in Figure 12 show C6−C3 catabolites being converted by two α-996 
oxidations to C6-C1 compounds by microflora and/or mammalian enzymes.  However, it is plausible 997 
the C6−C3 catabolites progress directly to C6−C1 structures via β-oxidation and that C6−C2 catabolites 998 
arise independently, possibly by α-oxidation.  In reality, further complexity is introduced as there 999 
are multiple points at which catabolites might be absorbed. For example, a percentage of some 1000 
C6−C3 catabolites could be absorbed and undergo β-oxidation and/or mammalian phase II 1001 
conjugation, while the balance is subjected to microbial hydrogenation and/β-oxidation prior to 1002 
absorption and mammalian conjugation. Also, for some catabolites mammalian conjugation either 1003 
does not occur or is incomplete. 1004 
 1005 
The bioavailability of [6,8,10,3',5'-13C5]cyanidin-3-O-glucoside 1006 
A notable anthocyanin feeding study is the previously mentioned investigation by Czank et al. 1007 
(2013) and de Ferrars et al. (2014b) who fed 13C5-labelled cyanidin-3-O-glucoside to human 1008 
participants. Volunteers ingested 1114 µmol (500 mg) of the glucoside and, after 48 h, recovery was 1009 
established as 44% of the 13C dose, with 6.9% in breath, 32% in feces, and 5.4% urine.  The 1010 
particular advantage of using [6,8,10,3',5'-13C5]cyanidin-3-O-glucoside was that it had three 13C 1011 
molecules incorporated into the A-ring and two into the B-ring (Figure 13). An array of phenolic 1012 
products was detected in plasma and urine, and because of the 13C-label, it was possible to ascertain 1013 
whether they were derived from the A- or B-ring of cyanidin. The capacity to determine relatively 1014 
low levels of incorporation of the 13C label into the pools of phenolic compounds enabled cyanidin-1015 
derived catabolites to be identified and quantified in much more detail than the above reported 1016 
raspberry feeding study of Ludwig et al. (2015) where catabolites derived from cyanidin were 1017 
reported only where there was a statistically significant increase in the urinary pool after 1018 
supplementation. The utility of the 13C labelling design is emphasised with respect to the 1019 
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identification of urinary hippuric acid, as the incorporation of 13C label enabled the amounts derived 1020 
from [13C5]cyanidin-3-O-glucoside to be distinguished from the unlabelled endogenous, or 1021 
background diet-derived hippuric acid, which in the raspberry study was not possible.  1022 
At present the effects of dose, matrix, age, genetics, background diet, and lifestyle on the 1023 
metabolism and bioavailability of anthocyanins are unknown, making it difficult to compare, in 1024 
detail, findings of different feeding studies. With this in mind, the plasma pharmacokinetic profiles 1025 
(Figure 11) and the structural conversions illustrated in Figure 12 are based primarily on outputs 1026 
from raspberry interventions, and are broadly in line with the array of 13C-labeled products 1027 
detected by Czank et al. (2013) and de Ferrars et al. (2014b). Differences in findings between the 1028 
two studies may be a consequence of matrix, anthocyanin glycosylation, and difference in dose.  1029 
The investigations of Czank et al. (2013), de Ferrars et al. (2014b), and Ludwig et al. (2015) 1030 
have provided novel details of the extensive metabolism and catabolism of cyanidin-3-O-glucoside 1031 
63 following ingestion, and when these events are taken into consideration, anthocyanins appear 1032 
much more bioavailable than previously reported. Other feeding studies with an elderberry extract 1033 
(de Ferrars et al. 2014a) and cranberry juice (McKay et al., 2015, Feliciano et al., 2016), which have 1034 
very different anthocyanin profiles to that of raspberries, have also shown the important role of 1035 
phenolic and aromatic catabolites in the bioavailability of anthocyanins. Having orders of magnitude 1036 
higher plasma/serum Cmax and significantly longer half-lives, all evidence points towards the 1037 
phenolic and aromatic catabolites as being the primary bioavailable products of anthocyanin 1038 
consumption and, therefore, as discussed in Section 4, most likely are responsible for the reported 1039 
bioactivity of not just anthocyanins but also other dietary (poly)phenols and flavonoids. 1040 
 1041 
Anthocyanin bioavailability and matrix effects 1042 
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Most investigations on the bioavailability of anthocyanins and other flavonoids, with few 1043 
exceptions, have focused on the acute intake of a single product, such as a juice, fruit or vegetable, 1044 
after volunteers had been on low-polyphenol diets for 2-3 days. Information on matrix effects and 1045 
the impact of other dietary constituents of anthocyanin ADME is therefore limited. 1046 
 1047 
Strawberry anthocyanins 1048 
Mullen et al. (2008b) reported on a feeding study in which strawberries, containing 222 µmol 1049 
of the anthocyanin pelargonidin-3-O-glucoside 65, were consumed with and without 100 mL of 1050 
double cream (48% fat).  The cream reduced, but not significantly, the plasma Cmax of the main 1051 
metabolite, a pelargonidin-O-glucuronide. It did, however, significantly extend the Tmax of the 1052 
glucuronide, from 1.1 h to 2.4 h. The 0-2 h urinary excretion of the glucuronide and smaller 1053 
quantities of other metabolites was also significantly reduced when the strawberries were eaten 1054 
with cream but increased in the 5-8 h excretion period, suggesting the addition of cream had no 1055 
impact on absorption, only gastric emptying or metabolite kinetics. Overall, there was no significant 1056 
difference in the 0-24 h excretion of the metabolites, which was equivalent to ~1% of anthocyanin 1057 
intake. In keeping with these observations, measurement of plasma paracetamol and breath 1058 
hydrogen established that cream delayed gastric emptying and extended mouth-to-cecum transit 1059 
time (Mullen et al., 2008b). 1060 
In a recent study by Sandhu et al. (2016) 14 overweight volunteers ingested a strawberry 1061 
beverage either with, or 2 h before or 2 h after, a morning meal consisting of a croissant with butter 1062 
and apple jelly, cereal, whole milk, and sausages and providing 838 kcal. Co-ingestion of the drink 1063 
with the meal had a major impact on the plasma Cmax of the main anthocyanin, a pelargonidin-O-1064 
glucuronide, which fell significantly to 12.8 ± 2.1 nmol/L compared to 38.0 ± 6.6 and 35.5 ± 2.1 1065 
nmol/L when the drink was ingested, respectively, before and after the meal. Co-ingestion with the 1066 
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meal also extended the Tmax from ~1.8 h to 2.9 h (Figure 14).  Although urinary excretion was not 1067 
reported, preventing a quantitative assessment of change in the absorption of anthocyanins, it is 1068 
evident that the timing of consumption of a multicomponent meal can have a marked impact on the 1069 
profile and kinetics of anthocyanin metabolites appearing in the circulatory system.  1070 
 1071 
Flavanones 1072 
All citrus fruits, orange, tangerine, lemon, lime and grapefruit contain relatively high amounts 1073 
of flavanones (Crozier et al., 2006). Most bioavailability studies have used orange juice, which is 1074 
widely consumed and contains mainly hesperetin-7-O-rutinoside 80 (hesperidin) and naringenin-7-1075 
O-rutinoside 17, which occur alongside lower levels of other flavanone glycosides and the flavone 1076 
apigenin-6,8-C-diglucoside 81. Ferulic acid-4'-O-glucoside 82 and coumaric acid-4'-O-glucoside 83 1077 
have also been tentatively identified (Pereira-Caro et al., 2014, 2016).  [Insert Structures 80-84] 1078 
 1079 
Progress of research since 1990s 1080 
Studies in the 1990s identified small amounts of glucuronide metabolites of flavanones in 1081 
human urine, indicating flavonones were bioavailable to some extent (Ameer, Weintraub, Johnson, 1082 
Yost, & Rouseff, 1996; Fuhr, & Kummert, 1995). Subsequently, more detailed studies, using HPLC 1083 
with electrochemical detection, further identified glucuronide and sulfate conjugates post-1084 
hydrolysis with glucuronidase/sulfatase enzymes (Erlund, Meririnne, Alfthan, & Aro, 2001; Manach, 1085 
Morand, Gil-Izquierdo, Bouteloup-Demange, & Rémésy, 2003). The study by Manach et al. (2003) 1086 
revealed the appearance of enzyme-released aglycones in plasma at a sub μmol/L Cmax and ∿5 h Tmax  1087 
after drinking 500 mL orange juice containing 363 μmol of hesperetin-7-O-rutinoside and 83 μmol 1088 
of naringenin-7-O-rutinoside. Plasma elimination kinetics pointed to absorption in the distal GI tract. 1089 
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Urinary excretion over a 24-h period after supplementation indicated a recovery of 4.5% of 1090 
hesperetin and 7.1% of narigenin. Increasing the intake of juice to 1 L doubled the Cmax, but did not 1091 
affect Tmax and only marginally increased urinary recovery as a percentage of intake (Manach et al., 1092 
2003). 1093 
Studies comparing the bioavailability of hesperetin-7-O-rutinoside 80 to orange juice treated 1094 
with α-rhamnosidase, converting the rutinoside to hesperetin-7-O-glucoside 84, revealed the 1095 
importance of the conjugating sugar moiety to flavanone absorption. The glucoside was much more 1096 
bioavailable as indicated by significantly higher Cmax, area-under-the-curve and urinary recovery of 1097 
the flavanone metabolites. Elimination kinetics identified the Tmax of metabolites of the glucoside at 1098 
0.6  ± 0.1 h, while the Tmax of hesperetin-7-O-rutinoside metabolites was 7.0  ± 3.0 h (Nielsen et al., 1099 
2006). These differences in elimination kinetics suggested that CBG/LPH enzymes in the small 1100 
intestine are able to hydrolyze hesperetin-7-O-glucoside, releasing hesperetin prior to phase II 1101 
metabolism.  In contrast, only limited hydrolysis of hesperetin-7-O-rutinoside appears to take place 1102 
in the small intestine, allowing passage to the distal GI tract where microbial hydrolysis of the 1103 
rutinoside occurs, releasing the aglycone for absorption and phase II metabolism. 1104 
 1105 
Interindividual variations in flavanone bioavailability 1106 
Brett et al. (2008) investigated the absorption, metabolism, and elimination of flavanones in 1107 
20 volunteers after the ingestion of orange fruit and juice, and they reported no difference in plasma 1108 
profiles or urinary excretion between the treatments. A larger population study, feeding orange 1109 
juice to 129 volunteers aged 18 to 80 years, revealed that with increasing age there was a small but 1110 
significant reduction in the excretion of hesperetin 60 but not naringenin 16. However, excretion 1111 
was not affected by gender, body mass index, or contraceptive pill use. Substantial inter-individual 1112 
variation was observed for excretion recovery, ranging from 1.6 to 59% of intake of naringenin 1113 
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(9.9% median recovery) and 0 to 25% for hesperetin (3.1% median). Possibly, the lack of effect of 1114 
age and gender suggests the variability resulted from person-to-person differences in intestinal 1115 
microbiota, although other factors could contribute, including analytical methodology, dose, and 1116 
juice processing method which affects soluble and precipitated flavanone levels (Tomás-Navarro, 1117 
Vallejo, Sentandreu, Navarro, & Tomás-Barberán, 2014; Vallejo et al., 2010). Variable urinary 1118 
excretion of orange juice flavanone metabolites has been reported across a number of studies, with 1119 
the recovery of naringenin typically higher than hesperetin (Silveira et al.,2014).  1120 
  1121 
Identification of hesperetin and naringenin phase II metabolites 1122 
Using HPLC-MS and authentic standards, Brett et al. (2008) identified hesperetin-3'-O-1123 
glucuronide 85, hesperetin-7-O-glucuronide 86, naringenin-4’-O-glucuronide 87, and naringenin-7-1124 
O-glucuronide 88 in plasma and urine after orange juice intake. In addition, two hesperetin 1125 
diglucuronides and a hesperetin sulfo-glucuronide were detected. The identified hesperetin 1126 
metabolites were confirmed by Bredsdorf et al. (2010) who also identified hesperetin-3',7-O-1127 
diglucuronide 89, hesperetin-5,7-O-diglucuronide 90, and hesperetin-3'-sulfate 91. This study 1128 
confirmed that hesperetin-7-O-glucoside was absorbed more readily than the 7-O-rutinoside, and, 1129 
similarly, naringenin-7-O-glucoside was also absorbed more rapidly, with metabolites excreted in 1130 
urine in ~7-fold higher amounts than those derived from naringenin-7-O-rutinoside (Bredsdorff et 1131 
al., 2010). Potential routes for the formation of hesperetin metabolites are illustrated in Figure 15. 1132 
[Insert Structures 85-91] 1133 
 1134 
 Absorption of flavanone-derived compounds in the proximal and distal GI tract 1135 
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Borges et al. (2010) investigated the absorption and elimination of a (poly)phenol-rich drink 1136 
containing a diverse spectrum of (poly)phenolic and flavonoid compounds including 45 µmol of 1137 
hesperetin-7-O-rutinoside.  Hesperetin-7-O-glucuronide 84 and a second glucuronide, most 1138 
probably hesperetin-3'-O-glucuronide 85, together with a sulfated-glucuronide, were excreted in 1139 
human urine collected 0-24 h post-intake, with total recovery established as 12.0 % of ingested 1140 
hesperetin-7-O-rutinoside.  In a subsequent study, where ileostomists consumed the same beverage, 1141 
the quantity of hesperetin metabolites detected in urine was 3.5% of intake (Borges, Lean, Roberts, 1142 
& Crozier, 2013).  The differing levels of hesperetin metabolites excreted in urine by the 1143 
ileostomists and volunteers with a functioning colon indicates absorption of hesperetin is not 1144 
exclusive to the large intestine but that around ⅓ is absorbed in the upper GI tract and ⅔ in the 1145 
lower bowel.  The plasma pharmacokinetic profile of the hesperetin-O-glucuronides obtained when 1146 
the drink was consumed by volunteers with a colon is in line with this observation, as although the 1147 
Tmax was 3.7 h, the profile indicated that absorption began within 30 min of hesperetin-7-O-1148 
rutinoside ingestion (Figure 16).  1149 
 1150 
Progress since 2014 1151 
Urinary excretion of hesperetin and naringenin metabolites and their phenolic and aromatic 1152 
acids was detailed in an orange juice feeding study in which participants consumed 584 µmol of 1153 
(poly)phenolic compounds, including 348 µmol of hesperetin-O-glycosides, 165 µmol of naringenin-1154 
O-glycosides, and 5 µmol of eriodictyol-7-O-rutinoside 92 (Pereira-Caro et al., 2014). A number of 1155 
flavanone metabolites were detected in 0-24 h urine after juice consumption that were not present 1156 
in the urine of the volunteers collected after drinking a flavanone-free placebo drink. This study 1157 
reported an 83 µmol excretion of metabolites, principally the 3'-O- and 7-O-glucuronides of 1158 
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hesperetin, hesperetin-3'-sulfate, and the 4′-O- and 7-O-glucuronides of naringenin, which 1159 
corresponds to 16% of the flavanone intake. [Insert Structures 92-93] 1160 
Unlike the flavanone metabolites, baseline urine does contain phenolic and aromatic acids, as 1161 
they are produced by endogenous pathways as well as being metabolic products of dietary 1162 
flavanones and other (poly)phenolic compounds.  However, eight phenolic catabolites were 1163 
excreted in urine in significantly higher amounts 0-24 h after orange juice consumption compared 1164 
with excretion after intake of the flavanone-free placebo drink (Table 8) (Pereira-Caro et al., 2014).  1165 
3-(3'-Hydroxy-4'-methoxyphenyl)hydracrylic acid 93 was excreted in substantial amounts after 1166 
orange juice intake, yet was absent in placebo urine. 3-(3'-Hydroxyphenyl)hydracrylic acid 37, 1167 
although present in trace amounts in the control urine, increased >10-fold after orange juice 1168 
consumption, while excretion of 4'-hydroxhippuric acid increased ~100-fold from 0.2 to 19 µmol. 1169 
The overall increase in phenolic catabolites, excluding hippuric acid, after orange juice consumption 1170 
was 134 µmol, which is 23% of the 584 µmol intake of (poly)phenolic compounds (Table 8). 1171 
Addition of 134 µmol to the 83 µmol excretion of flavanone glucuronide and sulfate metabolites 1172 
indicates a recovery of 37% of intake.  1173 
Excretion of hippuric acid 58 was not included in the reported 37% recovery as the placebo 0-1174 
24 h urine contained 232 ± 21 µmol of the glycinated benzoic acid derivative (Pereira-Caro et al., 1175 
2014). Although post-intervention levels increased significantly by 378 µmol to 610 ± 48 µmol 1176 
following orange juice intake, exactly how much of this increase in hippuric acid was related to 1177 
flavanone metabolism intake is difficult to ascertain because of the contribution of endogenous 1178 
sources. If increased hippuric acid was included in the calculation, the overall flavanone recovery 1179 
would be ~100%. It is, therefore, apparent that when both metabolites and catabolites are taken 1180 
into consideration, hesperetin- and naringenin-7-O-rutinosides are highly bioavailable (Pereira-1181 
Caro, et al., 2014).   1182 
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In order to further elucidate the metabolism pathways of flavanones, hesperetin and 1183 
naringenin were incubated in vitro with human fecal slurries cultured under anaerobic conditions 1184 
(Pereira-Caro, et al.,2015a).  Incubations were also carried out with ferulic acid 94, as orange juice, 1185 
as well as flavanones, also contains ferulic acid-4′-O-glucoside 82 (Pereira-Caro et al., 2014). 1186 
Comparisons were made between fecal incubations and in vivo urinary excretion data to establish 1187 
the potential involvement of microbial and mammalian metabolism in the pathways illustrated in 1188 
Figs. 17 and 18.  To summarize, naringenin is likely to undergo microbiota-mediated ring fission 1189 
producing 3-(4′-hydroxyphenyl)propionic acid which is dehydroxylated and converted mainly to 3-1190 
(phenyl)propionic acid, which in vivo could potentially contribute to the urinary pool of hippuric 1191 
acid (Figure 17).  Colonic ring fission of hesperetin produces dihydroisoferulic acid [3-(3'-hydroxy-1192 
4'-methoxyphenyl)propionic acid] which is demethylated producing dihydrocaffeic acid [3-(3',4'-1193 
dihydroxyphenyl)propionic acid]. This, in turn, via successive dehydroxylations, is converted to 3-1194 
(3'-hydroxyphenyl)propionic acid and 3-(phenyl)propionic acid, which could be further converted 1195 
to the respective urinary pools of 3'-hydroxyhippuric acid and hippuric acid (Figure 18).  In vitro 1196 
degradation of hesperetin also yields small quantities of 3-(4'-hydroxyphenyl)propionic acid and 4'-1197 
hydroxyphenylacetic acid, which, via the pathway illustrated in Figure 18, and like the naringenin 1198 
catabolites, could be further converted to 4'-hydroxyhippuric acid. Previously reported colonic 1199 
bacteria potentially involved in some of the proposed conversions illustrated, in Figs. 17 and 18, are 1200 
Eubacterium limosum and members of the Enterobacter and Escherichia genera, which possess O-1201 
demethylase and hydrolase activity (De Weerd et al., 1988; Grbić-Galić, 1986; Hur & Rafii, 2000). 1202 
[Insert Structures 94-96] 1203 
Among the phenolic acids excreted in urine in increased amounts after orange juice 1204 
consumption (Table 8) are 3-(3'-methoxy-4'-hydroxyphenyl)propionic acid 95 (dihydroferulic acid) 1205 
and 3'-methoxy-4'-hydroxyphenylacetic acid 96, which because of the 3'-methoxy group are 1206 
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unlikely to be catabolites of hesperetin which has a 4’-methoxy group.  They could, however, be 1207 
derived from ferulic acid-4'-O-glucoside.  In vitro, fecal incubations with ferulic acid indicate this is 1208 
feasible, as the hydroxycinnamate was converted principally to 3'-methoxy-4'-1209 
hydroxyphenyl)propionic acid and its demethoxy-derivative 3-(4'-hydroxyphenyl)propionic acid, 1210 
along with smaller amounts of their phenylacetic acid counterparts (Pereira-Caro et al., 2015a).  1211 
Potential routes for these transformations are illustrated in Figure 17, which again shows the 1212 
possible conversion of 4'-hydroxyphenylacetic acid to 4’-hydroxyhippuric acid. As with the 1213 
conversions depicted in Figure 12 in Section 3.3.3, for convenience, the pathways in Figs. 17 and 18 1214 
show C6−C3 catabolites being converted by two α-oxidations to C6-C1 compounds by microflora 1215 
and/or mammalian enzymes.  However, the C6−C3 catabolites may progress directly to C6−C1 1216 
structures via β-oxidation and that C6−C2 catabolites arise independently, possibly by α-oxidation. 1217 
Orange juice intake was also characterized by urinary excretion of 3-(3'-hydroxy-4'-1218 
methoxyphenyl)hydracrylic acid and 3-(3'-hydroxyphenyl)hydracrylic acid (Table 8) (Pereira-Caro 1219 
et al., 2014), neither of which was reported to be produced from flavanones in fecal incubations 1220 
(Pereira-Caro et al., 2015a, 2016).  Because of their compatible B-ring substituent pattern, they 1221 
would appear to be catabolites of hesperetin and products of a combination of gut flora 1222 
transformations and colonocyte and/or hepatic conversions, possibly via the route shown in Figure 1223 
18. The involvement of the microbiota is supported by a human study which showed urinary 1224 
excretion of 3-(3'-hydroxy-4'-methoxyphenyl)hydracrylic acid following oral intake of hesperetin-7-1225 
O-rutinoside, but only trace amounts when absorption of the rutinoside was confined to a 20-cm 1226 
segment of the proximal jejunum using a Loc-I-gut intestinal perfusion catheter (Actis-Goretta et al., 1227 
2015), previously mentioned in the context of (−)-epicatechin absorption in Section 3.3.2.3. 1228 
 1229 
Flavanone bioavailability and matrix effects 1230 
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Co-consumption of yogurt with flavanones had no impact on the plasma Cmax and Tmax of 1231 
hesperetin-O-glucuronides when volunteers drank orange juice containing 168 µmol of hesperetin-1232 
7-O-rutinoside with and without a 150 mL yogurt (3.8% fat) (Mullen, Archeveque, Edwards, & 1233 
Crozier, 2008a). The 0-5 h urinary excretion of the flavanone metabolites was reduced significantly 1234 
by the yogurt, but the total quantity of metabolites in urine collected over 0-24 h, corresponding to 1235 
~7.0% of intake, was not different. The yogurt had no effect on either gastric emptying or on the 1236 
mouth-to-cecum transit time of the ‘head’ of the meal, both of which were delayed by double cream 1237 
when co-ingested with strawberries (Mullen et al., 2008b).  These incongruities could reflect the 1238 
differences in fat content of the matrices as the double cream contained 48% fat compared to only 1239 
3.8% of the yogurt. Higher levels of fat are likely to stimulate both duodenal and ileal fat receptors 1240 
and thereby delay both gastric emptying and the mouth-to-cecum transit time of the head of the 1241 
meal (Rao, Lu, & Schulze-Delrieu, 1996; Welch, Cunningham, & Read, 1988), whereas the lower fat 1242 
content of the yogurt would have a lesser impact. Therefore, the initial significant delay in urinary 1243 
excretion of flavanone metabolites when orange juice was consumed with the yogurt may simply 1244 
reflect the slower delivery of the bulk of the meal. 1245 
In the subsequent analysis of colon-derived urinary phenolic catabolites from the orange 1246 
juice-yogurt study, 0-24 h urine contained a total of 62 ± 18 µmol of hydroxy- and methoxy-phenolic 1247 
catabolites, equivalent to 37% of the ingested flavanones (Roowi, Mullen, Edwards & Crozier, 2009). 1248 
However, urinary levels of microbial catabolites fell to 9.3 ± 4.4 µmol in the juice-plus-yogurt group.  1249 
The reason for this substantial decline in microbial catabolite excretion requires further 1250 
investigation, but one possible explanation is that yogurt potentially slowed the bulk of the meal 1251 
reaching the large intestine, thereby increasing upper intestinal absorption and limiting microbiota-1252 
mediated breakdown of the flavanones.  1253 
 1254 
Page 56 of 257Comprehensive Reviews in Food Science and Food Safety
 55
Flavanone bioavailability and probiotics 1255 
Co-administration of a microencapsulated probiotic (Bifidobacterium longum R0175) and 1256 
orange juice flavanones (Pereira-Caro et al., 2015b), comprising a total of 196 µmol of (poly)phenols 1257 
(56 µmol naringenin-O-glycosides and 111 µmol hesperetin-O-glycosides), was explored in an acute 1258 
study following a single oral bolus of orange juice with and without the probiotic. Subsequently, the 1259 
same orange juice was consumed acutely after daily supplementation with the probiotic for a period 1260 
of 4 weeks. Bioavailability was assessed by 0-24 h urinary excretion, and it was similar when the 1261 
orange juice was consumed with or without acute probiotic intake.  Hesperetin-O-glucuronides, 1262 
hesperetin-3′-sulfate, and naringenin-O-glucuronides were the main metabolites identified, 1263 
corresponding to 22% of intake, while excretion of key phenolic and aromatic acids, excluding 1264 
hippuric acid, was equivalent to 21% of the ingested (poly)phenols. Acute orange juice consumption 1265 
after 4 weeks of probiotic intake significantly increased excretion of flavanone metabolites to 27% 1266 
of intake, while excretion of the phenolic catabolites also increased significantly to 43% of 1267 
(poly)phenol intake, giving an overall bioavailability of 70%.  It is unclear as to how this increased 1268 
bioavailability is mediated as neither the probiotic bacterial profiles of stools, nor stool moisture, 1269 
weight, pH, or levels of short-chain fatty acids and phenols differed significantly between treatments.  1270 
However, as noted in Section 3.3.3.2, in vitro fecal bacterial profiles do not necessarily accurately 1271 
represent the microbial population in the colon as not all microbiota are voided in feces, and many 1272 
that are, cannot be cultured successfully in vitro (Stewart, 2012).  1273 
In vitro the intestinal bacterium B. longum R0175 possessed -rhamnosidase activity when 1274 
assayed by the method of Ávila et al. (2009) using p-nitrophenyl-α-L-rhamnopyranoside as a 1275 
substrate. However, in vitro anaerobic incubations of the bacterium with hesperetin-7-O-rutinoside 1276 
and naringenin-7-O-rutinoside did not result in the conversion of either rutinoside to a glucoside or 1277 
glycoside to an aglycone (Pereira-Caro et al., 2015a). Assuming the gut environment does not induce 1278 
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α-rhamnosidase and/or β-glucosidase expression in vivo, it is unlikely that cleavage of sugar 1279 
residues represents a key mechanism by which chronic intake of the probiotic enhances the 1280 
bioavailability of the orange juice flavanones. Although the mechanism responsible for these 1281 
differences in bioavailability remains elusive, further investigation of the impact of long-term 1282 
supplementation of probiotics on the bioavailability and health-promoting benefits of flavanones, as 1283 
well as other flavonoids and (poly)phenolics, is warranted. 1284 
 1285 
 Biomarkers of flavanone intake 1286 
The main metabolites detected in urine after orange juice intake, which are absent in baseline 1287 
urine, are the hesperetin metabolites, hesperetin-3′-O-glucuronide 85 and hesperetin-3′-sulfate 91. 1288 
Hesperetin, which has an unusual 3'-hydroxy-4'-methoxy B-ring structure so its phenolic catabolite 1289 
3-(3'-hydroxy-4'-methoxyphenyl)hydracrylic acid 93, is likely to be a good marker of hesperetin 1290 
intake as it is absent in baseline urine and unlikely to be derived from other dietary flavonoids 1291 
(Pereira-Caro et al., 2014, 2015b).  1292 
 1293 
Bioactivity  1294 
This section describes in detail the perception of the flavonoid research field over time, as 1295 
captured in previously published works, often reviews, summarizing the expansion in diversity of 1296 
therapeutic targets and functional endpoints, with the goal of informing and refining the focus of 1297 
future investigations. Consequently, where significant corroborating literature exists, suitable 1298 
reviews were often referenced rather than the individual source, and, although the review may have 1299 
extended beyond the referenced timeline/timeframe, the source publication did not. Furthermore, 1300 
we focus on modern theories, which have been brought to the forefront of flavonoid research in 1301 
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recent years, and, perhaps most significantly, special attention is centered on colonic metabolites. 1302 
Attention is given to beneficial health effects of monomeric flavonoids, excluding medicinal plant 1303 
sources, synthetic, pharmacological or topical treatments, or studies describing deleterious effects 1304 
which primarily relate to cytotoxic activity at pharmacological concentrations (Galati & O'Brien, 1305 
2004; Nijveldt et al., 2001; Skibola & Smith, 2000), phytoestrogenic effects (Cassidy, Bingham, & 1306 
Setchell, 1994; D'Adamo & Sahin, 2014), or drug interactions (Ameer & Weintraub, 1997).  1307 
Isoflavones, as noted in Section 1, have been excluded as they have their own unique history 1308 
warranting a separate review.  1309 
 1310 
Research 1930-to-1980  1311 
In the 1930s, there were investigations on the activity of an unknown plant constituent having 1312 
“vitamin-like” qualities, which was originally referred to as vitamin P. The evidence was initially 1313 
based on the clinical study of scurvy, where compounds in citrus were reported to act in association 1314 
or synergy with ascorbic acid on hemorrhagic symptoms associated with capillary fragility.  A 1315 
crystalline component, originally termed “citrin”, appeared to influence the biological activity of 1316 
vitamin C on micro-vessel permeability, and it was subsequently shown to be a mixture of 1317 
hesperetin-7-O-rutinoside 80 (hesperidin) and an eriodictyol-O-glucoside (Zilva, 1937; Roger, 1318 
1988). 1319 
By the 1950s an extensive literature was accumulating on the bioactivity of 1320 
flavonoids/vitamins, and Clark (1949) and Clark, MacKay, Mary, & Bryant (1950) noted, despite 1321 
extensive clinical and experimental studies into the biological activity of flavonoids, that there was a 1322 
need for more studies to establish their bioavailability. This sentiment would become a common 1323 
theme of the next half-century in flavonoid research. Shils & Good-Hart (1956) published a review, 1324 
citing nearly 300 publications, on vitamin-P that questioned the “essential” nature of flavonoids. 1325 
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This was followed by harsh editorials directly criticizing the flavonoid literature, stating that the 1326 
evidence presented was confusing and conflicting and that studies were poorly controlled, lacking 1327 
statistical power and reporting weak biological activity (Bean, 1956; Bryan, 1956). The editorials 1328 
went so far as to state, it was a ‘sad reflection of editorial judgment’ to see these studies in press. 1329 
Finally, in 1957 a review in JAMA by Pearson (1957) concluded there was no convincing evidence of 1330 
flavonoids being a ‘required’ dietary nutrient, ending the pursuit of vitamin P as an essential 1331 
nutrient. Yet, the field persevered, as although many of the criticisms were appropriate, and 1332 
flavonoids appeared non-essential for life, a significant number of animal and in vitro studies 1333 
identified biological activity. Despite these early criticisms, the number of publications on flavonoids 1334 
continued to increase at an almost exponential rate (Figure 19). 1335 
In the 1960s, publications began emerging reporting that flavonoids from oats, sorghum, 1336 
berries, and tea had significant antioxidant activity, in addition to their previously reported action 1337 
on capillary permeability (Harper, Morton, & Rolfe, 1968, 1969; Lynn & Luh, 1964; Yasumatsu, 1338 
Nakayama, & Chichester, 1965). There was even an obscure report of feasibility studies into the 1339 
effects of anthocyanins on night blindness (Borges, 1965). Against this background, interest in 1340 
flavonoid research continued to diversify over the next decade. 1341 
Mechanisms of action research in the 1970s extended into various tissues, leveraging data 1342 
from early observations on vascular permeability and capillary function, including the eye (Varma, 1343 
1976), renal and intestinal tissues (Robinson, L'Herminier, & Claudet, 1979). Studies of vascular 1344 
effects (vessel dilation) and blood pressure (BP) reduction in animal models still predominated 1345 
(Petkov & Manlov, 1978), while emerging targets included membrane transport (Robinson et al., 1346 
1979), enzyme inhibition (Borchardt & Huber, 1975), antimicrobial activity, and impact on metal 1347 
chelation and anti-tumor activity (Brown, 1980; Fujita, Nagao, Varma, & Kinoshita, 1976). Early 1348 
Page 60 of 257Comprehensive Reviews in Food Science and Food Safety
 59
studies into the activity of flavonoids focused more on enzyme activity while later works 1349 
concentrated on antioxidant effects. 1350 
Clinical studies on flavonoid-rich foods, such as tea, focused primarily on nutritive value 1351 
(vitamin, mineral contents, etc.), rather than flavonoid content, although some researchers were 1352 
starting to propose that flavonoids also contributed to the reported health effects. A review by Stagg 1353 
& Millin (1975) highlighted the likely “contribution of flavonoids to the health effects” of tea. 1354 
Interestingly, Kühanu (1976) echoed the sentiments of many current flavonoid researchers, 1355 
suggesting despite their non-essentiality, flavonoids likely played a role in promoting “optimal 1356 
health”. At this time, the hypothesized mechanisms of action were still very much linked to 1357 
processes affecting capillary function.  1358 
 1359 
Research 1980-to-1990  1360 
The 1980s saw a further proliferation of mechanistic targets in animal and in vitro studies. 1361 
In addition, there was increased focus on flavonoid subclasses beyond citrus-derived flavanones, 1362 
including flavonols, most notably quercetin 1 and flavan-3-ols. There was also a substantial number 1363 
of publications on the bioactivity of flavonoids from tea and traditional medicines, many of which 1364 
were published in Chinese, Japanese and Russian and had never been translated into English. 1365 
Reports of possible mechanisms of action continued to grow, such as effects on membrane transport, 1366 
enzyme and antioxidant activities, with research extending into impact on prostaglandin synthesis 1367 
and anti-cancer activities.  1368 
Flavonoids were still primarily considered drug or “drug-like” in the 1980s, and were 1369 
studied following a pharmaceutical model, by comparing the effects of aglycones and plant-derived 1370 
glycosides at high μmol/L concentrations and equating them with established pharmaceutical 1371 
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agents in animal and cell culture models. Additionally, anticancer properties were most often 1372 
attributed to cytotoxicity. It would be some time before nutrition and food scientists began studying 1373 
the effects of flavonoids at levels more relevant to the diet. Even in the 1980s, reviews were 1374 
beginning to note the apparent diversity of reported mechanisms of action of flavonoids, as stated 1375 
by Roger (1988) “the various effects of flavonoids suggest that numerous pharmacological 1376 
mechanisms are involved”. 1377 
 1378 
Vascular activity  1379 
The flavonol quercetin 1 is arguably the most investigated flavonoid to date, and onions and 1380 
apples are the most commonly consumed dietary sources, though most studies have used pure 1381 
quercetin (Toh, Tan, Lim, Lim, & Chong, 2013). The antithrombotic action of quercetin and 1382 
quercetin-3-O-rutinoside 13 was commonly reported in vivo, in various culture models associated 1383 
with preventing platelet aggregation and inhibiting lipoxygenase (LOX) activity (Gryglewski, Korbut, 1384 
Robak, & Swies, 1987). In animal models, 3,3'-O-dimethylquercetin 97 was also reported to improve 1385 
vascular tone in isolated vascular smooth muscle (Abdalla et al., 1989; Toh et al., 2013) [insert 1386 
structure 97] , Reports of the vascular activity of anthocyanins from berries were also emerging, 1387 
for example, anthocyanins from bilberry (Vaccinium myrtillus) were shown to prevent an increase 1388 
in vascular permeability in animal models of hypertension (Detre, Jellinek, Miskulin, & Robert, 1389 
1986).  1390 
 1391 
Anti-cancer activity  1392 
Interest in anti-cancer properties of flavonoids and flavonoid-rich foods was increasing, with 1393 
studies reporting an impact of flavonoids on phase II enzymes associated with chemo-protection 1394 
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(Talalay, 1989). Quercetin was reported to suppress phospholipid metabolism by tumor promoters 1395 
(Nishino, Nagao, Fujiki, & Sugimura, 1983) and to inhibit squamous cell carcinoma cell growth 1396 
(Castillo et al. 1989), while green tea flavonoids were shown to possess anti-mutagenic activities 1397 
(Wang et al., 1989).  1398 
 1399 
Mechanisms of action  1400 
The 1980s would witness a drastic increase in the diversity of mechanisms of action reported 1401 
for flavonoids, particularly anti-inflammatory, enzyme, and membrane transport effects. There was 1402 
an accumulation of studies reporting the ability of flavonols and flavanones to act as anti-1403 
inflammatory agents (Brasseur, 1989; Middleton & Kandaswami, 1992), including interfering with 1404 
leukocyte migration, basophil histamine release (Middleton, 1986), arachidonic acid metabolism, 1405 
and prostaglandin biosynthesis (Moore, Griffiths, & Lofts, 1983; Panthong, Tassaneeyakul, 1406 
Kanjanapothi, Tantiwachwuttikul, & Reutrakul, 1989; Welton, Hurley, & Will, 1988). Other studies 1407 
reported various actions on enzyme function (Nagai, Miyaichi, Tomimori, & Yamada, 1989) 1408 
including: activity of flavonols on protein kinase inhibition (Cochet, Feige, Pirollet, Keramidas, & 1409 
Chambaz, 1982; Ferriola, Cody, & Middleton, 1989; Rogers & Williams, 1989); flavone-induced liver 1410 
monooxygenase activity (Siess, Guillermic, Le Bon, & Suschetet, 1989); the impact of flavonoids on 1411 
xenobiotic metabolizing enzymes such as cyclooxygenase (COX) and lipoyxgenase (LOX) (Roger, 1412 
1988; Wood, Smith, Chang, Huang, & Conney, 1986); the effects of quercetin on enzyme secretory 1413 
mechanisms, including interference of neutrophil enzyme transport (Long et al.,1981); and effects 1414 
of quercetin and quercetin-3-O-rutinoside on lysosomal enzymes in fibroblasts (Vladutiu & 1415 
Middleton, 1986). Flavonoids were also reported to have high affinities for membrane transport 1416 
proteins (Kohrle, Spanka, Irmscher, & Hesch, 1988). Quercetin was shown to affect ATP-driven 1417 
pumps, including Na/K-ATPase and calcium-ATPase, consequently affecting ion exchange flux 1418 
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(Bakker-Grunwald, Andrew, & Neville, 1980; Breitbart, Stern, & Rubinstein, 1983; Racker, 1986). 1419 
There was continued pursuit of the redox behavior of flavonoids where many speculated 1420 
electrochemical properties of flavonoids were driving their observed biological effects (Hodnick, 1421 
Milosavljevic, Nelson, & Pardini, 1988). 1422 
 1423 
Research 1990-to-2000  1424 
Flavonoid-rich foods, supplements, and extracts became more of a focus in the 1990s as 1425 
opposed to the earlier more pharmacological study designs. Particular attention was given to rich 1426 
sources of quercetin 1 and (−)-epicatechin 38/(+)-catechin 28 (Williamson & Manach, 2005). A 1427 
large number of reviews focused on tea and its cardiovascular and anti-cancer activities, while 1428 
studies exploring the impact of wine on cardiovascular disease (CVD) were also increasing, 1429 
recognizing flavonoids as a contributory factor to the observed benefits of moderate wine 1430 
consumption (Rosenberg Zand, Jenkins, & Diamandis, 2002).  1431 
A proliferation of human intervention studies was seen in the 1990s, whereas animal and in 1432 
vitro studies had dominated the literature in previous decades. An expanding number of health 1433 
outcomes was reported, with a focus on reduction of oxidative stress biomarkers, BP, lipids, 1434 
lipoproteins, and various mechanisms of vascular function (Williamson & Manach, 2005). The field 1435 
was also diversifying, exploring more novel flavonoid activities, including impact on energy 1436 
expenditure, body weight, mental performance, anti-viral activity, renal function, and oral disease 1437 
(Nijveldt et al., 2001; Sakagami, Oi, & Satoh, 1999; Williamson & Manach, 2005). 1438 
 1439 
The French Paradox and the Mediterranean diet  1440 
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The introduction of the French Paradox (Dolnick, 1990;  Renault & de Lorgeril, 1992), which 1441 
arose from the observation that the French population had a low incidence of CHD despite having a 1442 
high fat intake (Constant, 1997), led to a significant change of focus of research in the 1990s. The 1443 
difference between the French diet and that of other non-Mediterranean cultures was reported to 1444 
be a higher consumption of red wine, and this sparked new interests in flavonoid research as red 1445 
wine was recognized as a rich source of flavonoids (Formica & Regelson, 1995). This would also 1446 
lead to renewed interest in the Mediterranean Diet, which contains other flavonoid- and 1447 
(poly)phenol-rich foods such olive oil, fruits, coffee, and nuts (Davis, Bryan, Hodgson, & Murphy, 1448 
2015; Trichopoulou, Vasilopoulou, & Lagiou, 1999). Meta-analyses of studies published prior to 1449 
2000 reported beneficial effects of low-to-moderate red wine consumption on cardiovascular 1450 
events (Rotondo, Di Castelnuovo, & de Gaetano, 2001). Studies using red wine or red wine extracts 1451 
reported numerous mechanisms of action, including: attenuation of myocardial ischemic 1452 
reperfusion injury, inhibition of platelet aggregation, promotion of endothelial nitric oxide synthase 1453 
(eNOS), inhibition of thromboxane synthesis, modulation of lipoprotein secretion, inhibition of 1454 
carcinogenesis, low-density lipoprotein (LDL) oxidation, phospholipase A2 (PLA2), COX and 1455 
phosphodiesterase, increase in cyclic nucleotide concentrations, and inhibition of protein kinases 1456 
involved in cell signaling (Das et al., 1999; Halpern et al., 1998; Soleas, Diamandis, & Goldberg, 1457 
1997). For an extensive review of the current evidence of wine flavonoids in health and disease 1458 
refer to Fernandes, Perez-Gregorio, Soares, Mateus, & de Freitas (2017).  1459 
 1460 
Vascular activity  1461 
Tea was the focus of many cohort studies in the 1990s, most notably the Zutphen study, which 1462 
reported that the incidence of stroke was significantly decreased in those having the highest intake 1463 
of flavonols and flavones (Hertog et al., 1993). Moreover, cohort studies reported reduced risk of 1464 
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CVD, while randomized controlled trials (RCTs) focused on risk factors such as LDL-cholesterol and 1465 
homocysteine-lowering activity. Even though most authors at that time agreed that the mechanisms 1466 
of action of flavonoids were not fully understood, the vast consensus was that radical scavenging 1467 
was somehow involved (Ursini, Tubaro, Rong, & Sevanian, 1999). In the 1980s, researchers 1468 
recognized the importance of nitric oxide (NO) in regulating vascular homeostasis, including 1469 
regulating vascular tone, blood flow, leukocyte adhesion, platelet reactivity, and smooth muscle cell 1470 
proliferation (Higashi, Noma, Yoshizumi, & Kihara, 2009; Kawashima & Yokoyama, 2004; Tomasian, 1471 
Keaney, & Vita, 2000). As NO is a free radical itself, and flavonoids were known to possess 1472 
antioxidant properties, protection of NO provided a logical avenue to explore the antioxidant 1473 
properties of flavonoids. At the time, it was believed that dietary antioxidants could preserve NO by 1474 
preventing its reaction with superoxide and/or other oxygen-centered radicals, maintaining 1475 
vasodilatory response, and, subsequently, vascular homeostasis. Most of this evidence came from 1476 
studies using tocopherols and vitamin C, however, investigations were already pursuing the impact 1477 
of flavonoids on redox chemistry, and epidemiological studies reported associations between 1478 
consumption and incidence of vascular disease, particularly for wine and tea; consequently, this 1479 
avenue would become a significant focus of flavonoid research (Ursini et al., 1999). In opposition to 1480 
the theory of preserved NO bioavailability, oxidative modification of LDL was also known to be an 1481 
initiating factor in plaque formation, and as flavonoids were observed to scavenge radicals in vitro, 1482 
this would also become a substantial area of flavonoid research (Chopra & Thurnham, 1999; Ursini 1483 
et al., 1999). These avenues of research were primarily explored using animal models, where 1484 
flavonoids were observed to reduce the severity of vascular disease (Duthie & Bellizzi, 1999). For a 1485 
detailed review of the role of flavonoids in vascular health, describing the state of research in the 1486 
1990s, refer to Ursini et al. (1999).  1487 
 1488 
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Anti-cancer activity  1489 
A substantial increase in the number of studies into the anti-cancer effects of tea in both human 1490 
cohort and animal studies was reported, detailing reduced incidence of cancers of the mouth, 1491 
esophagus, stomach, pancreas, lung, prostate, bladder, colon, and rectum (Isemura, et al. 2000; 1492 
Lamson & Brignall, 2000; Trevisanato & Kim, 2000). 1493 
 1494 
 Mechanisms of action  1495 
Despite the growing focus of studies exploring the radical-scavenging effects of flavonoids on 1496 
LDL-cholesterol and NO bioavailability, effects on immune and inflammatory cell functions 1497 
continued to be of interest, but they were largely overshadowed by studies focusing on antioxidant, 1498 
vascular, and anti-cancer effects. With respect to anti-inflammatory properties, studies continued to 1499 
report impacts on enzyme systems associated with immune cell action and inhibition of 1500 
prostaglandin synthesis (Manthey, 2000; Middleton, 1998). Other reported mechanisms included: 1501 
inhibition of cell proliferation and induced apoptosis; modulation of phase I and II enzyme systems; 1502 
inhibition of protein kinases; and inhibition of phosphorylation of c-jun and p44/42 mitogen-1503 
activated protein kinase (MAPK) (Ahmad & Mukhtar, 1999; Brown, 1999; Lin & Liang, 2000; Yang et 1504 
al., 2000; Yang, Lee, Chen, & Yang, 1997). 1505 
 1506 
The radical-scavenging hypothesis 1507 
Reviews in the 1990s often reported on antioxidant properties of flavonoids, citing direct 1508 
radical-scavenging activity or action through inhibition of endothelial eNOS or xanthine oxidase 1509 
(Formica & Regelson, 1995; Rice-Evans & Miller, 1996), and in much of the literature the in vitro 1510 
antioxidant capacity of foods was thought to translate to in vivo protection of free-radical damage 1511 
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(Rice-Evans & Miller, 1996; Catapano, 1997; Wiseman, Balentine, & Frei, 1997; Duthie & Bellizzi, 1512 
1999; Eastwood, 1999). Numerous ex vivo and in vitro effects were observed, including increased 1513 
plasma/serum antioxidant capacity, and decreased phospholipid hydroperoxides, superoxide 1514 
dismutase activity, DNA damage, plasma malondialdehyde, and urinary 8-hydroxy-2'-1515 
deoxyguanosine (Sakagami, Oi, & Satoh, 1999; Nijveldt et al., 2001; Williamson & Manach, 2005). 1516 
There was growing interest in measuring the in vitro total antioxidant activity of foods, using assays 1517 
such as the Trolox equivalent antioxidant activity (TEAC) assay, which measured concentration of a 1518 
water-soluble vitamin E analog relative to the production of a stable radical cation chromophore, 1519 
ABTS·+ (Rice-Evans, Miller, & Paganga, 1996; Williamson & Manach, 2005). 1520 
Despite near saturation of the literature with studies following the antioxidant hypothesis, 1521 
some researchers were beginning to question its biological relevance. A review by Bors, Michel, & 1522 
Stettmaier (1997) stated “despite the numerous reports of flavonoids acting as specific scavengers 1523 
for superoxide, few report rate constants or utilize appropriate methodologies”, listing pulse 1524 
radiolysis and electron paramagnetic resonance spectroscopy as being required to prove direct 1525 
radical-scavenging activity. They concluded their review with, “flavonoids in vivo play a much wider 1526 
role than acting merely as antioxidants”, which has been the consensus of most flavonoid 1527 
researchers for decades and remains so today. Many experts still ponder where the field would be 1528 
today if the radical-scavenging theory of flavonoid activity had not been not pursued for so long. 1529 
 1530 
Research 2000-2010  1531 
Tea and red wine studies were at the forefront of flavonoid research in the 2000s, flavan-3-ol-1532 
rich cocoa and chocolate studies were on the rise, and berry research was also gaining momentum. 1533 
Evidence continued to amount for the cardiovascular and anti-cancer activity of flavonoids while 1534 
the diversity of therapeutic targets was also growing, which included an impact on cognitive decline, 1535 
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type-2 diabetes, and anti-allergic properties. In addition, recognition of an obesity-induced 1536 
metabolic imbalance referred to as ‘metabolic syndrome’ provided new avenues for flavonoid 1537 
research, providing a mechanistic link between the obesity-related disorders, type-2 diabetes and 1538 
cardiovascular disease. The persistent focus on antioxidant activity of flavonoids was beginning to 1539 
be questioned, despite its increased interest by industry as a marketing tool. While there were 1540 
considerable data describing the potential health benefits of flavonoid intake, conclusive and direct 1541 
evidence of their disease prevention mechanisms remained unresolved, possibly as a result of 1542 
mechanistic activity being primarily explored by using unmetabolized aglycones, and their sugar 1543 
conjugates of plant origin, in cultured cells. Although it was not universally accepted at the time, as 1544 
discussed in Section 3, bioavailability studies were accumulating, indicating that the principal 1545 
flavonoid-derived structures in the circulation, in addition to their phase II metabolites, were 1546 
phenolic acid and aromatic metabolites originating from microbial catabolism in the lower intestine. 1547 
The first studies were starting to emerge focusing on the impact of this metabolism on flavonoid 1548 
bioactivity, leading to an acknowledgement that radical-scavenging capacity may not be the “holy 1549 
grail” of flavonoid action, as metabolism often abolished radical-scavenging activity (Del Rio et al., 1550 
2010; Kay, 2010; Williamson & Clifford, 2010). 1551 
 1552 
Cardiovascular/cardio-metabolic disease  1553 
Epidemiological studies describing associations between long-term intake of flavonoid-rich 1554 
foods and decreased incidence of CVD were accumulating in the 2000s, while animal models 1555 
following administration of flavonoids reported improvement in atherosclerotic endpoints such as 1556 
reduction in oxidized LDL-cholesterol, BP, and myocardial and cerebral infraction (Del Rio, et al., 1557 
2013). Foods most consistently reported as having cardio-protective effects included cocoa, tea, red 1558 
wine, berries, and citrus. There was continued focus on the radical-scavenging effects of flavonoids 1559 
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on NO bioavailability, however, some investigators were beginning to link flavonoids known 1560 
enzyme activities to numerous other CVD mechanisms, including inhibition of the superoxide anion-1561 
producing enzyme, NADPH oxidase (NOX) (Schewe, Steffen, & Sies, 2008). Structure-activity 1562 
relationship studies of (−)-epicatechin 38 and its metabolites in a human umbilical vein endothelial 1563 
cell model of angiotensin II-stimulated superoxide production revealed methylation of the catechol 1564 
B-ring, or sole presence of a 4’-OH group, resulted in NOX inhibitory activity despite the absence of 1565 
the reactive catechol structure (Steffen, Schewe, & Sies, 2007; Steffen, Gruber, Schewe, & Sies, 2008). 1566 
This finding not only identified an alternative mechanism to radical scavenging, but provided early 1567 
proof that metabolism did not necessarily confer reduced activity. Furthermore, several animal 1568 
models of vascular disease showed that quercetin 1 induced a dose-dependent reduction in BP, 1569 
while a few others provided evidence of beneficial effects on vascular endothelial function and renal 1570 
hypertrophy (Perez-Vizcaino, Duarte, Jimenez, Santos-Buelga, & Osuna, 2009). Interestingly, 1571 
quercetin-3-O-glucuronide 21 was shown to accumulate in foam cells within human atherosclerotic 1572 
lesions (Kawai et al., 2008) revealing the direct presence of quercetin metabolites at the site of 1573 
tissue injury.  1574 
The emerging role of flavonoid-rich cocoa and chocolate in cardiovascular health was 1575 
becoming more evident in the 2000s. Like quercetin-3-O-glucuronide, epicatechin-3-O-gallate 98 1576 
was also shown to accumulate in foam cells within human atherosclerotic lesions (Kawai, Tanaka, 1577 
Murota, Naito, & Terao, 2008). [insert structure 98] There was an increase in studies exploring the 1578 
impact of chocolate and cocoa on human endothelium-dependent brachial artery vasodilation, 1579 
where findings in previous decades relied on cell and animal models. Three separate meta-analyses 1580 
published in the 2000s concluded that RCTs feeding flavanol-3-ol-rich cocoa, for various durations, 1581 
resulted in reduced biomarkers of CVD risk, including BP (Desch et al., 2010; Shrime et al., 2011), 1582 
high-density lipoprotein (HDL), LDL, insulin, mean arterial pressure and endothelial function as 1583 
Page 70 of 257Comprehensive Reviews in Food Science and Food Safety
 69
measured by flow-mediated vasodilation (FMD) (Engler & Engler, 2006; Shrime et al., 2011). 1584 
Acute/short-term feeding studies (2-12 week) with flavan-3-ol-rich-cocoa also significantly 1585 
increased FMD response in healthy, obese, hypercholesterolemic, and hypertensive adults (Del Rio 1586 
et al., 2013), while hypocholesterolemic effects and improvement in glycemic response were 1587 
reported in humans and rodent models (Kim et al., 2014). Most clinical studies focused on vascular 1588 
endpoints such as BP and FMD, with a few studies reporting significant activity on lipids, P-selectin, 1589 
vascular cell adhesion molecule-1 (VCAM-1), and platelet activation (Hooper et al., 2012; Del Rio et 1590 
al., 2013; Kim et al., 2014). Yet, the ex vivo antioxidant capacity of flavan-3-ols was still the focus of 1591 
many publications, including reports of positive impact on oxidized biomarkers, such as oxidized-1592 
LDL and F2 isoprostanes (Engler & Engler, 2006).   1593 
At this time, the perceived mechanism behind the impact of cocoa on endothelial function was 1594 
increased NO bioavailability, potentially through sacrificial radical scavenging by flavonoids (Engler 1595 
& Engler, 2006). However, some were beginning to report a more likely scenario where flavan-3-ols 1596 
acted by regulating cell-signaling cascades involving nuclear factor kappa-light-chain-enhancer of 1597 
activated β cells (NF-ĸβ) and nuclear factor (erythroid-derived 2)-like 2 (Nrf2) (Fraga & Oteiza, 1598 
2011). Furthermore, new avenues in neuronal function and cognition were becoming more 1599 
pronounced in chocolate research, where studies reported improved special memory, memory and 1600 
learning, and peripheral and cerebral vascular blood flow, primarily using rodent models (Kim et al., 1601 
2014).  1602 
Studies on black tea reported positive impacts on BP and FMD, with a few reporting effects on 1603 
lipids, lipoproteins, and platelet aggregation, while studies on green tea most commonly reported 1604 
beneficial effects on BP, FMD, body mass index (BMI), and insulin resistance (González-Gallego, 1605 
García-Mediavilla, Sánchez-Campos, & Tuñón, 2010; Del Rio et al., 2013). It should be noted that 1606 
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many other studies reported no effect of green or black tea on CVD risk factors (Hodgson, 2006; Del 1607 
Rio et al., 2013). 1608 
Investigations involving moderate red wine consumption produced mixed results, particularly 1609 
when comparing red wine to dealcoholized red wine. Investigations observing significant effects 1610 
generally describe activity on FMD, BP, and heart rate (HR), with a few studies reporting positive 1611 
impacts on lipoproteins, insulin sensitivity, and platelet aggregation (Del Rio et al., 2013). 1612 
Research with berry and berry-derived juices found improvements in BP, with a few studies 1613 
detailing positive impact on lipids and lipoproteins, pulse wave velocity, and insulin sensitivity; yet 1614 
many others described a lack of efficacy of chronic intake of anthocyanin-rich foods on BP (Del Rio 1615 
et al., 2013). Animal studies noted endothelium-dependent relaxation of isolated porcine coronary 1616 
arterial rings, elicited by chokeberry and bilberry extracts (Bell & Gochenaur, 2006). Publications 1617 
most often have associated beneficial effects of berry consumption with their high levels of 1618 
anthocyanins (Del Rio et al., 2013; Bell & Gochenaur, 2006).  1619 
Despite the extensive consumption of oranges/orange juice in the USA and early focus with 1620 
respect to ‘vitamin P-like’ activity, citrus was an understudied dietary source of flavonoids in the 1621 
2000s, although a few investigations observed beneficial effects on BP, HDL-cholesterol, and 1622 
triacylglycerol levels. For an extensive review of health-promoting effects of the citrus flavanone 1623 
hesperetin-7-O-rutinoside 80 (hesperidin) see Li and Schluesener (2017).  1624 
 1625 
Diabetes  1626 
Flavonoids in multiple studies have been reported to i) improve glucose tolerance, ii) enhance 1627 
glucose uptake in peripheral tissues, iii) increase insulin resistance, iv) directly impact glucose 1628 
transporters, v) regulate rate-limiting enzymes involved in carbohydrate metabolism, including α-1629 
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glucosidase and aldose reductase, and vi) improve platelet function (Cazarolli et al., 2008; Nicolle, 1630 
Souard, Faure, & Boumendjel, 2011; Del Rio et al., 2013). Although the first papers on flavonoids and 1631 
starch-digesting enzyme activity appeared in the 1980s (Griffiths, 1986), the action of flavonoids on 1632 
glycemic control was not fully explored until after 2000.  Publications describing the inhibition of 1633 
carbohydrate-digesting enzymes showed that flavonoids had the potential to inhibit post-prandial 1634 
glucose spikes (see Hanhineva et al.  2010); however, in vivo studies with human volunteers would 1635 
not be conducted for some time. 1636 
 1637 
Cancer  1638 
A considerable number of animal and cell culture studies support anticancer mechanisms of 1639 
flavonoids, however, epidemiological studies provide inconsistent evidence, especially when 1640 
considering the results of prospective cohort studies. Inhibition of cancer cell growth, angiogenesis, 1641 
and migration has been reported in animal studies for flavonoids, however, most mechanistic 1642 
evidence is derived from culture studies using unmetabolized flavonoids. For a detailed review of 1643 
the available evidence for the anti-cancer activity of flavonoids refer to Zhou et al. (2016).    1644 
 1645 
Cognition 1646 
The 2000s would see new therapeutic targets emerge, particularly cognition, age-related 1647 
neurodegeneration, and cognitive decline. Observational data suggested that regular moderate 1648 
intake of flavonoid-rich foods, such as cocoa, berries, and red wine provided cognitive benefit. 1649 
Although evidence in humans was lacking, evidence from animal studies, primarily rodent, 1650 
identified a positive impact of berries, cocoa, wine, apples, and citrus on cognitive outcomes. 1651 
Researchers primarily observed improved learning, working memory, special memory, and memory 1652 
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acquisition and retention, most often by feeding juice extracts. The reported effects were linked to 1653 
improvement in cerebrovascular blood flow and inhibition on neuro-inflammation (Del Rio et al., 1654 
2013; Kim et al., 2014; Vafeiadou, Vauzour, & Spencer, 2007).   1655 
 1656 
Mechanism of action  1657 
The therapeutic effect of flavonoids was observed in many disease pathology models, including 1658 
atherosclerosis, ischemia-reperfusion, metabolic syndrome, inflammatory bowel disease, brain and 1659 
skin inflammation, toxic shock and asthma. These pathologies share common underlying processes 1660 
or mechanisms, most notably inflammation (Gonzales et al., 2011). For example, endothelial 1661 
dysfunction is an early-stage pathology in the development of atherosclerosis, often considered a 1662 
consequence of decreased NO bioavailability leading to a failure to maintain vascular endothelium 1663 
homeostasis (Figure 20). However, the presence of NO also aids in suppressing NFĸβ activation, 1664 
consequently inhibiting the release of pro-inflammatory and anti-thrombotic proteins (Montezano 1665 
et al., 2011; Rajendran et al., 2013). In disease states a lack of homeostasis leads to increased 1666 
expression of adhesion molecules, recruitment of leucocytes, and progression of the pathology 1667 
(Granger, Vowinkel, & Petnehazy, 2004). Even though the most commonly reported activity of 1668 
flavonoids is their ability to alter cardiovascular function, in vitro studies often report mechanisms 1669 
which have a shared role in anti-inflammatory homeostasis, including: scavenging of free radicals, 1670 
metal chelation, impact on ion channel regulation, inhibition of xanthine oxidase, NOX and 1671 
lipoxygenase , regulation of inducible nitric oxide synthase (iNOS), COX-2 expression, leukocyte 1672 
activation, and platelet aggregation (Gilbert & Liu, 2010; Hidalgo et al. 2012; Lazze et al. 2006; 1673 
Mladenka, Zatloukalova, Filipsky, & Hrdina, 2010; Scholz, Zitron, Katus, & Karle, 2010; Williamson, 1674 
Barron, Shimoi & Terao, 2005).  Based on this evidence researchers postulated flavonoids may 1675 
prevent the development of atherosclerosis by either restoring endothelial homeostasis or 1676 
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attenuating the initiation or progression of inflammation (Chen et al., 2011; Quintieri et al., 2013; 1677 
Romero et al., 2009; Sudano et al., 2012).  1678 
 1679 
Anti-inflammatory effects 1680 
Although not fully understood, the health-promoting effects of flavonoids were often speculated 1681 
to involve the modulation of key enzymes and cell-signaling cascades involved in 1682 
antioxidant/xenobiotic metabolism and/or cytokine regulation (Perez-Vizcaino, Duarte, Jimenez, 1683 
Santos-Buelga, & Osuna, 2009). In human studies, reports of anti-inflammatory activity are 1684 
somewhat limited; however, a few feeding studies observed reduced C-reactive protein (CRP), 1685 
interleukins/chemotactic proteins, adhesion proteins/molecules, and oxidative biomarkers. Animal 1686 
and cell culture studies reflected the human investigations, but they reported additional activities, 1687 
including inhibition of tumor necrosis factor-α (TNF-α), interferon gamma (IFN-γ), iNOS, 1688 
COX1/COX2, LOX, PLA2, selectins, and upregulated expression of heme oxygenase (HO-1)(Bousova 1689 
& Skalova, 2012; Del Rio et al., 2013; Gomes, Fernandes, Lima, Mira, & Corvo, 2008; González-1690 
Gallego et al., 2010; Hodgson, 2006; Romero et al., 2009; Ryter, Otterbein, Morse, & Choi, 2002; 1691 
Sanchez et al., 2006, 2007; Sorrenti et al., 2007). The anti-inflammatory evidence spanned many cell 1692 
types, including macrophages, osteoblasts, dendritic cells, lymphocytes, mastocytes, neutrophils, 1693 
endothelial cells, fibroblasts, and epithelial cells (Gonzalez et al., 2011; Gonzalez-Gallego, Garcia-1694 
Mediavilla, Sanchez-Campos, & Tunon, 2010).  1695 
Despite reports of anti-inflammatory activity, many studies demonstrate effects to be much 1696 
lower than pharmacological steroidal and non-steroidal anti-inflammatory drugs (Rajendran et al., 1697 
2013), suggesting a role in line with the attenuation of a low-level inflammatory insult over 1698 
pharmacological treatment. Furthermore, the sheer number of activities reported suggests either 1699 
some unknown overlapping mechanism of action or multiple mechanism are at play (Gomes et al., 1700 
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2008; Kim et a. 2004; Rajendran et al., 2013). For a detailed review presenting pathway diagrams 1701 
which reflect the state of knowledge of mechanisms of action at that time, see Gomes, Fernandes, 1702 
Lima, Mira, & Corvo (2008). Additionally, Gonzalez et al. (2011) and Gonzalez-Gallego, Garcia-1703 
Mediavilla, Sanchez-Campos, & Tunon, (2010) provide notable reviews of research summarizing 1704 
2000-2010 studies, defining activity by flavonoid class and cell type. 1705 
 1706 
Anti-cancer  1707 
New evidence has identified direct anti-cancer mechanisms of action of flavonoids, with 1708 
flavonol and flavan-3-ol studies pointing to epigenetic modifications through histone or DNA 1709 
methylation or acetylation (Gilbert & Liu, 2010). Multiple molecular mechanisms of action were 1710 
reported for many unmetabolized flavonoids, such as quercetin 1, (−)-epigallocatechin-3-O-gallate 1711 
12, and anthocyanins (Androutsopoulos, Papakyriakou, Vourloumis, Tsatsakis, & Spandidos, 2010; 1712 
Chen & Chen, 2013; Del Rio et al., 2013; Kandaswami et al., 2005; Moon, Wang, & Morris, 2006; 1713 
Nishiumi et al., 2011; Singh & Agarwal, 2006; Spagnuolo et al., 2012), ranging from activities on cell 1714 
cycle, apoptosis and autophagy, and kinase and transcription factor regulations (Zhou et al., 2016). 1715 
But again, authors were beginning to question the physiological relevance of much of the in vitro 1716 
culture data, given the use of unmetabolized flavonoids which, at best, have very limited occurrence 1717 
in vivo (Androutsopoulos et al., 2010; Moon et al., 2006). Despite the vast amount of literature 1718 
reporting the anti-cancer actions of flavonoids, their impact on cancer incidence and mortality in 1719 
longitudinal studies has not been established (see Del Rio et al., 2013). 1720 
 1721 
Neuroprotection  1722 
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Neuroprotection was beginning to be a prominent endpoint in the landscape of flavonoid 1723 
research, with reported mechanisms of action continuing to grow during the 2000s. Effects in 1724 
animal models included improvement in cerebrovascular blood flow and inhibition of 1725 
neuroinflammation, which were potentially linked to selective interactions with protein kinase and 1726 
lipid kinase signaling cascades (Del Rio et al., 2013; Spencer, 2010). The majority of mechanistic 1727 
evidence stemmed from studies using quercetin 1, luteolin 5, (−)-epigallocatechin-3-O-gallate 12, 1728 
and (+)-catechin 28 in cultured cells, primarily microglial cells, and reporting activity on heme 1729 
oxygenase-1 (HO1) and thioredoxin, inhibition of iNOS and NOX expression, reduction of 1730 
prostaglandin E2 (PGE2) and pro-inflammatory chemokines (TNF-α, IL-1β, IL-6, IL-8, IP-10, 1731 
monocyte chemoattractant protein-1 [MCP-1], RANTES,) inhibition of CCAAT/enhancer activator 1732 
protein delta, activator protein 1, cluster of differentiation 40 ligand (CD40L), signal transducer and 1733 
activator of transcription-1, p38, extracellular signal-regulated kinase (ERK), c-Jun N-terminal 1734 
kinase (JNK), protein kinase B (Akt), Janus Kinase and receptor tyrosine-protein kinase 2, and 1735 
stimulation of TRX1. For an extensive review of flavonoids, food sources, and neuro-cognitive effects 1736 
refer to Spencer, Vafeiadou, Williams, & Vauzour (2012) and Rodrigues-Mateos et al. (2014c). 1737 
 1738 
Antioxidants  1739 
Studies exploring the antioxidant hypothesis continued to grow in the 2000s, along with 1740 
significant interest in endothelial dysfunction and the use of FMD as a surrogate marker of vascular 1741 
health.  At that time, the perceived mechanistic link between flavonoid consumption and improved 1742 
FMD response was the action of flavonoids as a ‘sacrificial’ radical scavenger, preserving the 1743 
bioactivity of NO. A large number of studies explored the biological impact of wine, berries, olive oil, 1744 
cocoa/chocolate, and tea, the ‘so called’ antioxidant-rich foods (Kay, Kris-Etherton, & West, 2006). 1745 
This level of attention was no doubt perpetuated by scientists and industry relating the in vitro 1746 
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antioxidant capacity of various foods to health effects, and utilizing tests such as the TEAC, oxygen 1747 
radical absorbance capacity (ORAC), and ferric reducing antioxidant potential (FRAP) assays to 1748 
promote the potential health effects of foods and food-derived products. The fact that many reviews 1749 
were being published at the time focusing on the antioxidant activity of flavonoids indicates that 1750 
this was still an area of substantial research focus. Furthermore, as ex vivo antioxidant assays were 1751 
relatively simple to carry out and results were frequently positive, and as all flavonoids are radical 1752 
scavengers to some extent, it was relatively easy to publish these results. Statements such as “the 1753 
pharmacological effects of flavonoids are mainly due to their antioxidant activity” were 1754 
commonplace in publications, although an almost equal weight was beginning to be given to the 1755 
counterargument, focusing on the apparent ability of flavonoids to modulate both antioxidant and 1756 
anti-inflammatory enzymes (Amic et al., 2007; Tsuji, Stephenson, Wade, Liu, & Fahey, 2013).  1757 
Studies reporting antioxidant activity over the decades often focused on the structure-1758 
activity relationships of the various flavonoid classes and subclasses, where activity was related 1759 
mainly to the impact of hydroxylated phenol rings, nucleophilic regions, and Michael acceptor 1760 
functionalities (Amic et al., 2007; Dinkova-Kostova et al., 2007; Tsuji et al., 2013). The one nuance of 1761 
this area of research was that studies were beginning to explore the impact of phase II metabolism 1762 
on antioxidant activity. Much of this work focused on quercetin (Terao, 2009).  1763 
By 2010 researchers had started to to acknowledge that the health effects of flavonoids were 1764 
likely not only a result of direct antioxidant activity, but also included inhibition of radical-forming 1765 
enzymes such as xanthine oxidase, NOX and lipoxygenase, in addition to impacts on platelet 1766 
aggregation, leukocyte adhesion, and vasodilatory properties. It was becoming apparent that 1767 
flavonoids had differential bioactivity across various cells, tissues, and disease states (i.e., healthy vs 1768 
disease models) (Mladenka et al., 2010). Furthermore, radical-scavenging data were not supported 1769 
by the growing literature on flavonoid bioavailability. Initially this ‘missing link’ was assumed to be 1770 
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activity of phase II conjugates of aglycones, however, as early as 2000 the need to better assess the 1771 
role of the colonic microflora in flavonoid bioactivity was beginning to be discussed (Scalbert & 1772 
Williamson, 2000). Researchers soon established that gut metabolites of quercetin 1, such as 3,4-1773 
dihydroxyphenylacetic acid 25 (Rechner et al., 2002), had comparable activity to quercetin in some 1774 
assay systems, suggesting that metabolism, in this case microbial catabolism, did not necessarily 1775 
reduce biological activity (Glasser, Graefe, Struck, Veit, & Gebhardt, 2002). 1776 
 1777 
Metabolism: impact on bioactivity 1778 
In the early 2000s a few research groups began to focus on phase II conjugation of flavonoid 1779 
aglycones/glycosides post-absorption.  Even though the microbial catabolism of flavonoids had 1780 
been reported (Blaut, Schoefer, & Braune, 2003; Scalbert, Morand, Manach, & Remesy, 2002), it had 1781 
yet to be accepted as playing a significant role in the biological functionality of flavonoids. The 1782 
impact of phase II metabolism, principally glucuronidation and methylation, on the biological 1783 
activity of quercetin and various flavan-3-ols was a major focus at that the time (Williamson, Barron, 1784 
Shimoi, & Terao, 2005). Interestingly, in opposition to the previous antioxidant research, which 1785 
predicted that conjugation would result in a reduced bioactivity, studies were reporting increased 1786 
or differential activity of flavonoid metabolites on multiple enzyme systems (Beekmann et al., 2012). 1787 
For example, cultured lung cancer cells were shown to have reduced proliferation and increased 1788 
apoptosis when treated with an extract of quercetin glucuronides isolated from rabbits (Yang et al., 1789 
2006), while metabolites isolated from rats were shown to inhibit vascular endothelial cell 1790 
hyperglycemic-induced apoptosis through a mechanism involving the inhibition of JNK and caspase-1791 
3 (Chao, Hou, Chao, Weng, & Ho, 2009). Quercetin metabolites, both glucuronide and sulfate, were 1792 
reported to inhibit lipid peroxidation, COX-2, 15-lipoxygenase, xanthine oxidase, JNK, caspase-3, and 1793 
vascular endothelial growth factor (VEGF), and to prevent endothelin-1-induced endothelial cell 1794 
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dysfunction, as well as angiogenesis in various cell models (Beekmann et al., 2012; Day, Bao, Morgan, 1795 
& Williamson, 2000; Del Rio et al., 2013; Lodi et al., 2009). Pretreatment of endothelial cells with 1796 
methylated (+)-catechin 28 metabolites was also reported to decrease cell adhesion whereas the 1797 
unmetabolized precursors had no effect (Koga & Meydani, 2001b). In addition, (−)-epicatechin 28 1798 
and (−)-epigallocatechin 99 metabolites isolated from human and rat urine inhibited tyrosine 1799 
nitration and the release of arachidonic acid from colorectal adenocarcinoma cells (Lu et al., 2003; 1800 
Williamson, Barron, Shimoi & Terao, 2005). Finally, the enzyme which converted flavonoid 1801 
glucuronides back to their aglycone forms, β-glucuronidase, was activated during inflammation in 1802 
certain systems (Kawai et al. 2008), potentially indicating that more active aglycones would also be 1803 
present at sites of inflammation. 1804 
 1805 
Microbiome  1806 
By the late 2000s it had become evident that intestinal microbiota played a crucial role in the 1807 
metabolism of phytochemicals. A global focus had been spearheaded with the goal of understanding 1808 
the relationships between the human epigenome, metabolome, and microbiome. These initiatives 1809 
included the: NIH Jumpstart Program (launched in 2007) & NIH Human Microbiome Project (2008, 1810 
USA); Irish ELDERMET initiative (2007); Metagenomics of the Human Intestinal Tract (MetaHIT, 1811 
2008) initiative; French National Agency for Research project MicroObes (2008); Australian 1812 
Jumpstart Human Microbiome project (CSIRO, 2009); Canadian Human Microbiome Initiative 1813 
(2009); Korean Microbiome Diversity initiative (2010); European Commission on International 1814 
Human Microbiome Standards (IHMS, 2011); and the French initiative MetaGenoPolis (France INRA 1815 
2012) (Duda-Chodak, Tarko, Satora, & Sroka, 2015; Lepage et al., 2013). With this new focus on 1816 
intestinal microflora, publications exploring flavonoid microbial activity began to emerge. 1817 
Page 80 of 257Comprehensive Reviews in Food Science and Food Safety
 79
The earliest studies exploring the impact of flavonoids on the intestinal microflora were 1818 
primarily focused on either increasing the population of so-called ‘beneficial bacteria’ (probiotic 1819 
effects) or inhibiting the growth of perceived ‘deleterious species’ (antimicrobial activity). Some 1820 
flavonoids appeared to be potent inhibitors of microorganism growth, particularly the green and 1821 
black tea flavan-3-ol monomers, (+)-catechin 28, (−)-epicatechin 38, (−)-epigallocatechin 99, and 1822 
(+)-gallocatechin 100, which were reported to inhibit pathogenic microbial growth (Duda-Chodak, 1823 
Tarko, Satora,  & Sroka, 2015). For example, incubations with (−)-epicatechin and (+)-catechin were 1824 
observed to promote the growth of Eubacterium rectale/Clostridium coccoides, Lactobacillus spp., 1825 
and Bifidobacterium spp. and to decrease growth of Clostridium histolyticum. A significant increase 1826 
in the growth of Eubacterium rectale/Clostridium coccoides was also reported with the inoculation of 1827 
(+)-catechin (Tzounis et al., 2008). [insert structures 99-103] Alternatively, (−)-epicatechin, (+)-1828 
catechin, gallic acid 101, 3-O-methyl-gallic acid 102, and caffeic acid 103 all suppressed the growth 1829 
of pathogens like Clostridium perfrigens, Clostridium difficile, and Bacteroides spp. Caffeic acid was 1830 
reported to be the strongest inhibitor, especially for E. coli, Salmonella, Pseudomonas, Clostridium, 1831 
and Bacteroides (Lee, 2006).  1832 
 1833 
Mechanism of action of microbial metabolites 1834 
A mixture of flavan-3-ol metabolites from rats was reported to reduce monocyte adhesion in 1835 
human aortic endothelial cells (Koga & Meydani, 2001a). 3-O-Methyl-gallic acid and 2,4,6-1836 
trihydroxybenzaldehyde 104 were shown to induce apoptosis and inhibit cell proliferation in Caco-1837 
2 cells, while valerolactones, the microbial-derived catabolites of flavan-3-ols (see Section 3.2), were 1838 
identified as inhibitors of cancer cell growth, matrix metalloproteinase, and NO production by 1839 
macrophages (Blaut, et al., 2003; Grimm, Schafer, & Hogger, 2004; Lambert, Rice, Hong, Hou, & Yang, 1840 
2005; Scalbert et al., 2002; Selma, Espin, & Tomas-Barberan, 2009). 1841 
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[insert structures 104 & 105] 1842 
 Incubation of a phenolic extract containing primarily phenylpropionic, phenylacetic and 1843 
benzoic acids, derived from the in vitro microbial fermentation of blueberries, was reported to 1844 
decrease prostanoids in cultured colon cells, suggesting the actions of berry flavonoids may exist in 1845 
the colon even prior to absorption (Russell, Labat, Scobbie, & Duncan, 2007). In the case of 1846 
anthocyanins, their in vitro instability had been established for decades, however, their in vivo 1847 
metabolism has only recently come to light, with a large number of microbial catabolites recently 1848 
identified (Czank et al. 2013; Kay, Pereira-Caro, Ludwig, Clifford, & Crozier, 2017) (see Section 3.3). 1849 
Probably the first catabolite of anthocyanins to be studied was 3,4-dihydroxybenzoic acid 105 1850 
(protocatechuic acid). This phenolic acid exists in some traditional medicines and had known 1851 
biological activity in cell and animal studies, which reported inhibition of monocyte adhesion, 1852 
reduced VCAM-1, intracellulular adhesision molecule (ICAM)-1, TNF-α and MCP-1 expression, and 1853 
activity towards iNOS and angiotensin-converting enzyme (ACE). 3,4-Dihydroxybenzoic acid is also 1854 
of dietary origin, occurring in cereals, dried fruit, juices, nuts, etc. When studied as a pure compound, 1855 
it has been reported to inhibit cell proliferation and induce apoptosis in cancer cells, and to 1856 
stimulate proliferation and increase stem cell viability of neuronal cells. Reported mechanisms of 1857 
action include phosphorylation and activation of JNK, p38MAPK, and p65/NF-ĸβ (Gonzalez-Sarrias, 1858 
Larrosa, Tomas-Barberan, Dolara, & Espin, 2010; Wang, Wei, Yan, Jin, & Ling, 2010a).  1859 
The effect of 3-(3′,4′-dihydroxyphenyl)propionic acid 79 (dihydrocaffeic acid), a colonic 1860 
metabolite derived from multiple food sources, including cocoa, apples, and strawberries, was 1861 
tested in a rat model of dextran sodium sulfate-induced colitis, and revealed that fecal water content 1862 
and weight loss were less pronounced in treated rats relative to control animals (Larrosa et al., 1863 
2009). It was also shown that distal colon mucosa homogenates from rats treated with the phenolic 1864 
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acid had diminished expression of TNF-α, IL-8, IL-1β, and reduced malonyldialdehyde and 8-oxo-2'-1865 
deoxyguanosine concentrations. 1866 
Considerable evidence was accumulating that highlighted the importance of the microbiome to 1867 
human health, not only the direct impact of phytochemical metabolites on tissues but also the 1868 
impact of flavonoids on gut microbial populations themselves (Blaut, Schoefer & Braune, 2003; 1869 
Scalbert et al., 2002; Selma, Espín & Tomás-Barbéran, 2009). However, considerable obstacles still 1870 
exist in establishing the impact of dietary flavonoids on the microbiome. For example, there is a 1871 
significant diversity of microbial species in the gut and substantial inter-individual variability in 1872 
bacterial populations as a result of differing diet, lifestyle, ethnicity, etc. Furthermore, only a small 1873 
proportion of intestinal bacteria can be cultivated in vitro, making it difficult to explore mechanisms 1874 
of action (Duda-Chodak et al., 2015; Lepage et al., 2013). Despite these difficulties, it is clear that 1875 
flavonoids can alter microbiota ecology, as observed by reported bacteriostatic or bactericidal 1876 
actions (Etxeberria et al., 2013), suggesting the microbiome can become somewhat ‘normalized' to 1877 
certain types of diet. For a comprehensive review of the state of knowledge at this time, regarding 1878 
the interaction of flavonoids with the intestinal microbiota, see Selma et al. (2009) and Duda-1879 
Chodak et al. (2015). 1880 
 1881 
 Research 2010-2017  1882 
The greatest changes in the direction of flavonoid research have probably occurred in the past 1883 
decade. First and foremost, the accumulation of information describing microbial metabolites as 1884 
being key to establishing the bioactivity of flavonoids. Furthermore, the realisation that previous 1885 
mechanistic findings, established by using aglycone/un-metabolized flavonoids at 1886 
supraphysiological concentrations, require reconsideration. Finally, the appreciation that the 1887 
antioxidant hypothesis holds ‘little’ physiological relevance brought further motivation in the past 1888 
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decade to refine previous theories. While our understanding of the mechanism of action of 1889 
flavonoids is still evolving (Figure 21), the underlying ideology that flavonoids protect against 1890 
various forms of biological stress remains valid. Unlike established micronutrients of which dietary 1891 
exclusion leads to nutritional deficiency disease, there is no officially recognized deficiency disease 1892 
associated with suboptimal flavonoid consumption. However, flavonoids have been proposed to be 1893 
“lifespan essential” (Holst & Williamson, 2008,) as a diet deficient in flavonoids (i.e. low in fruit and 1894 
vegetables) is a strong risk factor for developing chronic degenerative diseases globally (Ezzati & 1895 
Riboli (2013). Therefore, the concept that flavonoids protect against the “stresses” of aging, 1896 
including the associated chronic diseases, remains consistent in the literature.    1897 
 1898 
Antioxidant/radical scavenging hypothesis  1899 
By the end of the 2000s the antioxidant hypothesis as it relates to direct radical-scavenging 1900 
activity of phytochemicals was, for the most part, considered a ‘debunked’ theory. In the review 1901 
titled “Unravelling of the health effects of polyphenols is a complex puzzle complicated by 1902 
metabolism”, Hollman (2014) concluded that “although elegant, the antioxidant hypothesis must be 1903 
rejected”, the compelling argument being that, overall, flavonoid metabolites occur in the serum and 1904 
tissues at greater than 50-fold lower concentrations than the pool of endogenous radical 1905 
scavengers/antioxidants, and as such their contribution to global redox status is likely to be 1906 
extremely low, relative to other more stable endogenous oxidizable substrates, including urate, 1907 
bilirubin, proteins/enzymes, unsaturated fatty acids, thiols, tocopherols, and ascorbic acid. 1908 
Additionally, flavonoids’ known enzyme activity often negates their contribution to the radical-1909 
scavenging “pool”. For example, Shi and Williamson (2016) reported that quercetin reduced plasma 1910 
urate, a recognized radical scavenger, in moderately hyperuricemic men, through the partial 1911 
inhibition of xanthine oxidoreductase, a major producer of intracellular superoxide and driver of 1912 
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uric acid synthesis.  In line with these observations, the USDA concluded there is no evidence to 1913 
support the bioactivity of flavonoid-rich foods as it relates to their in vitro antioxidant capacity, as 1914 
established by total antioxidant capacity assays. This led to a decision in 2012 to remove the ORAC 1915 
Database for Selected Foods from the USDA's Nutrient Data Laboratory (NDL). 1916 
 1917 
The French Paradox  1918 
Moderate red wine consumption has long been associated with decreased CVD mortality in 1919 
several epidemiological studies (Gaziano et al., 1993; Rimm et al., 1991), and may be partly credited 1920 
to the anthocyanin content of wine (Dell'Agli, Busciala, & Bosisio, 2004; Erdman et al., 2007). 1921 
However, after nearly 30 years of publicity, the French Paradox appears to have lost momentum, 1922 
leaving many questions still unresolved. The main criticisms of those opposing the theory relate to a 1923 
lack of understanding of dose, what phytochemical components of wine are responsible for the 1924 
effect, the contribution of alcohol to the observed effects, and ethical issues associated with 1925 
recommending consumption to non-drinkers. It is clear that moderate alcohol intake alone can 1926 
positively affect vascular mechanisms of action, and that excessive intake and binge drinking has 1927 
many negative health consequences (Biagi & Bertelli, 2015; Mochly-Rosen & Zakhari, 2010; Tonelo, 1928 
Providencia, & Goncalves, 2013).  In recent years numerous mechanistic studies have been 1929 
conducted using concentrations of the C6-C2-C6 stilbene trans-resveratrol 106 greatly in excess of 1930 
anything that would be reached systemically following moderate red wine consumption. Most of 1931 
these studies were conducted from a pharmacological perspective in view of resveratrol’s ability to 1932 
enhance the longevity of a variety of organisms (Baur et al. 2006; Baur & Sinclair, 2006; Pallauf, 1933 
Rimbach, Ruppo, Chin & Wolf 2016).  [insert structures 106 & 107] The low amounts of 1934 
resveratrol in red wines suggest it is extremely unlikely to be responsible for the reported beneficial 1935 
effects following moderate red wine consumption (Corder, Crozier & Kroon, 2003).  Despite the 1936 
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unconvincing mechanistic evidence relative to moderate levels of red wine phytochemicals, such as 1937 
resveratrol, catechins, or anthocyanins, an alternative possibility is that the more abundant 1938 
procyanidins are the key bioactives. In contrast to (−)-epicatechin 38 and (+)-catechin 28, 1939 
procyanidins have been shown to inhibit platelet aggregation in vitro and to suppress the synthesis 1940 
of endothelin-1 by cultured endothelial cells (Corder 2008). It is, however, unlikely that 1941 
procyanidins, such as proanthocyanidin B2 dimer 107, let alone oligomeric and polymeric forms, 1942 
enter the circulatory system in sufficient quantity to elicit bioactivity. However, the consumption of 1943 
procyanidin-rich red wine made from Tannat grapes has been associated with increased male 1944 
longevity in the départment of Gers in the Midi-Pyrenees region of Southwest France (Corder et al. 1945 
2006). If physiological concentrations of colonic catabolites of procyanidins such as 5-(4′-1946 
hydroxyphenyl)-γ-valerolactone-3′-sulfate 55 and 5-(4′-hydroxyphenyl)-γ-valerolactone-3′-O-1947 
glucuronide 56 were implicated in cell culture or in vivo studies, the French Paradox and the 1948 
underlying mode of action would find renewed interest. 1949 
 1950 
Cardiovascular disease  1951 
Epidemiological evidence published over the past two decades indicates that consumption of 1952 
flavonoid-rich food and beverages is inversely associated with the risk of CVD, though it should be 1953 
noted that not all studies support this association (Curtis et al., 2009; Geleijnse & Hollman, 2008; 1954 
Wallace, 2011).  Flavonoid intake was associated with lower CVD incidence and mortality in six of 1955 
the twelve published cohort studies reviewed by Peterson et al. (2012), where the strongest 1956 
associations were found for reduced risk of mortality from CHD and flavonol/flavone intake 1957 
(Peterson, Dwyer, Jacques, & McCullough, 2012). Anthocyanin intake has been reported to be 1958 
associated with an 8% reduction in the risk of hypertension during a 14-year follow-up of 34,647 1959 
cases of hypertension in individuals from the Nurses’ Health Study (NHS II) and Health 1960 
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Professionals’ Follow-up-Study (HPDS) (Cassidy et al., 2011). In a subsequent analysis, increased 1961 
intake of flavanones in women was associated with a reduction in risk of ischemic stroke in 1800 1962 
incident strokes over a 14-year period (Cassidy et al., 2012). Jennings et al. (2012) reported higher 1963 
anthocyanin intake associated with lower arterial stiffness and central BP in 1900 women from the 1964 
Twins UK registry cohort, and calculated that the incorporation of 1-2 portions of berries daily 1965 
would reduce overall atherosclerosis risk. An association between higher anthocyanin intake and a 1966 
32% decrease in the risk of myocardial infarction (MI) was also reported in a cohort of nearly 1967 
100,000 women of 25-45 years of age after a follow-up of 18 years (Cassidy et al., 2013). Finally, a 1968 
meta-analysis of 14 prospective studies also found a reduced CVD risk associated with the 1969 
consumption of flavonols, anthocyanins, flavones, flavan-3-ols, and flavanones (Wang, Ouyang, Liu, 1970 
& Zhao, 2014). 1971 
Positive impacts of flavonoids on blood lipids, specifically LDL, HDL, and total cholesterol, are 1972 
reported across numerous RCTs. Improvements in lipid status are most often reported for quercetin, 1973 
chocolate, green tea, grapes, wine, and berries (Hugel, Jackson, May, Zhang, & Xue, 2016; Lilamand 1974 
et al., 2014; Rodriguez-Mateos et al., 2014a). Intervention studies of individuals with hypertension, 1975 
metabolic syndrome, and diabetes mellitus report positive impact of foods rich in all five subclasses 1976 
of flavonoids on BP (Clark, Zahradka, & Taylor, 2015; Hugel et al., 2016). Other commonly reported 1977 
biomarkers favorably altered in flavonoid interventions include: CRP, VCAM-1, ICAM-1, TNF-α, 1978 
interleukins (IL) IL-4, IL-6, IL-8, IL-13, and interferon-γ (Gonzalez-Gallego et al., 2010). It is 1979 
important to note that a number of studies have also reported no effect on many of these 1980 
biomarkers (Hooper et al., 2012; Rodriguez-Mateos et al., 2014a,c). 1981 
 1982 
Apples/flavan-3-ols  1983 
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The European Prospective Investigation into Cancer (EPIC; a cohort of > 400,000 individuals 1984 
and a 13-year follow-up) reported a nearly 30% risk reduction in CVD mortality associated with 1985 
high flavonoid intake, with the greatest risk reduction (40%) for flavonols (Zamora-Ros et al., 2013). 1986 
Serban et al. (2016) summarized several human RCTs, indicating that quercetin intake greater than 1987 
500 mg/day is required to decrease systolic BP (SBP) and diastolic BP (DBP) in individuals with 1988 
metabolic syndrome or type 2 diabetes, although the clinical relevance is unclear given this level of 1989 
quercetin is unlikely to be attained following ‘normal’ dietary consumption. Both animal studies and 1990 
human RCTs have reported beneficial impact of quercetin on BP, particularly SBP, triacylglycerols 1991 
(TAG), HDL-cholesterol and endothelin-1 (Marunaka et al., 2017; Rodriguez-Mateos et al., 2014c). 1992 
Additionally, healthy subjects consuming apple flesh for 4 weeks were revealed to have enhanced 1993 
FMD, and pulse pressure as well as increases in nitrite S-nitrosothiols. Even though there is 1994 
extensive evidence of the BP- and cholesterol-lowering effects of quercetin in animal models, in 1995 
humans such evidence remains mixed (Larson, Symons, & Jalili, 2012; Toh, Tan, Lim, Lim, & Chong, 1996 
2013).  1997 
Hypertensive rodent models have shown quercetin to improve endothelial-dependent aortic 1998 
dilatation, vascular relaxation, decreased body fluid volume, and modulation of the renin-1999 
angiotensin system (Marunaka et al., 2017). Some report that the vascular activity of quercetin is 2000 
the result of its action on angiotensin-converting enzymes, while quercetin glucuronide and methyl 2001 
metabolites have been reported to induce eNOS in aortic cells and to prevent endothelial 2002 
dysfunction (Rodriguez-Mateos, 2014c).  2003 
 2004 
Cocoa, dark chocolate/flavan-3-ols  2005 
Cocoa and chocolate feeding sydies often report beneficial effects on multiple biomarkers in 2006 
healthy volunteers and at risk groups, including: improved glucose uptake, homeostatic model 2007 
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assessment of insulin resistance, quantitative insulin sensitivity check index, and insulin sensitivity 2008 
indices, lipid metabolism (reduced LDL- and HDL-cholesterol), and antioxidant defence; reduced 2009 
total cholesterol-to-HDL ratio, plasma insulin and insulin resistance, BP (decreased overnight 2010 
ambulatory SBP, DBP, and heart rate), angiotensin-converting enzyme activity, platelet activity, p-2011 
selectin expression, endothelin-1, adhesion molecules, plasma nitrite, oxidized LDL, and urinary 2012 
isoprostanes (Ellam & Williamson, 2013; Grassi et al., 2015). The cumulative benefit of affecting 2013 
such a diverse array of vascular biomarkers was observed in a recent human RCT reporting a 2014 
significant lowering of 10-year risk for CVD and CHD as established by the Framingham Risk Score 2015 
(Sansone et al., 2015). Significant evidence exists for the contribution of (−)-epicatechin 38 to the 2016 
benefits of cocoa consumption (Schroeter et al., 2006), yet interestingly a recent human RCT 2017 
revealed that beneficial changes to FMD, pulse wave velocity (PWV), DBP, and circulating angiogenic 2018 
cells were more pronounced when cocoa flavan-3-ols were ingested with methylxanthines, 2019 
principally in the form of theobromine 46, implicating the impact of multiple bioactives present 2020 
within cocoa (Sansone et al., 2017). For extensive reviews summarizing cocoa intervention studies 2021 
refer to Ellam and Williamson (2013), Heiss et al. (2015), Kuhnle, (2017), Sansone et al. (2015, 2022 
2017), and Schroeter et al. (2006).   2023 
 2024 
Tea/flavan-3-ols 2025 
Epidemiological evidence suggests daily consumption of 3 cups of tea is associated with a 2026 
reduced risk of CVD mortality while 4 cups significantly decreases body weight and BMI and lowers 2027 
lipid peroxidation and markers of cardiometabolic disease risk (Vuong, 2014). Consistent with these 2028 
findings, de Koning et al. (2010), established black tea consumption (3-6 cups daily) was inversely 2029 
associated with CHD in a large cohort of over 37,000 participants in The Netherlands involving a 13-2030 
year follow-up. A study with over 75,000 Japanese green tea drinkers also reported the risk of CHD 2031 
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was decreased by more than 50% in women drinking as little as 1-2 cups per day relative to those 2032 
who consumed no tea (Mineharu et al., 2011). Kokubo et al. (2013) investigated the association 2033 
between green tea intake and stroke incidence in > 80,000 Japanese, aged 45-74 years, and reported 2034 
a reduced relative risk of stroke when consuming in excess of 1 cup per day. Additionally, a meta-2035 
analysis, including 11 trials, reported green tea was consistently associated with decreased SBP and 2036 
DBP by 3 mmHg (Hartley et al., 2013), while another meta-analysis, including 20 studies, concluded 2037 
that foods rich in flavan-3-ols lowered SBP and DBP by 2-3 mmHg in as little as 2 weeks (Ried, 2038 
Sullivan, Fakler, Frank, & Stocks, 2012). Finally, a systematic review and meta-analysis summarizing 2039 
378 subjects from 11 RCTs also found daily consumption of black tea for more than one week was 2040 
associated with significant reductions in BP (Greyling et al., 2014). Acute intervention studies have 2041 
similarly reported beneficial effects on FMD, lipids, lipoproteins, and platelet aggregation, although 2042 
others have reported no activity on these endpoints or mixed results (Grassi, Desideri, & Di Giosia, 2043 
2013; Hartley et al., 2013; Hodgson et al., 2012).  2044 
 2045 
Berries, grapes/anthocyanins  2046 
Evidence from epidemiological studies suggests that daily intake of anthocyanin-rich foods, 2047 
such as berries, provides cardio-protective benefits. For example, the Iowa Women’s Health 2048 
Prospective Study reported a reduced risk of CHD and CVD-related mortality associated with 2049 
elevated anthocyanin-rich berry intake in a population of 35,000 postmenopausal women followed 2050 
for 16 years. Anthocyanin intake was associated with a lower risk of fatal CVD in the Cancer 2051 
Prevention Study II Nutrition Cohort (>100,000 men and women) during 7 years follow-up 2052 
(McCullough et al., 2012) and inversely correlated with risk of myocardial infarction in 93,600 2053 
young- and middle-aged women from the NHS II study over 18 years of follow-up (Cassidy et al., 2054 
2013).  Moreover, an inverse relationship between anthocyanin intake and arterial stiffness (via 2055 
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pulse wave velocity), peripheral systolic, central systolic, and mean arterial pressure was reported 2056 
in a cross-sectional study of 1898 women drawn from the TwinsUK registry (Jennings et al., 2012a). 2057 
Another large cross-sectional study with nearly 2000 women showed inverse associations between 2058 
higher anthocyanin intakes and arterial stiffness (Jennings et al., 2012b). Despite these positive 2059 
reports, several epidemiological studies have found no relationship between berry intake and many 2060 
of the above risk factors (Riso et al., 2013; Rodriguez-Mateos, et al. 2014a). 2061 
A systematic review of RCTs concluded that anthocyanins significantly improved LDL 2062 
cholesterol, but not other markers of CVD risk (Wallace, Slavin, & Frankenfeld, 2016). Clinical 2063 
intervention studies report lower BP, arterial stiffness, FMD, PWV, lipids, lipoproteins, VCAM-1, CRP, 2064 
IL-2, IL-1beta, insulin sensitivity, postprandial hyperglycemia, and platelet function following berry 2065 
intervention (blueberries, bilberries, strawberries, or cranberries) in healthy individuals and 2066 
volunteers at elevated risk of CVD and metabolic syndrome (Giampieri et al., 2015; Rodriguez-2067 
Mateos et al., 2014c; Toh et al., 2013). In a recent wild blueberry dose-response intervention study, 2068 
feeding a beverage containing 776-to-1,791 mg of total polyphenols, improvements in FMD were 2069 
reported at 1, 2, and 6 h post consumption, which correlated with elimination kinetics of the 2070 
phenolic metabolites/catabolites. Similar observations were made using a baked blueberry product, 2071 
demonstrating that the efficacy of blueberries is maintained following minimal processing 2072 
(Rodriguez-Mateos, et al., 2013, 2014b). Studies on animal models using diabetic apo-E-deficient 2073 
mice, supplemented with cyanidin-3-O-glucoside, have reported reduced aortic lesion area and 2074 
improved endothelium-dependent vaso-relaxation, supporting the human clinical and observational 2075 
findings (Rodriguez-Mateos et al., 2014c). Still, other RCTs with berries have found no change in 2076 
serum glucose or insulin (Rodriguez-Mateos et al., 2014a). Feeding studies using grapes have also 2077 
observed effects which parallel those reported for berries, such as reductions in SBP, DBP, TAG, and 2078 
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LDL-cholesterol, and improvements in FMD, but, as reviewed by Wightman & Heuberger (2015), 2079 
others have reported no effects.  2080 
 2081 
Citrus flavanones  2082 
Epidemiological evidence suggests a higher intake of citrus flavanones is associated with a 19% 2083 
decreased risk of stroke (Cassidy et al., 2012). Studies exploring the vascular effects of citrus are 2084 
more limited than other flavonoid-rich foods, but have reported significant improvements in DBP, 2085 
HDL-cholesterol, triacylglycerol, FMD, and postprandial microvascular endothelial reactivity. 2086 
However, feeding pure hesperetin 60 and naringenin 16 produced no cholesterol-lowering effects 2087 
in hypercholesterolemic patients (Kurowska et al., 2000; Morand et al., 2011; Toh et al., 2013). The 2088 
citrus flavanones naringenin-7-O-rutinoside 17 and hesperetin-7-O-rutinoside 80 have been 2089 
reported to have various beneficial effects in rodent models including: hypoglycemic, hypolipidemic, 2090 
antihypertensive, and antithrombotic effects, improvement in NO-mediated endothelial function, 2091 
reduced fatty livers, improved histological features in models of stroke (Hugel et al., 2016), and 2092 
improved cognitive outcomes, including neurological score, locomotor activity, hanging wire latency, 2093 
delayed fall-off time, and increased memory retention (Li & Schluesener, 2017).  2094 
 2095 
Metabolic syndrome and obesity  2096 
Flavonoids positively affect many risk factors associated with metabolic syndrome (Kawser 2097 
Hossain et al., 2016), including hypertension, insulin resistance, hypercholesterolemia, and 2098 
hypertriglyceridemia, but direct evidence of flavonoids preventing, attenuating, or reversing 2099 
metabolic syndrome is limited. In agreement with the CVD data described above, and using mostly 2100 
animal models of obesity, hypertension, dyslipidemia, diabetes and insulin resistance, flavonoid 2101 
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studies have reported improved dyslipidemia and reduced BP, reduced lipid absorption, and 2102 
obesity-induced inflammation. Flavan-3-ols have shown promising activity on mechanisms 2103 
associated with obesity and metabolic syndrome, including the ability to decrease body weight and 2104 
adipose tissue, improve glucose homeostasis, inhibit lipid accumulation in tissues and increase the 2105 
anti-inflammatory cytokine IL-10. Berry studies also report reduced hepatic lipogenesis and 2106 
prevention of body weight gain, while studies with citrus flavanones and obese mouse models have 2107 
observed increased adiponectin, improved dyslipidemia, and reduced obesity, BP, and inflammatory 2108 
cytokines such as TNA-α (Alam et al., 2014; Greyling et al., 2014). 2109 
A meta-analysis of 15 RCTs with green tea flavan-3-ols identified significant improvements in 2110 
body mass index, and waist circumference, but associations could not be disentangled from the 2111 
known metabolic effects of caffeine (Phung et al., 2010). A further human study showed significant 2112 
reduction in body weight following 4 weeks of apple juice consumption. Conversely, in a large study 2113 
of African-American women (n = 46,906, over 12 years), no association between tea consumption 2114 
and reduced diabetes risk was observed (Boggs, Rosenberg, Ruiz-Narvaez, & Palmer, 2010; Grassi, 2115 
Desideri, & Di Giosia, 2013). It should be noted that the available evidence is primarily derived from 2116 
models exploring obesity or CVD rather than metabolic syndrome directly; human clinical and 2117 
animal evidence is required to establish the direct effect of flavonoids on metabolic syndrome. For 2118 
reviews of flavonoids and metabolic syndrome refer to Galleano et al. (2012) and Kawser Hossain et 2119 
al. (2016). 2120 
 2121 
Cancer  2122 
In vitro and animal mechanistic findings indicate flavonoids have anti-cancer properties; 2123 
however, clinical, epidemiological, and longitudinal cohort studies are lacking and describe mixed 2124 
results (Del Rio et al., 2013; Zhou et al., 2016). Of the positive epidemiological studies, evidence 2125 
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suggests that foods and beverages rich in flavonoids appear primarily protective against colon 2126 
cancer development (Rodrigues-Mateos et al., 2014c). A recent Cochrane Review of the possible 2127 
effects of flavonoids on colorectal cancer prevention identified a significant decrease in the 2128 
incidence of colorectal cancer from eight studies involving 390,769 participants spanning 3-to-13 2129 
years, associated with (−)-epicatechin 38, flavonol and total flavanone intake (Andrews, 2013).  2130 
Studies on quercetin using rodent and culture models report many anticancer mechanisms of 2131 
action, including down-regulating cell survival, inhibition of proliferation, induced apoptosis, 2132 
angiogenesis, and reduced breast cancer cell growth and migration, while results with (−)-2133 
epigallocatechin-3-O-gallate 12 include anti-proliferative effects, suppression of prostate cancer 2134 
growth, migration and invasion of lung cancer cells, estradiol-induced breast cancer cell growth, and 2135 
cancer stem cell growth (Zhou et al., 2016). Evidence of the anti-cancer effects of berries is primarily 2136 
derived from rodent studies where multiple models have been utilized, including oral, colon, lung, 2137 
breast, bone, and skin cancer, reporting various effects, including: reduction of premalignant lesions, 2138 
number and size of metastases, tumor volume, and micro vessel density, and inhibition of tumor 2139 
development and body weight loss (Giampieri et al., 2015). For a detailed review of anti-cancer 2140 
activity reported over the last 5 years consult Zho et al. (2016) and on mechanisms of action see 2141 
Kerimi and Williamson (2017).  2142 
 2143 
Cognition  2144 
Epidemiological studies report higher total flavonoid intake associated with slower rates of 2145 
cognitive decline and reduction in dementia risk in healthy aging individuals (Rodriguez-Mateos et 2146 
al. 2014c; Vauzour, 2014). Clinical studies have also shown elevated flavonoid intake to be 2147 
associated with improved language and episodic and verbal memory in healthy adults (Matias, 2148 
Buosi, & Gomes, 2016). 2149 
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Quercetin has been reported to improve symptoms of cognitive decline and mental fatigue, 2150 
increase posterior parietal activity, synaptic excitation, and neural information-processing speed 2151 
(Vauzour, 2014; Dajas et al., 2015).  Diets high in cocoa flavan-3-ols have been shown to improve 2152 
cognitive abilities in healthy, older adults and those at risk of early dementia. Cognitive outcomes 2153 
that are significantly affected include: improved choice reaction time, working memory 2154 
performance, verbal fluency, reaction time, rapid visual information processing (RVIP), visual 2155 
spatial working memory, trail making task, serial 3s’ subtraction tasks, and reduced mental fatigue 2156 
(Bell, Lamport, Butler, & Williams, 2015; Ellam & Williamson, 2013). Tea consumption has been 2157 
shown to significantly affect mood (Bell et al., 2015).  Associations between strawberry 2158 
consumption and a reduced rate of cognitive decline was reported in older women in the Nurses’ 2159 
Health Study (Giampieri et al., 2015).  Furthermore, consuming blueberry and Concord grape juice 2160 
for 12 weeks improved paired associate learning and word list recall in subjects with dementia 2161 
(Vauzour, 2014). Outcomes significantly affected by berry consumption in cognitive performance 2162 
trials include: rapid visual information processing task, task switching, flanker task (spatial selective 2163 
attention), word recognition, image recognition, letter memory, and digit vigilance (Bell et al., 2015). 2164 
Cognitive outcomes significantly affected by citrus include: digit symbol substitution task, 2165 
continuous performance task, and finger tapping task (Bell et al., 2015). 2166 
 2167 
Others   2168 
Two human epidemiological studies found positive associations between total dietary flavonoid 2169 
intake and bone mineral density (BMD) in women (Welch & Hardcastle, 2014) and cross-sectional 2170 
studies also report positive associations between habitual tea consumption and BMD (Nash & Ward, 2171 
2017), although experimental evidence is limited. In rodent models quercetin 1 was shown to 2172 
improve bone mineral density (Kawabata, Mukai, & Ishisaka, 2015), hesperetin-7-O-rutinoside 2173 
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inhibited bone resorption (Li & Schluesener, 2017) and, although limited mechanistic data are 2174 
presently available, Nash & Ward (2017) proposed modulation of osteoblastic and osteoclastic 2175 
activity as a possible mechanism of action. 2176 
Flavonoids such as quercetin 1, hesperitin-7-O-rutinoside 80, (−)-epigallocatechin-3-O-gallate 2177 
12, naringenin 16, and cyanidin-3-O-glucoside 63, have shown promise as potential therapeutics in 2178 
many proinflammatory models of disease/disorder including experimental models of colitis (Vezza 2179 
et al., 2016), arthritis (Li & Schluesener, 2017), asthma and acute respiratory distress syndrome 2180 
(Lago et al., 2014; Li & Schluesener, 2017), UV-exposed skin damage (Kawabata et al., 2015), 2181 
glaucoma and ocular hypertension (Patel, Mathan, Vaghefi, & Braakhuis 2015), renal toxicity 2182 
(Kawabata et al., 2015; Li & Schluesener, 2017), obesity-associated hepatic steatosis (Kawabata et 2183 
al., 2015), and exercise-induced fatigue (Kawabata et al., 2015).  2184 
 2185 
Mechanisms of action 2186 
A commonly repeated statement in flavonoid literature is that ‘mechanistic evidence is needed 2187 
in support of the available observational data’. In this respect, the past decade has seen significant 2188 
advances in mechanistic findings using human and animal models, while flavonoid 2189 
conjugates/metabolites are beginning to be used in some in vitro cell culture models. Nevertheless, 2190 
it is worth mentioning that certain transporters are required to take up the flavonoid conjugates 2191 
into cells (see Section 2), and some of these transporters are not present in cultured or 2192 
immortalized cells. These aspects need to be considered in experimental design.  2193 
 2194 
Vascular mechanisms 2195 
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The most recognized activity of flavonoid-rich foods is their ability to maintain vascular 2196 
homeostasis (Hugel et al., 2016; Rodriguez-Mateos et al., 2014c). Three recent meta-analyses 2197 
support this observation, particularly with respect to the effect of cocoa and tea flavan-3-ols on 2198 
lowering both SBP and DBP and improving endothelial dysfunction, as measured mainly by FMD 2199 
(Fusi, Spiga, Trezza, Sgaragli, & Saponara, 2017; Hooper et al., 2012); improvements in endothelial 2200 
function are also often reported for quercetin, wine, berries, and grapes (Hugel et al., 2016; 2201 
Lilamand et al., 2014). It is clear that meta-analyses consistently show that flavonoid interventions 2202 
have beneficial impact on BP and endothelial function, yet the direct mechanism behind this activity 2203 
remains elusive. One of the earliest reported mechanisms linking BP and FMD is the activity of 2204 
flavonoids on calcium channel regulation, and these findings have been relatively consistent for 40 2205 
years, however, this evidence is primarily derived from studies using flavonoid aglycones, and in 2206 
light of the recent emphasis on the importance of testing flavonoid metabolites and catabolites in 2207 
vivo, it is difficult to discern the relevance of many of these previous findings. 2208 
Many cardiovascular biomarkers are altered in flavonoid interventions, such as CRP, 2209 
vascular cell adhesion molecules, and cytokines (Gonzalez-Gallego et al., 2010). These proteins are 2210 
regulated by pro-inflammatory transcription factor NF-κβ. Alternatively, considerable evidence 2211 
exists for direct activity on NO-mediated endothelial function, suggesting activity on the NO/cyclic 2212 
guanosine monophosphate (cGMP) pathway, which modifies protein kinase-mediated signal 2213 
transduction through Nrf2 activation (Brown & Griendling, 2015). As recent evidence indicates, 2214 
there is crosstalk between NF-κβ and Nfr2, which presents a logical target for future mechanistic 2215 
investigations (Cuadrado, Martin-Moldes, Ye, & Lastres-Becker, 2014; Ho et al., 2010; Kabirifar et al., 2216 
2017; Xu et al., 2005). 2217 
Supplementation with myricetin 4 in mice fed a high-fat, high-sugar diet resulted in 2218 
decreased body weight and improved hypercholesterolemia and hypertriglyceridemia, suggesting 2219 
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that multiple mechanisms of action of flavonoids are at play (Fusi et al., 2017). Similarly, cocoa 2220 
flavonoids have been reported to act on insulin secretion, glucose transport, thromboxane A2, P-2221 
selectin, MAPK, and NOX (Arranz et al., 2013; Grassi, Desideri, & Ferri, 2013; Kerimi & Williamson, 2222 
2015), thus supporting the ‘multiple mechanisms’ theory, as no single mechanism is likely to 2223 
regulate this diversity of pathways. Although one consistency in flavonoid research is their ability to 2224 
regulate various enzymes, and perhaps there is some unidentified mechanism involving universal 2225 
enzyme regulation. 2226 
Catabolism of flavonoids by the gut microbiota leads to a large number of compounds, 2227 
including 4-hydroxybenzoic acid 74, 3,4-dihydroxybenzoic acid 105, (protocatechuic acid), 3-2228 
methoxy-4-hydroxybenzoic acid 108 (vanillic acid), 3,5,-dimethoxy-4-hydroxybenzoic acid 109 2229 
(syringic acid), and  3,4,5-trihydroxybenzoic acid 101 (gallic acid) (Kay, Pereira-Caro, Ludwig, 2230 
Clifford & Crozier, 2017), and blood levels of many of these phenolics have been observed to 2231 
correlate with improved endothelial function (Rodriguez-Mateos et al., 2014c). [insert structures 2232 
108 &109] Moreover, healthy volunteers fed blueberries showed increased FMD response, which 2233 
correlated with plasma levels of microbial metabolites and decreased neutrophil NOX activity 2234 
(Hugel et al., 2016). An increase in serum cGMP in hypercholesterolemic individuals has also been 2235 
noted after supplementation with purified anthocyanins (Hugel et al., 2016). Finally, many 2236 
additional mechanisms have been reported for berry flavonoids in animal and in vitro studies and 2237 
include: increase serum cGMP, up-regulation of superoxide dismutase (SOD), glutathione reductase 2238 
(GSR), thioredoxin reductase 1, and paraoxonase, decreased production of endothelin-1, and 2239 
inhibition of angiotensin-converting enzyme (Chalopin et al., 2010; Edirisinghe, Banaszewski, 2240 
Cappozzo, McCarthy, & Burton-Freeman, 2011; Hidalgo et al., 2012; Lazze et al., 2006; Paixão et al., 2241 
2012; Persson, Persson, & Andersson, 2009; Rodriguez-Mateos et al., 2014a; Simoncini et al., 2011; 2242 
Xu, Ikeda, & Yamori, 2004a; Xu et al., 2004b). The diversity of such activities is paralleled in a 2243 
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microarray analysis of aortic tissue from apo E-deficient mice fed bilberry, indicating modulation of 2244 
over 1200 genes involved in cellular and molecular pathways relating to cholesterol metabolism, 2245 
inflammatory process, oxidative stress, and angiogenesis (Mauray et al. 2013). 2246 
 2247 
Anti-inflammatory mechanisms 2248 
Based on the disease endpoints most commonly reported for flavonoid activity, namely, 2249 
cardiovascular and cardio-metabolic disorders, cancer, and cognitive decline, it is reasonable to 2250 
consider an anti-inflammatory mechanism of action of flavonoids, as inflammation is an overlapping 2251 
mechanism responsible for the progression of these disease states. Unfortunately, proving this 2252 
directly in human intervention studies is inherently difficult, considering the extreme variation in 2253 
background cytokine production between seemingly homogeneous individuals. Compounding this 2254 
is the inadequacy of human nutrition studies to detect subtle changes in inflammatory status in 2255 
either healthy or at-risk individuals (Cesari et al., 2003; Smidowicz & Regula, 2015). Despite a lack 2256 
of clear evidence from human studies, anti-inflammatory mechanisms have consistently been 2257 
reported in animal and in vitro studies, including the suppression of the NF-ĸβ and Janus kinase-2258 
STAT-signaling pathways (Vezza et al., 2016). In addition, an increased number of publications 2259 
report interference of pro-oxidant enzyme-signaling cascades involving myeloperoxidase, NOX, 2260 
lipoxygenase, cyclooxygenase, phospholipase, NOS, etc., or the expression of adhesion molecules 2261 
such as ICAM, VCAM, E-selectin, and P-selectin (Tangney & Rasmussen, 2013).  2262 
Anti-inflammatory action of quercetin has been reported in humans, animals and cell culture 2263 
models, including reports on inhibition of cyclooxygenase and lipoxygenase activities (Marunaka et 2264 
al., 2017). Evidence suggests that metabolites of quercetin 1, such as quercetin-3-O-glucuronide 21, 2265 
could be deconjugated by macrophages, which could theoretically lead to increasing availability of 2266 
the quercetin aglycone in tissues (Kawabata et al., 2015), indicating that unmetabolized flavonoids 2267 
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could have biological relevance in tissues. Additionally, quercetin has been shown to inhibit the 2268 
activity of histone acetyl transferases in the promoter region of genes associated with inflammation, 2269 
including the activation of sirtuins (Joven, Micol, Segura-Carretero, Alonso-Villaverde, & Menendez, 2270 
2014). Liang et al. (2011) demonstrated that (−)-epigallocatechin-3-O-gallate 12 treatment could 2271 
significantly reduce MCP-1, and hesperetin-7-O-rutinoside 80 was shown to reduce circulating 2272 
inflammatory markers in individuals with metabolic syndrome (Rodriguez-Mateos et al., 2014c).  2273 
The physiological relevance of most cell culture studies exploring the mechanism of action of 2274 
flavonoids is uncertain for a number reasons: i) use of unmetabolized precursor structures; ii) use 2275 
of non-physiologically relevant concentrations; and iii) models explore the activity of single 2276 
compounds in isolation, while in vivo flavonoid metabolites exist as complex mixtures, likely 2277 
providing additive or synergistic activity. Recently a few investigators have explored the activity of 2278 
flavonoid metabolites of microbial origin, at physiologically relevant concentrations in isolation and 2279 
in combination. The colonic flavan-3-ol catabolite 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone 30 has 2280 
been shown to inhibit nitrite production and iNOS in macrophage models. Phenolic catabolites of 2281 
anthocyanins have also been reported to act on TNF-α, VCAM-1, ICAM-1, IL-6, and MCP-1 (Amin et 2282 
al., 2015; Rodriguez-Mateos et al., 2014c, Warner et al., 2016, 2017;). Flavonoid catabolites from the 2283 
serum of mice fed blueberries was also shown to inhibit TNF-α and IL-6, by reducing 2284 
phosphorylation of MAPK, JNK, p38, and ERK1/2 in macrophage cell lines (Rodriguez-Mateos et al., 2285 
2014a). Transcriptomic analysis has also revealed that flavan-3-ol metabolites affect the expression 2286 
of genes involved in cell-cell junctions and focal adhesion involved in monocyte migration and 2287 
adhesion (Rodriguez-Mateos et al., 2014c). 2288 
3,4-Dihydroxybenzoic acid 105 (protocatechuic acid), a catabolite of several flavonoids, 2289 
reduces monocyte adhesion to TNF-α-activated mouse aortic endothelial cells (Li & Schluesener, 2290 
2017; Wang, Wei, Yan, Jin, & Ling, 2010b). In another study, 6 flavonoids and 14 flavonoid 2291 
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metabolites were screened individually, and as 29 different mixtures, in a THP-1 monocyte model of 2292 
LPS-induced TNF-α secretion.  Individually 3-hydroxy-4-methoxy-benzoic acid 110 (isovanillic 2293 
acid), 4-methoxybenzoic acid-3-O-glucuronide 111 (isovanillic acid-3-O-glucuronide), 3-2294 
methoxybenzoic acid-4-O-glucuronide 112 (vanillic acid-4-O-glucuronide), 4-hydroxybenzoic acid-2295 
3-sulfate 113 (protocatechuic acid-3-sulfate), 3-hydroxybenzoic acid-4-sulfate 114 (protocatechuic 2296 
-sulfate), and benzoic acid-4-sulfate 115 all significantly reduced TNF-α secretion. [insert 2297 
structures 110-115] It is of note that four combinations of metabolites, which included 4-2298 
hydroxybenzoic acid, 3,4-dihydroxybenzoic acid, 3-methoxy-4-hydroxybenzoic acid, and the 2299 
glucuronide and sulfate conjugates of 4-hydroxybenzoic acid and 3,4-dihydroxybenzoic acid, 2300 
exhibited synergy and significantly reduced TNF-α secretion to a greater extent than when tested 2301 
individually (di Gesso et al., 2015). Additionally, Warner et al., (2017) investigated the activity of 1, 2302 
6, and 24 hour postprandial metabolite signatures of cyanidin-3-O-glucoside 63 in stimulated 2303 
endothelial cells. Here both IL-6 and VCAM-1 were significantly reduced in response to all 2304 
mixtures/signatures tested. Interestingly, activity was observed at concentrations 10-fold lower 2305 
than those occurring in plasma after ingestion of the precursor anthocyanin (Warner et al., 2017). 2306 
 2307 
Metabolic/diabetic mechanisms  2308 
Diabetic and obese rodent models have shown that quercetin 1 and quercetin glucosides 2309 
reduce hyperglycemia and increase insulin secretion (Kawser Hossain et al., 2016); naringenin 16 2310 
was shown to decrease hyperglycemia and increase superoxide dismutase (Kawser Hossain et al., 2311 
2016); and kaempferol 2 to reduce fasting glucose and body weight gain, improve insulin resistance, 2312 
increase muscle glucose uptake, reduce HbA1C, TNF-α, IL-6, and IL-1β secretion, increased beta-cell 2313 
survival, antioxidant defense proteins, peroxisome proliferator-activated receptor (PPAR)-γ, and 2314 
sterol regulatory-element-binding protein-1c. Effects were often reported to be associated with Akt, 2315 
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phosphatidylinositol-3-kinase, and protein kinase C, and also with enhanced cyclic adenosine 3',5'-2316 
monophosphate signaling (Li & Schluesener, 2017). Studies with (−)-epigallocatechin-3-O-gallate 12 2317 
using animal models also suggest improved insulin signaling and glucose homeostasis in adipose 2318 
tissue resulting from downregulation of the ERK/JNK-p53 pathway or attenuation of inflammatory 2319 
processes through interference of toll-like receptor-4 (Legeay, Rodier, Fillon, Faure, & Clere, 2015). 2320 
Studies on glycemic control by flavonoids have been reviewed in detail (Hanhineva et al., 2010; de 2321 
Bock, Derraik & Cutfield, 2012; Williamson, 2013) 2322 
 2323 
Anti-cancer mechanisms  2324 
Although human data are lacking, animal and cell culture studies of breast, colon, lung, prostate, 2325 
and bone cancer are accumulating, reporting activities such as: improvement of mitochondrial 2326 
dysfunction and decrease of mast cell density; inhibition of basal and testosterone-induced 2327 
accelerated proliferation; suppression of mesothelioma cell growth and Wnt/β-catenin regulation 2328 
(Li & Schluesener, 2017). Flavonoid actions on Wnt regulation have led some to suggest they may 2329 
have a therapeutic role in the treatment of colorectal cancer (Amado et al., 2014).  Various 2330 
mechanisms have been reported based on cell culture studies (Fernando, Rupasinghe & Hoskins, 2331 
2015; George et al. 2016; George, Dellaire & Rupasinghe, 2017; Giampieri et al., 2015; Joven et al., 2332 
2014; Khan et al., 2016; Li & Schluesener, 2017; Zhou et al., 2016), however, many of these studies 2333 
are at high concentrations and use unmetabolized flavonoids.   2334 
 2335 
Cognition and neuroprotective mechanism 2336 
Perhaps one the most contemporary foci of flavonoid research is the study of 2337 
neurodegeneration and cognitive performance. Here, significant advances have been made in 2338 
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animal models, with more recent studies investigating translation to childhood development, aging 2339 
and early cognitive decline in humans. Based on extensive evidence of the vascular activity of 2340 
flavonoids, many believe that the impact of flavonoids on blood flow to the brain is the most 2341 
probable cognitive mechanism of action. Indeed, rodent studies investigating the effects of dietary 2342 
flavonoids and flavonoid-rich foods have reported improvements in cognitive function associated 2343 
with improved cerebral vascular function and brain blood flow. Many flavonoid interventions, 2344 
particularly trials feeding berries and cocoa/chocolate, have observed beneficial effects on 2345 
endothelial function, which could account for improved cognitive outcomes. However, these positive 2346 
endothelial effects are reported to co-occur with other vascular mechanisms such as increased 2347 
vasodilation and cerebral blood flow, increased plasma NO, attenuation of blood glucose decline, 2348 
monoamine oxidase inhibition, and increased synthesis of brain-derived neurotrophic factor 2349 
(BDNF) (Bell et al., 2015). There is also substantial evidence to suggest a secondary or 2350 
complementary mechanism of action involving modulation of neuro-inflammation. It is conceivable 2351 
that these distinct mechanisms have different effects in models of cognitive performance in young 2352 
humans/animals relative to attenuation of age-related cognitive decline in older adults. Much of the 2353 
available mechanistic evidence on neuroinflammation comes from studies with cultured glial cells 2354 
(Matias et al., 2016), yet few studies are conducted using metabolised flavonoids.  2355 
Studies on cocoa in humans have revealed enhanced cognitive outcomes (Socci, Tempesta, 2356 
Desideri, De Gennaro, & Ferrara, 2017), including: increased global cognition scores (Neshatdoust et 2357 
al., 2016), working memory function (Camfield et al., 2012), spatial working memory performance, 2358 
choice reaction time (Field, Williams, & Butler, 2011), verbal fluency performance (Desideri et al., 2359 
2012; Mastroiacovo et al., 2015), serial 3s performance, visual information processing (Scholey et al., 2360 
2010), serial 7s subtraction performance, self-reported mental fatigue (Massee et al., 2015; Socci et 2361 
al., 2017), tail making test (Desideri et al., 2012; Mastroiacovo et al., 2015; Sorond, Hurwitz, Salat, 2362 
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Greve, & Fisher, 2013), and Benton task performance. Some of these findings were associated with 2363 
increased cerebral blood volume (Brickman et al., 2014). However, it should be noted that not all 2364 
studies have shown positive effects; no benefits to cognitive performance were observed in a study 2365 
by Pase et al. (2013), while Decroix et al. (2016) showed increased cerebral blood oxygenation with 2366 
no significant behavioral effect.  2367 
The impact of cocoa on the brain is believed to be the result of two underlying mechanisms, 2368 
either via improvement in blood-flow and angiogenesis in the brain or by direct interactions with 2369 
neuroprotective and neuromodulatory enzymes/proteins (Sokolov, Pavlova, Klosterhalfen, & Enck, 2370 
2013). For example, cocoa flavan-3-ols have been reported to increase mean blood flow velocity and 2371 
cerebral blood flow (CBF) in RCTs (Bell et al., 2015; Rendeiro et al., 2015). Animal feeding studies 2372 
with (−)-epicatechin 38 observed decreased neurologic deficit, brain infarcts in N-methyl-D-2373 
aspartate models, and anxiety, which were associated with increased Morris water maze (MWM), 2374 
BDNF, pro-BDNF, pAkt, pCREB and pCaMKII, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 2375 
acid receptor (AMAP)-GluR2, and decreased monoamine oxidase-A (Matias et al., 2016; Rendeiro et 2376 
al., 2015). (−)-Epicatechin has also been reported to have anti-amyloidogenic effect on amyloid β 2377 
peptide deposition (Kawabata et al., 2015). Animal studies feeding (+)-catechin 28 noted 2378 
improvements in MWM performance associated with increased CBF, myogenic tone, and FMD in 2379 
cerebral artery, and increased acetylcholine (ach) sensitivity to eNOS inhibition. Finally, (−)-2380 
epigallocatechin-3-O-gallate 12 has been shown to provide AMP-activated protein kinase-medicated 2381 
neuroprotection (Kawabata et al., 2015). For a recent detailed review summarizing the effects of 2382 
cocoa on cognitive function refer to Grassi et al. (2016). 2383 
Quercetin 1 supplementation has been reported to improve MWM outcomes and to increase 2384 
passive avoidance, where findings were associated with increased CBF, nitrite, ATP, 2385 
acetylcholisterase, and glutathione levels (Bell et al., 2015). Quercetin, kaempferol and myricetin 2386 
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were also reported to have anti-amyloidogenic effect on amyloid β peptide deposition (Kawabata et 2387 
al., 2015). Animal studies further indicated that improvement in ‘inhibition of the immobility time’ 2388 
may be associated with increased serotonin and noradrenaline in the frontal cortex and 2389 
hippocampus and also activation of the ERK pathway (Giampieri et al., 2015; Rendeiro, Rhodes, & 2390 
Spencer, 2015).  2391 
Anthocyanin supplementation has been shown to improve working memory and MWM 2392 
outcomes (Rendeiro et al., 2015). Enriched bilberry and blackcurrant extracts modulate amyloid 2393 
precursor protein processing and alleviate behavioral abnormalities in the APP/PS1 mouse model 2394 
of Alzheimer’s disease (Baptista, Henriques, Silva, Wiltfang, & da Cruz e Silva, 2014; Vepsalainen et 2395 
al., 2013). Moreover, cyanidin-3-O-glucoside 63 rescued cognitive impairments, which were 2396 
induced by amyloid β, via modulation of glycogen synthase kinase (GSK)-3Beta/tau in rats (Baptista 2397 
et al., 2014).  2398 
Orange juice has been reported to increase human cerebral blood flow (Bell et al., 2015). 2399 
Hesperetin-7-O-rutinoside 80 has shown activity in rodent models of Alzheimer’s disease, 2400 
Huntington’s disease, epilepsy, and neurotoxicity, where it is reported to have activity against 2401 
amyloid β-induced neurotoxicity, attenuate biochemical and mitochondrial alterations, and protect 2402 
brain and sciatic nerve tissues against oxidative damage.  2403 
Flavonols and their metabolites have been detected in rodent brains (Bell et al., 2015; 2404 
Kawabata et al., 2015), and even monomeric metabolites of proanthocyanidins were identified in 2405 
mouse brains, and they correlated with improved cognitive function in an Alzheimer’s disease 2406 
model where the beneficial effects were linked to improved synaptic plasticity (Wang et al., 2012).  2407 
Despite metabolites being reported in abundance in rodent studies, most neuro/cognitive 2408 
mechanisms of flavonoids have to date been reported in studies using neuronal cell lines and 2409 
unmetabolized flavonoids.  2410 
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 2411 
Microbiota: drivers of flavonoid bioactivity  2412 
The realization of the importance of the microbiome to health has led to new theories and 2413 
focus, including exploration of metabotypes, the interactome and epigenome (Kawser Hossain et al., 2414 
2016). The epigenome defines whether a gene will be active or silent under certain conditions, 2415 
while a metabotype describes an individual’s metabolic phenotype. It is believed that certain 2416 
individuals, populations, ethnic origins, etc., will cluster according to phenotypic characteristics 2417 
associated with metabolism and microbiome. Accumulating evidence suggests dietary flavonoids 2418 
are able to modify epigenetic pathways (Joven et al., 2014), and it is believed that understanding an 2419 
individual’s metabolic phenotype will bring us closer to establishing more personalized strategies 2420 
for disease prevention.  2421 
Research involving metabolic phenotypes (or metabotypes) involves using systems biology 2422 
to explore complex relationships between the genome, transcriptome, proteome, and environment 2423 
and it is a research direction many in the flavonoid field are beginning to explore (Ferrara & Sébédio, 2424 
2015). Linking these concepts together requires a multitude of analytical, biological, and 2425 
bioinformatics approaches. Jacobsen et al. (2013) stated “Despite the recent advances in the 2426 
biological principles that underlie microbial symbiosis in the gut of mammals, mechanistic 2427 
understanding of the contributions of the gut microbiome and how variations on the metabotypes 2428 
are linked to host health are obscure”. These investigators explored fecal samples of 124 Europeans 2429 
who were healthy, obese, or had inflammatory bowel disease, using metagenomics sequencing data, 2430 
and they found only 33 metabolites which affected protein complexes associated with disease 2431 
responses that involved adaptive immune-signaling pathways. Flavonoids were among these 2432 
metabolites. It was noted that, independent of healthy or diseased samples, individuals were 2433 
clustered having high, medium, or low metabolic potential. Additionally, quercetin was found to 2434 
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interact with disease protein complexes associated with a large number of OMIM disease label 2435 
identifiers, including obesity and inflammatory bowel disease (IBD). Functionality studies using 2436 
meta-transcriptomic or meta-metabolomic analysis are required to identify the direct mechanistic 2437 
links (Jacobsen et al., 2013). 2438 
Accumulating evidence suggests that gut-derived phenolic metabolites are responsible for 2439 
much of the mechanistic activity of flavonoids. Possibly the most studied bacterial catabolites of 2440 
flavonoids are 4-hydroxy-3-methoxycinnamic acid (ferulic acid) 94, 3,4,5-trihydroxybenzoic acid 2441 
101 (gallic acid) 3,4-dihydroxybenzoic acid 105 (protocatechuic acid), and 3-methoxy-4-2442 
hydroxybenzoic acid 108 (vanillic acid), which have all been consistently reported to have 2443 
biological activity, and are also found in the diet in their own right. Ferulic acid has been reported to 2444 
improve kidney structure and function in hypertensive rats (Hugel et al., 2016), to reduce apoptosis 2445 
and to cause cell cycle arrest (Zhou et al., 2016). 3,4-Hihydroxybenzoic acid inhibited ACE and 2446 
improved inflammatory stress in animal models (Hugel et al., 2016), inhibited TNF-α-stimulated 2447 
expression of VCAM-1 and ICAM-1, and decreased shear stress-induced platelet aggregation in 2448 
isolated human platelets (Wang et al., 2010b). Gallic acid decreased tumor size, proliferation, 2449 
invasion, and angiogenesis, inhibited migration, induced apoptosis, and attenuated the expression of 2450 
NOX, cytokines and receptor for advanced glycation end-products (Hugel et al., 2016; Zhou et al., 2451 
2016). The less often studied 3-methoxy-4-hydroxybenzoic acid has been shown to inhibit 2452 
angiotensin converting enzyme and to improve inflammatory stress in animal and cell models 2453 
(Amin et al., 2015; Hidalgo et al., 2012; Rodriguez-Mateos et al., 2014c; Warner et al., 2016).  2454 
In a pro-inflammatory screening study stimulating vascular endothelial cells with oxidized 2455 
LDL (oxLDL) or CD40L, cyanidin-3-O-glucoside 63 had no anti-inflammatory effects, while many of 2456 
its catabolites significantly reduced IL-6 secretion, with glucuronide and sulfate conjugates of 3,4-2457 
dihydroxybenzoic acid (protocatechuic acid) eliciting the highest response. Similarly, metabolites 2458 
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also reduced VCAM-1, with 4-hydroxy-3-methoxycinnamic acid (ferulic acid) inducing the greatest 2459 
effect (Amin et al., 2015). In another screening study of similar design, 14 phenolic metabolites and 2460 
6 flavonoids were evaluated for their ability to attenuate VCAM-1 secretion by human umbilical vein 2461 
endothelial cells stimulated with TNF-α. Of the 20 compounds screened, 3,4-dihydroxybenzoic acid 2462 
105 (protocatechuic acid), 3-hydroxy-4-methoxybenzoic acid 110 (isovanillic acid), 4-2463 
methoxybenzoic acid-3-O-glucuronide 111 (isovanillic acid-3-O-glucuronide), 4-hydroxybenzoic 2464 
acid-3-sulfate 113 (protocatechuic acid-3-sulfate), and 3-hydroxybenzoic acid-4-sulfate 114 2465 
(protecatechuic acid-4-sulfate) all significantly reduced VCAM-1 secretion (Warner et al., 2016), 2466 
indicating that colonic catabolism and phase II metabolism of flavonoids increase their anti-2467 
inflammatory efficacy (Figure 22).  2468 
Ellagic acid 11 metabolism also warrants mention, as it is a colonic metabolite of 2469 
ellagitannins, found in flavonoid-rich foods such as strawberries, raspberries, pomegranates, and 2470 
some aged wines. In experimental models, ellagic acid has been observed to suppress tumor growth 2471 
and angiogenesis, have anti-proliferative and pro-apoptotic effects, suppress cell invasion and 2472 
motility, and cause G0/G1 cell cycle arrest (Zhou et al., 2016).  2473 
 2474 
Influence of flavonoids on microbial growth  2475 
The activity of flavonoids is unlikely to be exclusively the result of reabsorbed microbial 2476 
metabolites acting directly on target tissue, as an extensive literature exists describing the 2477 
antimicrobial activity of flavonoids, extending over 50 years, where more recent evidence also 2478 
indicates probiotic effects (Duda-Chodak et al., 2015). It is apparent that flavonoids and their 2479 
microbial metabolites have direct activity in the gut, altering the microbiome, as well as the immune 2480 
status of the host (Duda-Chodak, 2012). However, the gut microbiome does not always change 2481 
measurably in studies where flavonoids have been administered (Williamson and Clifford, 2017). In 2482 
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some intervention studies, feeding flavonoid-rich beverages produced both antimicrobial and 2483 
probiotic effects on bacterial cell growth. It is clear there are inherently complex associations 2484 
between dietary flavonoids, microbial ecology, and human health (Figure 23), and disentangling 2485 
these association will require significant research focus over the coming years.  2486 
In vitro cultures of flavanones and flavonols screened for activity on intestinal bacterial 2487 
growth of Bacteroides galacturonicus, Lactobacillus spp., Enterococcus caccae, Bifidobacetrium 2488 
catenulatum, Ruminococcus gauvreauii, and Escherichia coli, revealed that naringenin 16 and 2489 
quercetin 1 exerted dose-dependent inhibitory effects on all the bacterial species that were 2490 
explored, while the flavanone glycosides were inactive (Duda-Chodak, 2012). Similarly, quercetin 2491 
and naringenin presented the highest antibacterial activities when the viability of E. coli, 2492 
Staphylococcus aureus, Salmonella typhimurium, and Lactobacillus rhamnosus was assessed in 2493 
culture. All tested flavonoids induced a decrease in bacterial growth with the exception of quercetin-2494 
3-O-rutinoside 13 (Parkar, Stevenson, & Skinner, 2008). In support of these findings, another study 2495 
reported that pure flavonoids influenced the viability of four bacterial species, E. coli, Staphylococcus 2496 
aureus, Salmonella typhimurium, and Lactobacillus rhamnosus. Again, all the tested compounds, 2497 
except quercetin-3-O-rutinoside, induced a decrease in bacterial growth, with the aglycones 2498 
quercetin and naringenin displaying the greatest antibacterial activity (Duda-Chodak, 2012).  2499 
Animal studies using apple juice reported inhibition of Bacteroides and promotion of 2500 
Bifidobacterium, Lactobacillus, and Bacteroidacae (Etxeberria et al., 2013).  A cocoa drink reduced 2501 
Bacteroides and Clostridium growth, while promoting growth of Eubacterium rectale, Lactobacillus 2502 
spp., Enterococcus spp., and Bifidobacterium spp.  (Cardona, Andres-Lacueva, Tulipani, Tinahones & 2503 
Queipo-Ortuno, 2013). Using an in vitro batch-culture model, Tzonuis et al. (2008) found that 2504 
flavan-3-ol monomers influenced bacterial populations even in the presence of other nutrients. (+)-2505 
Catechin 28 significantly inhibited growth of Clostridium coccoides-Eubacteriom rectale, while 2506 
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growth of Bifidobacterium and Lactobacillus spp. remained unaffected (Tzounis et al., 2008). A cocoa 2507 
intervention with rats showed a significant decrease in the proportion of Bacteroides, Clostridium, 2508 
and Staphylococcus genera (Massot-Cladera, Perez-Berezo, Franch, Castell, & Perez-Cano, 2012). 2509 
Interestingly, reductions in Clostridium species correlated with weight loss and BMI.  Finally, (−)-2510 
epicatechin 38 and (+)-catechin 28 were reported to stimulate the growth of beneficial bacterial 2511 
groups, Eubacterium rectale, Clostridium coccoides, Lactobacillus spp., and Bifidobacterium spp. 2512 
(Etxeberria et al., 2013; Kawabata, Sugiyama, Sakano, & Ohigashi, 2013). 2513 
A black tea extract promoted proliferation of Klebsiella spp., and Enterococci Akkermansia, 2514 
while green tea preparations inhibited Clostridium and Bacteroidaceae and promoted Lactobacillus 2515 
and Bifidobacterium spp. (−)-Epicatechin, (+)-catechin, gallic acid, 3-O-methylgallic acid, and caffeic 2516 
acid have also been reported to suppress the growth of pathogens such as Clostridium perfringens, 2517 
Clostridium difficile, and Bacteriodes spp. (Lee, 2006). 2518 
Consumption of a blueberry extract resulted in an increase in intestinal Bififobacterium 2519 
(Vendrame et al., 2011), while animal and in vitro studies using blueberry extracts observed the 2520 
promotion of Bifidobacterium breve, Lactobacillus rhamnosus, and Lactobacillus growth. Berry 2521 
extracts, including strawberry, cranberry, black currant, lingonberry and cloudberry, have also been 2522 
reported to inhibit the growth of Bacteroides, Clostridium perfringens, Clostridium perrfingens, 2523 
Staphylococcus, Escherichia coli, Lactobacillus rhamnosus, Salmonella, and Bifidobacterium lactis E-2524 
508 (Etxeberria et al., 2013).  2525 
The mechanism by which flavonoids modulate bacterial growth is unknown, however, recent 2526 
findings suggest flavonoids can up-regulate defensive protein secretion and down-regulate various 2527 
microbial metabolic and biosynthetic proteins, likely attributed to their ability to bind bacterial cell 2528 
membranes and to disturb normal membrane function (Kemperman, Bolca, Roger, & Vaughan, 2529 
2010). 2530 
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 2531 
Microbiota:  drivers of flavonoids impact on human health 2532 
The impact of flavonoids and/or their phenolic microbial catabolites on microbial speciation 2533 
can have a positive impact on host biochemistry and pathology. Although most of this research is 2534 
still in its infancy, a recent study of 122 subjects revealed an inhibitory role of flavonoid-rich fruits 2535 
and vegetables on the growth of potentially pathogenic clostridia in high- and low-flavonoid 2536 
consumers (Klinder et al., 2016). Correlations were identified between CVD risk factors and 2537 
bacterial populations in those who consumed fruits and vegetables containing high, medium, and 2538 
low levels of flavonoids. Positive correlations were observed for: body fat and 2539 
Bacteroides/Prevotella; waist circumference and Atopobium; cholesterol and Bifidobacterium; HDL 2540 
and Bacteroides; LDL and Bifidobacterium, Lactobacillus/Enterococcus, Bacteroides/Prevotella, 2541 
Clostridium leptum-Ruminococcus bromii/flavefaciens and Clostridium histolyticum/perfringens; 2542 
TNFα and Lactobacillus/Enterococcus, Bacteroides/Prevotella, Atopobium, Eubacterium 2543 
rectale/Clostridium coccoides, and Clostridium histolyticum/perfringens; ICAM and Eubacterium 2544 
rectale/Clostridium coccoides; and VCAM-1 and Lactobacillus/Enterococcus (Klinder et al., 2016). 2545 
Similarly, healthy mice fed flavonoid-enriched diets have shown increased Bifidobacterium spp. 2546 
which was associated with decreased pro-inflammatory marker TNF-α, PGE2, and leukotriene B4 2547 
(Espley et al., 2014). 2548 
In an 8-week feeding study with mice on a high-fat, high-glucose diet, cranberries brought 2549 
about an increased population of Akkermansia, a mucin-degrading bacterium within the intestine. 2550 
There was also decreased intestinal triglycerides, intestinal and hepatic inflammation, weight gain, 2551 
visceral obesity, and liver weight relative to mice not receiving cranberry (Anhe et al., 2015). 2552 
Another study feeding a black currant extract to mice for 8 weeks on high- and low-fat diets with 2553 
and without treatment with antibiotics also observed reduced weight gain and improved glucose 2554 
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homeostasis, but only in mice that did not receive the antibiotic cocktail and hence had an intact 2555 
microbiome. Interestingly, the anthocyanin content of feces from the antibiotic-treated mice was 2556 
15-fold higher than the feces of the mice with an intact microbiome.  This implies the microbiome is 2557 
directly involved with anthocyanin catabolism/metabolism, and both gut metabolites and 2558 
microbiome likely contribute to the observed effects on weight and glucose-processing (Esposito et 2559 
al., 2015).  2560 
In an 11-week study with mice fed a high-fat diet supplemented with or without a 2561 
lingonberry extract, reduced weight gain, inflammation, and endotoxemia were observed. 16s 2562 
rRNA-sequencing identified a higher abundance of Akkermansia and Faecalibacterium, which are 2563 
generally associated with promoting a healthy gut (Heyman-Linden et al., 2016). Furthermore, in 2564 
rodent studies where the maternal diets were enriched with trans-fatty acids, anthocyanin-2565 
supplemented animals had restored expression of Lactobacillus spp. and Bifidobacterium spp. DNA 2566 
and reduced inflammatory markers associated with down-regulation of NFĸβ in offspring (Morais, 2567 
de Rosso, Estadella, & Pisani, 2016).  2568 
It is clear that flavonoids can affect the microbiome, however, the impact of the metabolome 2569 
and microbiome on human health is inherently complex (Scalbert et al., 2014; van Duynhoven et al., 2570 
2011) and unraveling the complex interplay between flavonoids and health will require deployment 2571 
of complementary in vitro, animal and human studies. One hurdle in moving forward is the large 2572 
biological variation in the microbiome and human metabolism and the relatively subtle effects of 2573 
dietary interventions.  Furthermore, the links between flavonoid metabolism and the human gut 2574 
microbiome have yet to be captured by metabolomic and microbiomic approaches. It is clear that 2575 
the field needs a unified focus in order to successfully characterize the associations between 2576 
flavonoid consumption and disease risk (van Duynhoven et al., 2011, 2012). 2577 
 2578 
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Further considerations 2579 
New theories brought new vigor, concepts, and approaches to the field of flavonoid research 2580 
over the past 2 decades, including new concepts, such as metabolome, metabotype, microbiome, 2581 
interactone, nutrikinetics, and nutradynamics (van Duynhoven et al., 2012). The last decade has also 2582 
seen significant progress in understanding the contribution of the epigenome to the development of 2583 
chronic diseases, including the potential impact of diet and lifestyle. Despite all this, based on the 2584 
review of nearly 70 years of flavonoid research, one thing is clear: there is an almost linear 2585 
proliferation of reported activities and mechanism of action of flavonoids (Figure 21). The question 2586 
remains, why have so many different activities been reported? With that in mind, perhaps it is now 2587 
time to refocus efforts based on the accumulated breadth of knowledge. Either flavonoid-rich foods, 2588 
flavonoids, or their microbial metabolites have unique activities across a multitude of tissues and 2589 
biological pathways, which is unlikely, or they have shared activity in a few key pathways, or they 2590 
have a common mechanism of action involving a protein/enzyme or receptor which communicates 2591 
between signaling pathways (‘crosstalk’), regulating multiple transcription factors. Based on the 2592 
most commonly reported actions of flavonoids, i.e., CVD, cardio-metabolic disorders, type 2 diabetes, 2593 
cancer, and neurodegeneration, and the established overlapping mechanism linking these disorders, 2594 
namely inflammation and redox regulation, significant evidence points towards an overlapping 2595 
mechanism which ‘lies at the crossroads’ of a signaling pathway involving both inflammation and 2596 
redox regulation. In this case, the most likely candidate would involve crosstalk between NF-ĸβ and 2597 
Nrf2. Alternatively, there is evidence to suggest the involvement of VEGF or VEGF-receptor, or the 2598 
PPAR nuclear receptor family. However, any one of these mechanisms does not account for the 2599 
totality of activities reported across receptors, transcription factors, and associated up- and down-2600 
stream signaling proteins. It is also possible that flavonoids have multiple mechanism of action and 2601 
could act on VEGF, PPARs, and a common crosstalk protein linking the NF-ĸβ and Nrf2 pathways. 2602 
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Finally, it is just as possible that flavonoid activity is insufficient to produce sizable health effects on 2603 
their own, but in combination with their apparent actions on nutrient regulation (absorption, 2604 
metabolism), such as fat, carbohydrate and protein metabolism, produce a combined measurable 2605 
health effect. For example, flavonoids are reported to affect carbohydrate digestion and metabolism, 2606 
and lipid profiles, and these changes in combination with activity on transcription factors, as 2607 
detailed above, would provide powerful health effects. 2608 
 2609 
Vascular endothelial growth factor  2610 
VEGF and VEGF-receptors are key players in the regulation of vascular cell development and 2611 
are also involved in monocyte regulation, macrophage migration, angiogenesis, and vascular 2612 
permeability (Alvarez-Aznar, Muhl, & Gaengel, 2017), nerve regeneration, and attenuating vascular 2613 
complications associated with diabetes (Suganya, Bhakkiyalakshmi, Sarada, & Ramkumar, 2016). 2614 
Interference with the VEGF-signaling pathway has been proposed as a mechanism behind 2615 
flavonoids’ anti-cancer activity (Ci, Qiao, & Han, 2016) and VEGF is a suggested risk marker for 2616 
coronary heart disease (Wang et al., 2017). Quercetin and cocoa flavonoids have also been reported 2617 
to act on VEGF (Donnini et al., 2006; Kim et al., 2014), providing further evidence that VEGF is a 2618 
reasonable mechanistic target. 2619 
 2620 
Peroxisome proliferator-activated receptor-alpha   2621 
PPAR-α plays a key role in glucose homeostasis and lipid metabolism (Yang, Xiao, & Wang, 2622 
2017), while PPAR-γ is involved in regulating endothelial function, BP, oxidative stress response 2623 
(Kvandova, Majzunova, & Dovinova, 2016), mitochondrial dysfunction, and neuro-inflammation 2624 
(Agarwal, Yadav, & Chaturvedi, 2017). Although controversial, PPAR polymorphisms have also been 2625 
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suggested as being associated with coronary heart disease risk (Balakumar, Rose, & Singh, 2007; 2626 
Qian et al., 2016). The activity of flavonoids on PPAR has been reported as a possible mechanism of 2627 
action in studies of cardio-metabolic and cognitive health. Flavonoids such as kaempferol have been 2628 
reported to modulate PPAR-γ (Li & Schluesener, 2017). Based on the diverse roles of PPARs, they 2629 
are logical targets for future investigation. 2630 
 2631 
 Crosstalk  2632 
Evidence suggests a cycle or balance exists between NF-ĸβ and Nrf2 pathways (Cuadrado et 2633 
al., 2014; Wardyn, Ponsford & Sanderson, 2015) in which RAC1 may be a coordinating protein 2634 
(Cuadrado et al., 2014) and could be an important target for flavonoid research (Figure 24). RAC1 2635 
can activate NF-ĸβ to initiate an inflammatory response and also induce the Nrf2/ARE pathway 2636 
which in turn inhibits RAC1-dependent NF-ĸβ activation. Therefore, RAC1 appears to have the 2637 
ability to coordinate both the NF-ĸβ and Nrf2 pathways, thus modulating inflammation, oxidative 2638 
and metabolic pathways (Cuadrado et al., 2014; Wardyn, Ponsford & Sanderson, 2015). Quercetin 1, 2639 
gallic acid 101, and caffeic acid 103 have been reported to downregulate RAC1. Furthermore, the 2640 
involvement of RAC1 is implicated in the activity of flavonoids and their metabolites on NOX, HO-1, 2641 
and the attenuation of LPS-induced inflammatory stress (i.e., activation of TLR4 inducing the release 2642 
of pro-inflammatory cytokines) (Cuadrado et al., 2014; Ho et al., 2010; Kabirifar et al., 2017; Xu et al., 2643 
2005). Flavonoids are also reported to be active on other notable crosstalk points linking these two 2644 
pathways, including Keap1, GSK, Jun, HDAC, p65, IKK, and HO-1, as well as having direct activity on 2645 
NF-ĸβ and Nrf2 (Ahmad & Mukhtar, 1999; Baptista et al., 2014; Bousova & Skalova, 2012; Brown, 2646 
1999; Gomes, Fernandes, Ho et al., 2010; Gonzalez-Sarrias, Larrosa, Tomas-Barberan, Dolara, & 2647 
Espin, 2010; Kabirifar et al., 2017; Lima, Mira, & Corvo, 2008; Lin & Liang, 2000; Romero et al., 2648 
2009; Ryter, Otterbein, Morse, & Choi, 2002; Sanchez et al., 2006, 2007; Sorrenti et al., 2007; Wang, 2649 
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Wei, Yan, Jin, & Ling, 2010a; Xu et al., 2005; Yang, Lee, Chen, & Yang, 1997; Yang et al., 2000; Zhou et 2650 
al., 2016). 2651 
 2652 
Conclusions  2653 
Flavonoid research has recently undergone a transformation, and with the demise of the radical-2654 
scavenging antioxidant hypothesis and the realization that the microbiome is inherently integrated 2655 
with flavonoid metabolism and bioactivity, the field is primed for new discoveries. Researchers 2656 
should be mindful of the past 80 years of flavonoid research, and some of the past highlights and 2657 
low points have been discussed in this paper to help new scientists to the field avoid making some 2658 
of the same mistakes. Moving forward, there are a number of key findings on bioavailability and 2659 
bioefficacy which should be emphasized:  2660 
• Parent flavonoids are deglycosylated during digestion, are absorbed in the small intestine, 2661 
and appear in the blood as phase II metabolites.  2662 
• Flavonoids can act on processes of digestion in the gut lumen before absorption and affect 2663 
the rate and extent of absorption of macronutrients such as sugars.  2664 
• Flavonoid conjugates in the blood can act on the endothelial cells lining the blood vessels, as 2665 
well as the underlying smooth muscle cells, and regulate vascular tone, blood pressure, 2666 
vascular health, and cognitive function.  2667 
• The gut microbiome plays a major role in the metabolism and absorption of many flavonoids, 2668 
but the products absorbed are different chemical species to the ingested compounds, and 2669 
they can exhibit their own biological activities, which may perhaps even synergize with the 2670 
parent flavonoid.  2671 
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• Direct interactions between flavonoids and the gut microbiome are likely to alter host 2672 
immune and inflammatory status, and also influence microbiome diversity.  2673 
• The activity of absorbed parent compounds and of microbial metabolites appears to involve 2674 
action on key cell receptors or crosstalk between cell signaling pathways, ultimately 2675 
differentially affecting various cells and tissues, depending on the cell phenotype and 2676 
metabolic environment. 2677 
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Table 1 – Pharmacokinetic analysis of quercetin metabolites detected in plasma 0-24 h 4203 
after the consumption of 270 g of lightly fried onions containing 275 μmol of flavonol 4204 
glucosides by six volunteers (after Mullen, Edwards & Crozier 2006).  4205 
Metabolites Cmax (nmol/L)a Tmax (h)b AT1/2 (h)c 
Quercetin-3’-sulfate  665 ± 82 0.8 ± 0.1 1.7 
Quercetin-3-O-glucuronide  351 ± 27 0.6 ± 0.1 2. 3 
Isorhamnetin-3-O-glucuronide  112 ± 18 0.6 ± 0.1 5.3 
Quercetin-di-O-glucuronide 62 ± 12 0.8 ± 0.1 1.8 
Quercetin-O-glucuronide-sulfate 123 ± 26 2.5 ± 0.2 4.5 
Data expressed as mean values ± standard error (n = 6) 4206 
a Cmax – post-ingestion peak plasma concentration. 4207 
bTmax – time to reach Cmax 4208 
cAT1/2 - apparent elimination half-life. 4209 
 4210 
 4211 
 4212 
 4213 
 4214 
 4215 
 4216 
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Table 2 –Pharmacokinetic analysis of quercetin metabolites in the plasma of 4220 
volunteers after the consumption of 250 mL of tomato juice containing 176 4221 
µmol of quercetin-3-O-rutinoside  (after Jaganath, Mullen, Edwards & Crozier 4222 
2006). 4223 
Metabolites  
Cmax 
(nmol/L)a Tmax (h)b 
AT1/2 
(h)c 
Quercetin-3-O-glucuronide  12 ± 2 4.7 ± 0.3 1.67 
Isorhamnetin-3-O-glucuronide  4.3 ± 1.5 5.4 ± 0.2 1.66  
Data presented as mean values ± standard error (n = 6).  4224 
a Cmax – post-ingestion peak plasma concentration. 4225 
bTmax – time to reach Cmax 4226 
cAT1/2 - apparent elimination half-life. 4227 
 4228 
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 4229 
Table 3 – Identification of urinary metabolites of (+)-catechin in various species (based on Das 1974) 4230 
Species 
tested 5C-Ring fission metabolites  Phenolic acid metabolites 
Rat 5-(3'-Hydroxyphenyl)-γ-valerolactone 29 3-(3'-Hydroxyphenyl)propionic acid 32 
 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone 30 3'-Hydroxyhippuric acid 33 
 5-(3'-Methoxy-4'-hydroxyphenyl)-γ-valerolactone 31  
   Guinea pig 5-(3'-Hydroxyphenyl)-γ-valerolactone 29 3-Hydroxybenzoic acid 34 
 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone 30 3'-Hydroxyhippuric acid 33 
 5-(3'-Methoxy-4'-hydroxyphenyl)-γ-valerolactone 31  
   Rabbit 5-(3'-Hydroxyphenyl)-γ-valerolactone 29 3,4-Dihydroxybenzoic acid 35 
 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone 30 3-Methoxy-4-hydroxybenzoic acid 36 
 5-(3'-Methoxy-4'-hydroxyphenyl)-γ-valerolactone 31 3-Hydroxybenzoic acid 34 
   Man 5-(3'-Hydroxyphenyl)-γ-valerolactone 29 3-(3'-Hydroxyphenyl)hydracrylic acid 37 
 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone 30 3-(3'-Hydroxyphenyl)propionic acid 32 
 5-(3'-Methoxy-4'-hydroxyphenyl)-γ-valerolactone 31  
   Monkey 5-(3'-Hydroxyphenyl)-γ-valerolactone 29  3-(3'-Hydroxyphenyl)hydracrylic acid 37 
 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone 30 3-(3'-Hydroxyphenyl)propionic acid 32 
 5-(3'-Methoxy-4'-hydroxyphenyl)-γ-valerolactone 31 3-Hydroxybenzoic acid 34 
  3'-Hydroxyhippuric acid 33 
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 4233 
 4234 
 4235 
 4236 
 4237 
 4238 
 4239 
Table 4 – Pharmacokinetic analysis of SREMs and 5C-RFMs detected in human plasma 0-24 h 4240 
after ingestion of 300 μCi (207 μmol) of [14C]EC. Data expressed as mean values ± standard 4241 
error (n = 8)a. Based on the data of Ottaviani et al. (2016) and Borges et al. (2017). 4242 
 Cmax (nmol/L) C30 min (nmol/L) Tmax (h) AUC(tf) (nmol/L/h) AT1/2 (h) 
Total SREMs 1223 ± 104 854 ± 76 1.0 ± 0.1 4,943 ± 471 1.9 ± 0.1 
Total 5C-RFCs 588 ± 102 – 5.8 ± 0.4 14,352 ± 2264 5.7 ± 0.7 
.a SREMs, structurally-related (−)-epicatchin metabolites; 5C-RFMs, 5 carbon side-chain 4243 
ring fission metabolites; Cmax – peak plasma concentration; C30 min – plasma concentration 4244 
30 min after ingestion; Tmax – time to reach peak plasma concentration; AUC(tf) – area 4245 
under the plasma concentration from time 0 h to the time of final quantifiable sample; AT1/2 4246 
– apparent elimination half-life; −, not detected.   4247 
 4248 
 4249 
 4250 
 4251 
 4252 
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Table 5 – 14C-Labelled SREMs, 5C-RFMs and 2/3C-RFMs detected in urine 0-48 h after the ingestion of 300 Ci (207 moles) 4255 
of [14C]EC by 8 volunteers. Data expressed as mean values in moles ± standard error (n = 8); italicised figures in parentheses 4256 
represent urinary recoveries of metabolites as a percentage of -(–)-epicatechin intakea.  Based on the data of Ottaviani et al. 4257 
(2016) and Borges et al. (2017). 4258 
Metabolites  0-4 h 4-8 h 8-12 h 12-24 h 24-48 h 0-48 h 
Total SREMs 25.3 ± 3.1 9.2 ± 0.9 3.6 ± 0.8 2.5 ± 0.8 − 40 ± 4 (20%) 
Total 5C-RFMs 4.9 ± 1.6 43.3 ± 8.3 22.3 ± 4.1 16.4 ± 0.5 ± 0.5 87 ± 9 (42%) 
Hydroxyphenylacetic acid-sulfate  − 0.9 ± 0.5 0.8 ± 0.6 1.2 ± 0.4 − 2.9 ± 1.1 
3-(3'-Hydroxyphenyl)hydracrylic − 0.7 ± 0.4 2.2 ± 0.5 5.3 ± 2.3 3.3 ± 1.7 11.5 ± 4.4 
Total 2/3C-RFMS − 1.6 ±  0.6 3.0 ± 0.9 6.5 ± 2.4 3.3 ± 1.7 14 ± 4 (7%) 
Hippuric acid 0.6 ± 0.4 7.2 ± 3.9 5.6 ± 2.6 7.1 ± 2.1 5.9 ± 4.1 26.4 ± 7.1 
3'-Hydroxyhippuric acid − 1.6 ± 0.5 2.8 ± 0.7 7.0 ± 2.9 5.5 ± 2.3 16.9 ± 5.8 
Total hippuric acids 0.6 ± 0.4 8.8 ± 4.1 8.4 ± 2.5 14.1 ± 11.4 ± 43 ± 7 (21%) 
Total metabolites 30.8 ± 3.7 62.9 ± 11.3 37.3 ± 5.8 39.5 ± 15.2 ± 185 ± 16 (89 %) 
aSREMs, structurally-related (−)-epicatchin metabolites; 5C-RFMs, 5 carbon side-chain ring fission metabolites; 2/3C-RFMs, 2 4259 
and 3 carbon side-chain ring fission metabolites.; −, not detected 4260 
 4261 
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Table 6 –  Total and major individual fission metabolites voided in feces 0-72 h after the ingestion of [2-14C](–)-epicatechin (60 mg [207 μmol] 300 4262 
μCi) by 8 volunteers. Data expressed as in μmol and in italicised parentheses as a % of the ingested dose. Standard error of the individual values 4263 
<15% of the mean values a. Based on the data of Ottaviani et al. (2016) and Borges et al. (2017). 4264 
 Volunteers 
Metabolites 1 2 3 4 5 6 7 8 Mean  
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone 0.6 – 25.6 0.2 – – 1.5 −  
 5-(3'-Hydroxyphenyl)-γ-valerolactone-4'-sulfate – – 1.0 – – – 0.9 –  
 5-(4'-Hydroxyphenyl)-γ-valerolactone-3'-sulfate 1.3 4.3 – 0.8 1.6 – 0.2 0.2  
 Total phenyl)-γ-valerolactones 1.9 4.3 26.6 1.0 1.6 – 2.6 0.2 4.5 
          
5-(3′,4'-Dihydroxyphenyl)-γ-hydroxyvaleric acid – – 5.3 – – – – –  
 5-(3′-Hydroxyphenyl)-γ-hydroxyvaleric acid – – 5.9 – – – – –  
 5-(Phenyl)-γ-hydroxyvaleric acid 10.7 12.6 17.4 8.1 12.4 – 7.2 0.4  
 5-(3′-Hydroxyphenyl)-γ-hydroxyvaleric acid-4'-
sulfate 
1.1 – 15.4 0.1 0.3 – – 0.1  
 5-(Ph nyl)-γ-hydroxyvaleric acid-3'-sulfate – – 1.5 – – – – –  
 Total phenyl-γ-hydroxyvaleric acids 11.8 12.6 45.7 8.2 12.6 – 7.2 0.5 12.3 
          
3-(3'-Hydroxypheny)propionic acid 0.8 2.1 1.2 – 0.3 – 21.5 0.2 3.3 
          
Unknowns – – – 0.5 4.0 – 0.7 − 0.7 
          
Total metabolites 
14.5 
(7.0%
) 
19.0 
(9.2%) 
73.5 
(35.5%) 
9.7 
(4.7%) 
18.5 
(8.9%) 
– 
(0.0%) 
32.0 
(15.5%) 
0.9 
(0.4%) 
21.0 
(10.1%
) a –, not detected 4265 
 4266 
 4267 
 4268 
 4269 
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Table 7 – Compounds excreted in urine in increased amounts 0-48 h after ingestion of 300 g of 4271 
raspberries containing 292 μmol of anthocyanins. Based on data of Ludwig et al. (2015). 4272 
Compounds Increased 0-48 h excretion 
after raspberry intakea,b 
Caffeic acid-3’-sulfate 1.0 ± 0.1* 
Dihydrocaffeic acid-3’-sulfate 1.1 ± 0.3* 
Ferulic acid 5.9 ± 2.1* 
Ferulic acid-4′-sulfate 6.5 ± 2.6* 
Isoferulic acid-3′-sulfate 0.5 ± 0.2* 
Ferulic acid-4′-O-glucuronide 1.8 ± 0.5* 
Isoferulic acid-3′-O-glucuronide 1.0 ± 0.4* 
Total hydroxycinnamate derivatives 17.8 ± 5.3* 
  3',4'-Dihydroxyphenylacetic acid (homoprotocatechuic acid) 2.9 ± 1.3* 
3′-Methoxy-4′-hydroxyphenylacetic acid (homovanillic acid) 0.2 ± 0.2 
Total phenylacetic acids 3.1 ± 1.7* 
  4-Hydroxybenzoic acid  6.4 ± 4.8* 
3,4-Dihydroxybenzoic acid (protocatechuic acid) traces 
3-Methoxy-4-hydroxybenzoic acid (vanillic acid) traces 
4-Hydroxybenzoic acid-3-sulfate (protocatechuic acid-3-sulfate) 0.3 ± 0.1* 
3-Hydroxybenzoic acid-4-sulfate (protocatechuic acid-4-sulfate) 0.2 ± 0.1* 
Total benzoic acid derivatives 6.9 ± 5.0* 
  
4′-Hydroxyhippuric acid 16.1 ± 1.9* 
Hippuric acid 239 ± 55* 
  
Total phenolic derivatives (excluding hippuric acid) 43.9 ± 8.0* (15.0%)c 
a Data expressed in μmol as mean values ± S.E. (n = 9) 4273 
bContent of urine collected for 12 h prior to supplementation and on an excretion per hour basis 4274 
used to subtract from 0-48 h excretion values obtained after raspberry consumption to attain the 4275 
values cited.    4276 
cThe increased amount excreted expressed as a percentage of the dose of anthocyanins ingested 4277 
*Statistically significant higher excretion 0-48 h after raspberry intake (p ≤ 0.05). 4278 
 4279 
 4280 
 4281 
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Table 8 – Phenolic catabolites excreted in urine in significantly increased amounts (P <0.05) 0-24 h 4284 
after the ingestion of 250 mL of orange juice containing 584 µmol of (poly)phenolic compounds 4285 
compared to a (poly)phenol-free placebo drink (based on Pereira-Caro et al. 2014)a. 4286 
Phenolic catabolites 
Placebo 
drink  
Orange 
juice  
Increase 
with orange 
juice  
3-(3'-Hydroxy-4'-methoxyphenyl)hydracrylic acid n.d 72 ± 10 72 
3-(3'-Hydroxyphenyl)hydracrylic acid 2.5 ± 31 ± 4 29 
3-(3'-Hydroxy-4'-methoxyphenyl)propionic acid (dihydro- n.d. 4.7 ± 4.7 
3-(3'-Methoxy-4'-hydroxyphenyl)propionic acid n.d. 6.3 ± 6.3 
3'-Methoxy-4'-hydroxyphenylacetic acid 4.7 ± 7.3 ± 2.6 
3'-Hydroxyhippuric acid n.d. 0.8 ± 0.8 
4'-Hydroxyhippuric acid 0.2 ± 19 ± 4 19 
Hippuric acid 232 ± 610 ± 378  
Total minus hippuric acid 7 141 134 (23%) 
Total with hippuric acid 239 751 512 (88%) 
a Data expressed in μmol as mean values ± S.E.  Figures in italicised parenthesis are excretion as a 4287 
percentage of (poly)phenol intake. Not detected, n.d. 4288 
 4289 
 4290 
 4291 
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Figure Legends 4293 
 4294 
Figure 1 – Illustration of the transporters and metabolizing enzymes involved in polyphenol 4295 
metabolism throughout the body. (A) In the gut lumen, flavonoid glucosides are deconjugated by 4296 
LPH (lactase phloridzin hydrolase) in the brush border of the enterocyte. The flavonoid aglycone 4297 
can then enter the cell, and be conjugated by uridine diphosphate glucuronosyl transferase (UGT) or 4298 
sulfotransferase (SULT), and the conjugates exported either back to the lumen or into the blood by 4299 
various transporters. (B) Conjugated flavonoid metabolites in the blood can be imported into 4300 
hepatocytes via various uptake transporters, and then returned to the circulatory system, 4301 
alternatively they can be deconjugated intracellularly by enzymes such as β-glucuronidase (glcAase) 4302 
Certain conjugates may be exported into the bile although this probably a minor pathway for most 4303 
metabolites. Intracellular deconjugation is enhanced under inflammatory conditions. (C) Ultimately, 4304 
flavonoid conjugates can be excreted by the kidney, involving uptake into the proximal tubular cells 4305 
by transporters and excretion into the urine. The presence of OAT4 on the basolateral side implies 4306 
that conjugates could be reabsorbed into the kidney after excretion, but this has not been proven. 4307 
 4308 
Figure 2 – Concentration of (A) quercetin-3'-sulfate  and quercetin-3-O-glucuronide (B) 4309 
isorhamnetin-3-O-glucuronide, a quercetin-O-glucuronide and a quercetin-O-diglucuronide in the 4310 
plasma of volunteers collected 0-6 h after the ingestion of lightly fried onions containing 275 μmol 4311 
of flavonol-O-glucosides. Data expressed in nmol/L ± standard error (n = 6). Note no quercetin 4312 
metabolites were present in plasma in detectable amounts 24 h after supplementation (after Mullen, 4313 
Edwards & Crozier 2006). 4314 
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 4315 
Figure 3 – Potential routes for the metabolism of quercetin- and isorhamnetin-O-glucosides in in 4316 
the proximal gastrointestinal tract. Fine curved red arrow indicates position of sugar cleavage (after 4317 
Mullen, Edwards & Crozier 2006). 4318 
 4319 
Figure 4 – Concentration of quercetin-3-O-glucuronide and isorhamnetin-3-O-glucuronide in 4320 
plasma of volunteers collected 0-8 h after the ingestion of tomato juice containing 176 μmol of 4321 
quercetin-3-O-rutinoside. Data expressed in nmol/L ± standard error (n = 6). Note neither quercetin 4322 
metabolite was present in plasma in detectable amounts 24 h after supplementation (after Jaganath, 4323 
Mullen, Lean, Edwards and Crozier 2006). 4324 
 4325 
Figure 5 – Proposed pathways for the catabolism of quercetin-3-O-rutinoside resulting in the 4326 
production of hydroxyphenylacetic acids and benzoic acids based on feeds with tomato juice 4327 
containing quercetin-3-O-rutinoside and fecal incubations with quercetin. Curved fine arrows 4328 
indicate sugar cleavage and ring fission. Red arrows indication conversions catalysed by colonic 4329 
microbiota, and blue arrow indicate a conversion mediated with mammalian enzymes (after 4330 
Jaganath, Mullen, Edwards, & Crozier (2006).   4331 
 4332 
Figure – 6.  Stereochemistry-dependent epicatechin metabolism. Levels of individual epicatechin 4333 
metabolites at peak plasma concentration 2 h after the consumption of a cocoa drink containing 1.5 4334 
mg/kg body weight of (−)-epicatchin or (+)-epicatechin. Data expressed in nmol/L as mean values ± 4335 
standard error (n = 7). * Signifies statistically different from levels reached with the same 4336 
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metabolites after (−)-epicatechin consumption, p<0.05. (Ottaviani, Momma, Kuhnle, Keen, & 4337 
Schroeter, 2012).  4338 
 4339 
Figure 7 –  Radioactivity detected in plasma collected 0−24 h after the ingestion of 300 Ci (207 4340 
moles) of [2-14C](−)-epicatechin by volunteers. Data presented as mean values ± standard error (n 4341 
= 8) and expressed as a percentage of the ingested radioactivity.   4342 
 4343 
Figure 8 –  Pharmacokinetic profiles of the concentration of the SREMs (A) (−)-epicatechin 4344 
metabolites and (B) methyl-(–)-epicatechin metabolites and (C) the 5C-RFMs, -valerolactone and 4345 
valeric acid metabolites detected in plasma 0−24 h after the ingestion of 207 moles of [2-14C](−)-4346 
epicatechin by volunteers.  Data expressed as mean values in mol/L ± standard error (n = 8). EC-4347 
3'-GlcUA, (–)-epicatechin-3'-O-glucuronide; (–)-epicatechin-7-O-glucuronide (EC-7-GlcUA); (–)-4348 
epicatechin-3'-sulfate (EC-3'-S), (–)-epicatechin-5-sulfate (EC-5-S); (–)-epicatechin-7-sulfate (EC-7-4349 
S); 3'-O-methyl-(–)-epicatechin-4'-sulfate (3'-Me-EC-4'-S); 3'-O-methyl-(–)-epicatechin-5-sulfate (3'-4350 
Me-EC-7-S); 3'-O-methyl-(–)-epicatechin-7-sulfate (3'-Me-EC-7-S); 4'-O-methyl-(–)-epicatechin-5-4351 
sulfate (4'-Me-EC-5-S); 3'-O-methyl-(–)-epicatechin-5-O-glucuronide (3'-Me-EC-5-GlcUA); 3’-O-4352 
methyl-(–)-epicatechin-7-O-glucuronide (3'-Me-EC-7-GlcUA); 5-(4'-hydroxyphenyl)-γ-4353 
valerolactone-3'-sulfate (4'-OH-VL-3'-S); 5-(3′-hydroxyphenyl)-γ-valerolactone-4'-O-glucuronide 4354 
(3'-OH-VL-4'-GlcUA); 5-(4′-hydroxyphenyl)-γ-valerolactone-3'-O-glucuronide (4'-OH-VL-3'-GlcUA); 4355 
5-(hydroxyphenyl)-γ-hydroxyvaleric acid-sulfates (OH-VA-S) and 5-(3′-hydroxyphenyl)-γ-4356 
hydroxyvaleric acid-4'-O-glucuronide (3'-OH-VA-γ-GlcUA).  Based on the data of Ottaviani, et al. 4357 
(2016).   4358 
 4359 
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Figure 9 – Proposed routes for the human metabolism of [2-14C](−)-epicatechin, potentially in 4360 
enterocytes and hepatocytes, following its ingestion in the proximal gastrointestinal tract. Boxed 4361 
metabolite names indicate the main products to accumulate in plasma and urine after (–)-4362 
epicatechin intake.  Blue arrows indicate that the conversions are catalysed by mammalian enzymes. 4363 
Asterisks indicate potential intermediates that do not accumulate in detectable quantities in either 4364 
plasma or urine. T indicates the position of 14C-label. Based on the data of 4365 
Ottaviani, et al. (2016) and Borges et al. (2017).   4366 
 4367 
Figure 10 –  Proposed routes for the metabolism by colonic microbiota of [2-14C](−)-epicatechin 4368 
passing from the small to the large intestine (red arrows), and potential steps catalysed by 4369 
mammalian enzymes in colonocytes and/or hepatocytes (blue arrows).  Thin arrows indicate minor 4370 
routes. Boxed metabolite names indicate the main products to accumulate in plasma after (–)-4371 
epicatechin intake. Asterisks indicate potential intermediates that do not accumulate in detectable 4372 
quantities in either plasma or urine. T indicates the position of 14C-label. Based 4373 
on the data of Ottaviani et al. (2016) and Borges et al. (2017).     4374 
 4375 
Figure – 11. Pharmacokinetic profiles of phenolic catabolites in plasma following raspberry 4376 
consumption. Data expressed as mean values ± standard error (n = 9) (Ludwig et al. 2015). 4377 
Figure 12 – Proposed pathways for the conversion of cyanidin-based anthocyanins to phenolic 4378 
acids and related compounds. Blue arrows indicate potential steps catalyzed by mammalian 4379 
enzymes. Red arrows indicate steps that may be catalyzed by microbial enzymes. The formation of 4380 
caffeic acid from cyanidin, as well as enzymatic steps, may also involved pH-mediated or 4381 
microbiota-mediated degradation of the anthocyanidin (black arrows). Compounds with boxed 4382 
names indicate main urinary components after raspberry consumption. Based on the data of 4383 
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González-Barrio et al. (2011) and Ludwig et al. (2015). There is evidence for the formation of many 4384 
additional products including 3-hydroxy-4-methoxybenzoic acid, other hydroxy-methoxy isomers of 4385 
benzoic acid, and phase II metabolites of dihydroxyphenylacetic and hydroxy- and 4386 
dihydroxycinnamic acids. Other catabolites of cyanidin include 4-hydroxybenzyldehyde and 4387 
phloroglycinaldehyde (Czank et al. 2013, de Ferrars et al. 2014b). * - potential intermediates that 4388 
did not accumulate in detectable amounts, GlcUA - glucuronide 4389 
Figure 13 –  Structure of [6,8,10,3',5'-13C5]cyanidin-3-O-glucoside. 4390 
Figure 14 –  Plasma pharmacokinetic profile of a pelargonidin-O-glucuronide following the 4391 
consumption of a strawberry drink either  with, 2 h before, or 2 h after a morning meal consisting of 4392 
a croissant with butter and apple jelly, cereal, whole milk and sausages by overweight (BMI: 26 ± 2 4393 
kg/m2) volunteers. Data expressed as mean values ± standard error (n = 14).  Based on the data of 4394 
Sandhu et al. 2016). 4395 
Figure 15 –  Proposed pathways for the phase II metabolism and conversion of hesperetin 4396 
metabolites. 4397 
Figure 16 – Hesperetin-O-glucuronide plasma pharmacokinetic after the ingestion of a 4398 
(poly)phenol-rich drink containing 45 µmol of hesperetin-7-O-rutinoside by human volunteers. Data 4399 
expressed as mean values ± standard error (n = 6) Based on the data of Borges et al.( 2010).  4400 
Figure 17 –  Proposed pathways for the metabolism of naringenin and ferulic acid released by 4401 
cleavage of hesperetin-7-O-rutinoside and ferulic acid-4′-O-glucoside after the consumption of 4402 
orange juice by humans. Compounds with boxed names indicate major components in 0-24 h urine. 4403 
Curved green arrow indicates ring fission. Red arrows are potential microbiota-mediated 4404 
conversions and blue arrows indicate steps potentially catalysed by mammalian enzymes. * - 4405 
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potential intermediates that did not accumulate in detectable amounts. GlcUA - glucuronide.  Based 4406 
on data of Pereira-Caro et al. (2014, 2015a,b, 2016).   4407 
Figure 18 –  Proposed pathways for the colonic metabolism of hesperetin released by cleavage of 4408 
hesperetin-7-O-rutinoside after the consumption of orange juice by humans. Based on urinary 4409 
excretion in feeding studies and in vitro fecal incubations. Compounds with boxed names indicate 4410 
major components in 0-24 h urine. Curved green arrow indicates ring fission. Red arrows are 4411 
potential microbiota-mediated conversions and blue arrows are steps potentially catalysed by 4412 
mammalian enzymes. * - intermediate that did not accumulate in detectable amounts. GlcUA - 4413 
glucuronide.  Based on data of Pereira-Caro et al. (2014, 2015a,b, 2016, 2017). 4414 
Figure 19 – Reported number of flavonoid publications in PubMed. MEDLINE®/PubMed®, The 4415 
National Library of Medicine® (NLM®). 10/10/2017; https://www.ncbi.nlm.nih.gov/pubmed. 4416 
Figure – 20 Dissimilarity between functional and dysfunctial endothelium. (A) Healthy responsive 4417 
endothelium mediating endothelium-dependent vasodilation; (B) dysfunctional endothelium 4418 
mediating impaired vasodilation and leading to increased expression of adhesion molecules and 4419 
recruitment of leucocytes. CECs, circulating endothelial cells; CRP, C-reactive protein; EMPs, 4420 
endothelial microparticles; EPCs, endothelial progenitor cells; IL-6, interleukin-6; NO nitric oxide; 4421 
PAI-1, plasminogen activator inhibitor 1; PGI2, prostacyclin; ROS, reactive oxygen species; sICAM, 4422 
soluble intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion molecule; TNF-α, 4423 
tumor necrosis factor alpha; vWF, von Willebrand factor.  Based on the data of Arranz et al. (2013), 4424 
Baptista et al. (2014), Bousova, & Skalova (2012), 4425 
Brown, & Griendling (2015), Butler (2015), Cuadrado, Martin-Moldes, Ye, & Lastres-Becker (2014), 4426 
Day, Bao, Morgan, & Williamson G (2000), Fraga, & Oteiza (2011), González-Gallego et al. (2010), 4427 
Gonzalez-Sarrias et al. (2010), Grassi, Desideri, & Ferri (2013), Joven et al. (2014), Kabirifar et al. 4428 
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(2017), Kawser Hossain et al. (2016), Kerim & Williamson (2015), Khan et al. (2016), Li, & 4429 
Schluesener (2017), Li et al. (2008), Lodi et al. (2009), Matias, Buosim & Gomes (2016), Mladenka, 4430 
Zatloukalova, Filipsky, & Hrdina (2010), Morais, de Rosso, Estadella, & Pisani (2016),  Rendeiro, 4431 
Rhodes, & Spencer (2015), Romero et al. (2009), Ryter, Otterbein, Morse, & Choi (2002), Sanchez et 4432 
al. (2006, 2007), Scholz, Zitron, Katus, & Karle (2010), Sorrenti et al. (2017), Spencer, Vafeiadou, 4433 
Williams, & Vauzour (2012), Steffen, Gruber, Schewe, & Sies (2008), Steffen, Schewe, & Sies (2007), 4434 
Stepkowski, & Kruszewski (2011), Vauzour (2014), Wang, Wei, Yan, Jin, & Ling (2010), Xu et al. 4435 
(2005).  4436 
Figure 21 – Exponential proliferation of reported flavonoid activities. (A) Reported clinical 4437 
pathologies; (B) reported clinical endpoints/biomarkers; (C) reported mechanisms of action. 4438 
Figure 22 – OxLDL induced IL6 production. Data expressed as % relative to OxLDL treated 4439 
endothelial cells. *Significant relative to oxLDL-treated cells, p ≤ 0.05, ANOVA with Tukey post-hoc t-4440 
test n=3. Cyanidin-3-O-glucoside (C3G), 3,4-dihydroxybenzoic acid (protocatechuic acid; PCA), 3-4441 
methoxy-4hydroxybenzoic acid (vanillic acid; VA), 4-hydroxybenzoic acid-3-sulfate (protocatechuic 4442 
acid-3-sulfate (PCA-3-S), 4-hydroxybenzoic acid-3-O-glucuronide (protocatechuic acid-3-O-4443 
glucuronide) (PCA-3-GlcUA). 4444 
Figure 23 – Microbiota role in flavonoid bioavailability. 4445 
Figure 24. – Reported activity of flavonoids on Nrf2 and NF-ĸB regulated enzymes, chemokines and 4446 
“cross-talk” proteins. Figure adapted from reports identifying cross-talk between Nrf2 and NF-ĸB 4447 
pathways (Arranz et al., 2013; Baptista et al., 2014; Bousova & Skalova, 2012; Brown & Griendling, 4448 
2015; Cuadrado et al., 2014; Day et al., 2000a; Fraga & Oteiza, 2011; González-Gallego et al., 2010; 4449 
González-Sarrias et al., 2010; Grassi et al., 2013; Joven et al., 2014; Kabirifar et al., 2017; Kaeser 4450 
Hossain et al., 2016; Kerimi & Williamson, 2015; Khan et al., 2016. Li & Schluesener, 2017; Li et al., 4451 
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2008; Lodi et al., 2009; Matais et al., 2016; Mladenka et al., 2010; Morais et al., 2016; Rendeiro et al., 4452 
2015; Romero et al., 2009; Ryter et al., 2002; Sanchez et al., 2006, 2007; Scholz et al., 2010; Sorrenti 4453 
et al., 2007; Spencer et al., 2012; Steffen et al., 2007, 2008; Stepowski & Kruszewski, 2011; Vauzour, 4454 
2014; Wang et al., 2010a; Xu et al., 2005). Enzymes, proteins and transcription factors identified 4455 
have been previously reported to be affected by flavonoids or their metabolites (as referenced 4456 
throughtout this review).  4457 
 4458 
 4459 
 4460 
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OH
HOOC
OH
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Eriodictyol-7-O-rutinoside 92
OH
O
HO OH
HO
3-(3'-Hydroxy-4'-methoxyphenyl)hydracrylic acid 93
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HOOC
OH
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Ferulic acid 94
OH
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3'-Methoxy-4'-hydroxyphenylacetic acid 96
OH
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3-(3'-Methoxy-4'-hydroxyphenyl)propionic acid 95
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(+)-Gallocatechin 100
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(−)-Epigallocatechin 99
Gallic acid 101
(3,4,5-trihydroxybenzoic acid)
OH
HOOC
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2,4,6-Trihydroxybenzaldehyde 104
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(3,4-dihydroxybenzoic acid)
OH
HOOC
OH
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OH
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Vanillic acid 108
(3-methoxy-4-hydroxybenzoic acid)
OH
HOOC
OCH3
Syringic acid 109
(3,5-dimethoxy-4-hydroxybenzoic acid)
OH
HOOC
OCH3
OCH3
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Isovanillic acid 110
(3-hydroxy-4-methoxybenzoic acid)
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OH
Vanillic acid-4-O-glucuronide 112
(3-methoxybenzoic acid-4-O-glucuronide)
O
HOOC
OCH3
O
OH
OH
COOH
HO
Isovanillic acid-3-O-glucuronide 111
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Protocatechuic acid-3-sulfate 113
(4-hydroxybenzoic acid-3-sulfate)
OH
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Protocatechuic acid-4-sulfate 114
(3-hydroxybenzoic acid-4-sulfate)
OSO3-
HOOC
OH
Benzoic acid-4-sulfate 115
OSO3-
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